#FORMAT=WebAnno TSV 3.3
#T_SP=webanno.custom.ConceptLayer|identifier


#Text=Blunted Frontostriatal BOLD Signals Predict Stimulant and Marijuana Use
#Text=Background
#Text=Occasional, recreational stimulant (amphetamine and cocaine) use is an important public health problem among young adults because 16% of those who experiment develop stimulant use disorder (SUD).
1-1	0-7	Blunted	_	
1-2	8-22	Frontostriatal	_	
1-3	23-27	BOLD	_	
1-4	28-35	Signals	_	
1-5	36-43	Predict	_	
1-6	44-53	Stimulant	_	
1-7	54-57	and	_	
1-8	58-67	Marijuana	_	
1-9	68-71	Use	_	
1-10	72-82	Background	_	
1-11	83-93	Occasional	_	
1-12	93-94	,	_	
1-13	95-107	recreational	_	
1-14	108-117	stimulant	_	
1-15	118-119	(	_	
1-16	119-130	amphetamine	_	
1-17	131-134	and	_	
1-18	135-142	cocaine	_	
1-19	142-143	)	_	
1-20	144-147	use	_	
1-21	148-150	is	_	
1-22	151-153	an	_	
1-23	154-163	important	_	
1-24	164-170	public	_	
1-25	171-177	health	_	
1-26	178-185	problem	_	
1-27	186-191	among	_	
1-28	192-197	young	_	
1-29	198-204	adults	_	
1-30	205-212	because	_	
1-31	213-216	16%	_	
1-32	217-219	of	_	
1-33	220-225	those	_	
1-34	226-229	who	_	
1-35	230-240	experiment	_	
1-36	241-248	develop	_	
1-37	249-258	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-38	259-262	use	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-39	263-271	disorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-40	272-273	(	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-41	273-276	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-42	276-277	)	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder[1]	
1-43	277-278	.	_	

#Text=This study aimed to determine whether behavioral and/or neural processing measures can forecast the transition from occasional to problematic stimulant use.
2-1	279-283	This	_	
2-2	284-289	study	_	
2-3	290-295	aimed	_	
2-4	296-298	to	_	
2-5	299-308	determine	_	
2-6	309-316	whether	_	
2-7	317-327	behavioral	_	
2-8	328-331	and	_	
2-9	331-332	/	_	
2-10	332-334	or	_	
2-11	335-341	neural	_	
2-12	342-352	processing	_	
2-13	353-361	measures	_	
2-14	362-365	can	_	
2-15	366-374	forecast	_	
2-16	375-378	the	_	
2-17	379-389	transition	_	
2-18	390-394	from	_	
2-19	395-405	occasional	_	
2-20	406-408	to	_	
2-21	409-420	problematic	_	
2-22	421-430	stimulant	_	
2-23	431-434	use	_	
2-24	434-435	.	_	

#Text=Methods
#Text=Occasional stimulant users (OSU) completed a Risky Gains Task during functional magnetic resonance imaging and were followed up three years later.
3-1	436-443	Methods	_	
3-2	444-454	Occasional	_	
3-3	455-464	stimulant	_	
3-4	465-470	users	_	
3-5	471-472	(	_	
3-6	472-475	OSU	_	
3-7	475-476	)	_	
3-8	477-486	completed	_	
3-9	487-488	a	_	
3-10	489-494	Risky	_	
3-11	495-500	Gains	_	
3-12	501-505	Task	_	
3-13	506-512	during	_	
3-14	513-523	functional	_	
3-15	524-532	magnetic	_	
3-16	533-542	resonance	_	
3-17	543-550	imaging	_	
3-18	551-554	and	_	
3-19	555-559	were	_	
3-20	560-568	followed	_	
3-21	569-571	up	_	
3-22	572-577	three	_	
3-23	578-583	years	_	
3-24	584-589	later	_	
3-25	589-590	.	_	

#Text=Categorical analyses tested whether blood oxygen level dependent (BOLD) responses differentiated OSU who became problem stimulant users (PSU; n=35) from those who desisted stimulant use (DSU; n=75) at follow-up.
4-1	591-602	Categorical	_	
4-2	603-611	analyses	_	
4-3	612-618	tested	_	
4-4	619-626	whether	_	
4-5	627-632	blood	_	
4-6	633-639	oxygen	_	
4-7	640-645	level	_	
4-8	646-655	dependent	_	
4-9	656-657	(	_	
4-10	657-661	BOLD	_	
4-11	661-662	)	_	
4-12	663-672	responses	_	
4-13	673-687	differentiated	_	
4-14	688-691	OSU	_	
4-15	692-695	who	_	
4-16	696-702	became	_	
4-17	703-710	problem	_	
4-18	711-720	stimulant	_	
4-19	721-726	users	_	
4-20	727-728	(	_	
4-21	728-731	PSU	_	
4-22	731-732	;	_	
4-23	733-734	n	_	
4-24	734-735	=	_	
4-25	735-737	35	_	
4-26	737-738	)	_	
4-27	739-743	from	_	
4-28	744-749	those	_	
4-29	750-753	who	_	
4-30	754-762	desisted	_	
4-31	763-772	stimulant	_	
4-32	773-776	use	_	
4-33	777-778	(	_	
4-34	778-781	DSU	_	
4-35	781-782	;	_	
4-36	783-784	n	_	
4-37	784-785	=	_	
4-38	785-787	75	_	
4-39	787-788	)	_	
4-40	789-791	at	_	
4-41	792-801	follow-up	_	
4-42	801-802	.	_	

#Text=Dimensional analyses (regardless of PSU or DSU membership; n=144) tested whether BOLD responses predicted baseline and follow-up stimulant and marijuana use.
5-1	803-814	Dimensional	_	
5-2	815-823	analyses	_	
5-3	824-825	(	_	
5-4	825-835	regardless	_	
5-5	836-838	of	_	
5-6	839-842	PSU	_	
5-7	843-845	or	_	
5-8	846-849	DSU	_	
5-9	850-860	membership	_	
5-10	860-861	;	_	
5-11	862-863	n	_	
5-12	863-864	=	_	
5-13	864-867	144	_	
5-14	867-868	)	_	
5-15	869-875	tested	_	
5-16	876-883	whether	_	
5-17	884-888	BOLD	_	
5-18	889-898	responses	_	
5-19	899-908	predicted	_	
5-20	909-917	baseline	_	
5-21	918-921	and	_	
5-22	922-931	follow-up	_	
5-23	932-941	stimulant	_	
5-24	942-945	and	_	
5-25	946-955	marijuana	_	
5-26	956-959	use	_	
5-27	959-960	.	_	

#Text=Results
#Text=Categorical results indicated that relative to DSU, PSU: 1) made riskier decisions after winning feedback; 2) exhibited lower frontal, insular, and striatal BOLD responses to win/loss feedback after making risky decisions; 3) displayed lower thalamic but greater temporo-occipital BOLD responses to risky losses than wins.
6-1	961-968	Results	_	
6-2	969-980	Categorical	_	
6-3	981-988	results	_	
6-4	989-998	indicated	_	
6-5	999-1003	that	_	
6-6	1004-1012	relative	_	
6-7	1013-1015	to	_	
6-8	1016-1019	DSU	_	
6-9	1019-1020	,	_	
6-10	1021-1024	PSU	_	
6-11	1024-1025	:	_	
6-12	1026-1027	1	_	
6-13	1027-1028	)	_	
6-14	1029-1033	made	_	
6-15	1034-1041	riskier	_	
6-16	1042-1051	decisions	_	
6-17	1052-1057	after	_	
6-18	1058-1065	winning	_	
6-19	1066-1074	feedback	_	
6-20	1074-1075	;	_	
6-21	1076-1077	2	_	
6-22	1077-1078	)	_	
6-23	1079-1088	exhibited	_	
6-24	1089-1094	lower	_	
6-25	1095-1102	frontal	_	
6-26	1102-1103	,	_	
6-27	1104-1111	insular	_	
6-28	1111-1112	,	_	
6-29	1113-1116	and	_	
6-30	1117-1125	striatal	_	
6-31	1126-1130	BOLD	_	
6-32	1131-1140	responses	_	
6-33	1141-1143	to	_	
6-34	1144-1147	win	_	
6-35	1147-1148	/	_	
6-36	1148-1152	loss	_	
6-37	1153-1161	feedback	_	
6-38	1162-1167	after	_	
6-39	1168-1174	making	_	
6-40	1175-1180	risky	_	
6-41	1181-1190	decisions	_	
6-42	1190-1191	;	_	
6-43	1192-1193	3	_	
6-44	1193-1194	)	_	
6-45	1195-1204	displayed	_	
6-46	1205-1210	lower	_	
6-47	1211-1219	thalamic	_	
6-48	1220-1223	but	_	
6-49	1224-1231	greater	_	
6-50	1232-1249	temporo-occipital	_	
6-51	1250-1254	BOLD	_	
6-52	1255-1264	responses	_	
6-53	1265-1267	to	_	
6-54	1268-1273	risky	_	
6-55	1274-1280	losses	_	
6-56	1281-1285	than	_	
6-57	1286-1290	wins	_	
6-58	1290-1291	.	_	

#Text=In comparison, dimensional results indicated that lower BOLD signal to risky than safe choices in frontal, striatal, and additional regions predicted greater marijuana use at follow-up.
7-1	1292-1294	In	_	
7-2	1295-1305	comparison	_	
7-3	1305-1306	,	_	
7-4	1307-1318	dimensional	_	
7-5	1319-1326	results	_	
7-6	1327-1336	indicated	_	
7-7	1337-1341	that	_	
7-8	1342-1347	lower	_	
7-9	1348-1352	BOLD	_	
7-10	1353-1359	signal	_	
7-11	1360-1362	to	_	
7-12	1363-1368	risky	_	
7-13	1369-1373	than	_	
7-14	1374-1378	safe	_	
7-15	1379-1386	choices	_	
7-16	1387-1389	in	_	
7-17	1390-1397	frontal	_	
7-18	1397-1398	,	_	
7-19	1399-1407	striatal	_	
7-20	1407-1408	,	_	
7-21	1409-1412	and	_	
7-22	1413-1423	additional	_	
7-23	1424-1431	regions	_	
7-24	1432-1441	predicted	_	
7-25	1442-1449	greater	_	
7-26	1450-1459	marijuana	_	
7-27	1460-1463	use	_	
7-28	1464-1466	at	_	
7-29	1467-1476	follow-up	_	
7-30	1476-1477	.	_	

#Text=Conclusions
#Text=Taken together, blunted frontostriatal signals during risky choices may quantify vulnerability to future marijuana consumption, whereas blunted frontostriatal signals to risky outcomes mark risk for future SUD.
8-1	1478-1489	Conclusions	_	
8-2	1490-1495	Taken	_	
8-3	1496-1504	together	_	
8-4	1504-1505	,	_	
8-5	1506-1513	blunted	_	
8-6	1514-1528	frontostriatal	_	
8-7	1529-1536	signals	_	
8-8	1537-1543	during	_	
8-9	1544-1549	risky	_	
8-10	1550-1557	choices	_	
8-11	1558-1561	may	_	
8-12	1562-1570	quantify	_	
8-13	1571-1584	vulnerability	_	
8-14	1585-1587	to	_	
8-15	1588-1594	future	_	
8-16	1595-1604	marijuana	_	
8-17	1605-1616	consumption	_	
8-18	1616-1617	,	_	
8-19	1618-1625	whereas	_	
8-20	1626-1633	blunted	_	
8-21	1634-1648	frontostriatal	_	
8-22	1649-1656	signals	_	
8-23	1657-1659	to	_	
8-24	1660-1665	risky	_	
8-25	1666-1674	outcomes	_	
8-26	1675-1679	mark	_	
8-27	1680-1684	risk	_	
8-28	1685-1688	for	_	
8-29	1689-1695	future	_	
8-30	1696-1699	SUD	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	
8-31	1699-1700	.	_	

#Text=These behavioral and neural processing measures may prove useful for identifying ultra-high risk individuals prior to onset of problem drug use.
9-1	1701-1706	These	_	
9-2	1707-1717	behavioral	_	
9-3	1718-1721	and	_	
9-4	1722-1728	neural	_	
9-5	1729-1739	processing	_	
9-6	1740-1748	measures	_	
9-7	1749-1752	may	_	
9-8	1753-1758	prove	_	
9-9	1759-1765	useful	_	
9-10	1766-1769	for	_	
9-11	1770-1781	identifying	_	
9-12	1782-1792	ultra-high	_	
9-13	1793-1797	risk	_	
9-14	1798-1809	individuals	_	
9-15	1810-1815	prior	_	
9-16	1816-1818	to	_	
9-17	1819-1824	onset	_	
9-18	1825-1827	of	_	
9-19	1828-1835	problem	_	
9-20	1836-1840	drug	_	
9-21	1841-1844	use	_	
9-22	1844-1845	.	_	

#Text=Introduction
#Text=Recreational stimulant use is a growing concern among young adults, with 4.4% and 5–35% of college students endorsing cocaine and recreational amphetamine (Adderall, Ritalin) use, respectively, and 16% of cocaine experimenters developing dependence within 10 years.
10-1	1846-1858	Introduction	_	
10-2	1859-1871	Recreational	_	
10-3	1872-1881	stimulant	_	
10-4	1882-1885	use	_	
10-5	1886-1888	is	_	
10-6	1889-1890	a	_	
10-7	1891-1898	growing	_	
10-8	1899-1906	concern	_	
10-9	1907-1912	among	_	
10-10	1913-1918	young	_	
10-11	1919-1925	adults	_	
10-12	1925-1926	,	_	
10-13	1927-1931	with	_	
10-14	1932-1936	4.4%	_	
10-15	1937-1940	and	_	
10-16	1941-1942	5	_	
10-17	1942-1943	–	_	
10-18	1943-1946	35%	_	
10-19	1947-1949	of	_	
10-20	1950-1957	college	_	
10-21	1958-1966	students	_	
10-22	1967-1976	endorsing	_	
10-23	1977-1984	cocaine	_	
10-24	1985-1988	and	_	
10-25	1989-2001	recreational	_	
10-26	2002-2013	amphetamine	_	
10-27	2014-2015	(	_	
10-28	2015-2023	Adderall	_	
10-29	2023-2024	,	_	
10-30	2025-2032	Ritalin	_	
10-31	2032-2033	)	_	
10-32	2034-2037	use	_	
10-33	2037-2038	,	_	
10-34	2039-2051	respectively	_	
10-35	2051-2052	,	_	
10-36	2053-2056	and	_	
10-37	2057-2060	16%	_	
10-38	2061-2063	of	_	
10-39	2064-2071	cocaine	_	
10-40	2072-2085	experimenters	_	
10-41	2086-2096	developing	_	
10-42	2097-2107	dependence	_	
10-43	2108-2114	within	_	
10-44	2115-2117	10	_	
10-45	2118-2123	years	_	
10-46	2123-2124	.	_	

#Text=To develop cost-effective prevention and intervention strategies, it is crucial to identify ultra-high risk recreational users.
11-1	2125-2127	To	_	
11-2	2128-2135	develop	_	
11-3	2136-2150	cost-effective	_	
11-4	2151-2161	prevention	_	
11-5	2162-2165	and	_	
11-6	2166-2178	intervention	_	
11-7	2179-2189	strategies	_	
11-8	2189-2190	,	_	
11-9	2191-2193	it	_	
11-10	2194-2196	is	_	
11-11	2197-2204	crucial	_	
11-12	2205-2207	to	_	
11-13	2208-2216	identify	_	
11-14	2217-2227	ultra-high	_	
11-15	2228-2232	risk	_	
11-16	2233-2245	recreational	_	
11-17	2246-2251	users	_	
11-18	2251-2252	.	_	

#Text=However, little is known about biobehavioral markers forecasting trajectory of occasional stimulant use (OSU) to stimulant use disorder (SUD).
12-1	2253-2260	However	_	
12-2	2260-2261	,	_	
12-3	2262-2268	little	_	
12-4	2269-2271	is	_	
12-5	2272-2277	known	_	
12-6	2278-2283	about	_	
12-7	2284-2297	biobehavioral	_	
12-8	2298-2305	markers	_	
12-9	2306-2317	forecasting	_	
12-10	2318-2328	trajectory	_	
12-11	2329-2331	of	_	
12-12	2332-2342	occasional	_	
12-13	2343-2352	stimulant	_	
12-14	2353-2356	use	_	
12-15	2357-2358	(	_	
12-16	2358-2361	OSU	_	
12-17	2361-2362	)	_	
12-18	2363-2365	to	_	
12-19	2366-2375	stimulant	_	
12-20	2376-2379	use	_	
12-21	2380-2388	disorder	_	
12-22	2389-2390	(	_	
12-23	2390-2393	SUD	_	
12-24	2393-2394	)	_	
12-25	2394-2395	.	_	

#Text=Previous stimulant use research is predominantly cross-sectional, comparing individuals with chronic stimulant use to healthy individuals; although findings from these studies highlight brain disruptions related to drug use, they cannot disentangle whether disruptions preceded or were a result of chronic use.
13-1	2396-2404	Previous	_	
13-2	2405-2414	stimulant	_	
13-3	2415-2418	use	_	
13-4	2419-2427	research	_	
13-5	2428-2430	is	_	
13-6	2431-2444	predominantly	_	
13-7	2445-2460	cross-sectional	_	
13-8	2460-2461	,	_	
13-9	2462-2471	comparing	_	
13-10	2472-2483	individuals	_	
13-11	2484-2488	with	_	
13-12	2489-2496	chronic	_	
13-13	2497-2506	stimulant	_	
13-14	2507-2510	use	_	
13-15	2511-2513	to	_	
13-16	2514-2521	healthy	_	
13-17	2522-2533	individuals	_	
13-18	2533-2534	;	_	
13-19	2535-2543	although	_	
13-20	2544-2552	findings	_	
13-21	2553-2557	from	_	
13-22	2558-2563	these	_	
13-23	2564-2571	studies	_	
13-24	2572-2581	highlight	_	
13-25	2582-2587	brain	_	
13-26	2588-2599	disruptions	_	
13-27	2600-2607	related	_	
13-28	2608-2610	to	_	
13-29	2611-2615	drug	_	
13-30	2616-2619	use	_	
13-31	2619-2620	,	_	
13-32	2621-2625	they	_	
13-33	2626-2632	cannot	_	
13-34	2633-2644	disentangle	_	
13-35	2645-2652	whether	_	
13-36	2653-2664	disruptions	_	
13-37	2665-2673	preceded	_	
13-38	2674-2676	or	_	
13-39	2677-2681	were	_	
13-40	2682-2683	a	_	
13-41	2684-2690	result	_	
13-42	2691-2693	of	_	
13-43	2694-2701	chronic	_	
13-44	2702-2705	use	_	
13-45	2705-2706	.	_	

#Text=Young adulthood is a period of increased independence, often providing more opportunities for risky behavior such as drug experimentation.
14-1	2707-2712	Young	_	
14-2	2713-2722	adulthood	_	
14-3	2723-2725	is	_	
14-4	2726-2727	a	_	
14-5	2728-2734	period	_	
14-6	2735-2737	of	_	
14-7	2738-2747	increased	_	
14-8	2748-2760	independence	_	
14-9	2760-2761	,	_	
14-10	2762-2767	often	_	
14-11	2768-2777	providing	_	
14-12	2778-2782	more	_	
14-13	2783-2796	opportunities	_	
14-14	2797-2800	for	_	
14-15	2801-2806	risky	_	
14-16	2807-2815	behavior	_	
14-17	2816-2820	such	_	
14-18	2821-2823	as	_	
14-19	2824-2828	drug	_	
14-20	2829-2844	experimentation	_	
14-21	2844-2845	.	_	

#Text=Risky behavior can be defined as actions that may be subjectively desirable but are potentially harmful and is typically quantified in young adults by their degree of substance use, unprotected sex, health habits, and crime engagement.
15-1	2846-2851	Risky	_	
15-2	2852-2860	behavior	_	
15-3	2861-2864	can	_	
15-4	2865-2867	be	_	
15-5	2868-2875	defined	_	
15-6	2876-2878	as	_	
15-7	2879-2886	actions	_	
15-8	2887-2891	that	_	
15-9	2892-2895	may	_	
15-10	2896-2898	be	_	
15-11	2899-2911	subjectively	_	
15-12	2912-2921	desirable	_	
15-13	2922-2925	but	_	
15-14	2926-2929	are	_	
15-15	2930-2941	potentially	_	
15-16	2942-2949	harmful	_	
15-17	2950-2953	and	_	
15-18	2954-2956	is	_	
15-19	2957-2966	typically	_	
15-20	2967-2977	quantified	_	
15-21	2978-2980	in	_	
15-22	2981-2986	young	_	
15-23	2987-2993	adults	_	
15-24	2994-2996	by	_	
15-25	2997-3002	their	_	
15-26	3003-3009	degree	_	
15-27	3010-3012	of	_	
15-28	3013-3022	substance	_	
15-29	3023-3026	use	_	
15-30	3026-3027	,	_	
15-31	3028-3039	unprotected	_	
15-32	3040-3043	sex	_	
15-33	3043-3044	,	_	
15-34	3045-3051	health	_	
15-35	3052-3058	habits	_	
15-36	3058-3059	,	_	
15-37	3060-3063	and	_	
15-38	3064-3069	crime	_	
15-39	3070-3080	engagement	_	
15-40	3080-3081	.	_	

#Text=Risk-taking often occurs in clusters of maladaptive behaviors, suggesting underlying impairments in decision making.
16-1	3082-3093	Risk-taking	_	
16-2	3094-3099	often	_	
16-3	3100-3106	occurs	_	
16-4	3107-3109	in	_	
16-5	3110-3118	clusters	_	
16-6	3119-3121	of	_	
16-7	3122-3133	maladaptive	_	
16-8	3134-3143	behaviors	_	
16-9	3143-3144	,	_	
16-10	3145-3155	suggesting	_	
16-11	3156-3166	underlying	_	
16-12	3167-3178	impairments	_	
16-13	3179-3181	in	_	
16-14	3182-3190	decision	_	
16-15	3191-3197	making	_	
16-16	3197-3198	.	_	

#Text=Decision making involves several brain processes including learning, inhibition, and outcome assessment, specifically appraising positive (i.e. safety or reward) or negative (i.e. risk or punishment) valence of choices.
17-1	3199-3207	Decision	_	
17-2	3208-3214	making	_	
17-3	3215-3223	involves	_	
17-4	3224-3231	several	_	
17-5	3232-3237	brain	_	
17-6	3238-3247	processes	_	
17-7	3248-3257	including	_	
17-8	3258-3266	learning	_	
17-9	3266-3267	,	_	
17-10	3268-3278	inhibition	_	
17-11	3278-3279	,	_	
17-12	3280-3283	and	_	
17-13	3284-3291	outcome	_	
17-14	3292-3302	assessment	_	
17-15	3302-3303	,	_	
17-16	3304-3316	specifically	_	
17-17	3317-3327	appraising	_	
17-18	3328-3336	positive	_	
17-19	3337-3338	(	_	
17-20	3338-3341	i.e	_	
17-21	3341-3342	.	_	
17-22	3343-3349	safety	_	
17-23	3350-3352	or	_	
17-24	3353-3359	reward	_	
17-25	3359-3360	)	_	
17-26	3361-3363	or	_	
17-27	3364-3372	negative	_	
17-28	3373-3374	(	_	
17-29	3374-3377	i.e	_	
17-30	3377-3378	.	_	
17-31	3379-3383	risk	_	
17-32	3384-3386	or	_	
17-33	3387-3397	punishment	_	
17-34	3397-3398	)	_	
17-35	3399-3406	valence	_	
17-36	3407-3409	of	_	
17-37	3410-3417	choices	_	
17-38	3417-3418	.	_	

#Text=Functional magnetic resonance imaging (fMRI) research indicates that individuals with SUDs show impaired decision making associated with altered brain activation in executive control and reward processing regions.
18-1	3419-3429	Functional	_	
18-2	3430-3438	magnetic	_	
18-3	3439-3448	resonance	_	
18-4	3449-3456	imaging	_	
18-5	3457-3458	(	_	
18-6	3458-3462	fMRI	_	
18-7	3462-3463	)	_	
18-8	3464-3472	research	_	
18-9	3473-3482	indicates	_	
18-10	3483-3487	that	_	
18-11	3488-3499	individuals	_	
18-12	3500-3504	with	_	
18-13	3505-3509	SUDs	_	
18-14	3510-3514	show	_	
18-15	3515-3523	impaired	_	
18-16	3524-3532	decision	_	
18-17	3533-3539	making	_	
18-18	3540-3550	associated	_	
18-19	3551-3555	with	_	
18-20	3556-3563	altered	_	
18-21	3564-3569	brain	_	
18-22	3570-3580	activation	_	
18-23	3581-3583	in	_	
18-24	3584-3593	executive	_	
18-25	3594-3601	control	_	
18-26	3602-3605	and	_	
18-27	3606-3612	reward	_	
18-28	3613-3623	processing	_	
18-29	3624-3631	regions	_	
18-30	3631-3632	.	_	

#Text=Decision making is thought to involve a cooperative relationship between an impulsive system activated by immediate rewards and an inhibitory control system.
19-1	3633-3641	Decision	_	
19-2	3642-3648	making	_	
19-3	3649-3651	is	_	
19-4	3652-3659	thought	_	
19-5	3660-3662	to	_	
19-6	3663-3670	involve	_	
19-7	3671-3672	a	_	
19-8	3673-3684	cooperative	_	
19-9	3685-3697	relationship	_	
19-10	3698-3705	between	_	
19-11	3706-3708	an	_	
19-12	3709-3718	impulsive	_	
19-13	3719-3725	system	_	
19-14	3726-3735	activated	_	
19-15	3736-3738	by	_	
19-16	3739-3748	immediate	_	
19-17	3749-3756	rewards	_	
19-18	3757-3760	and	_	
19-19	3761-3763	an	_	
19-20	3764-3774	inhibitory	_	
19-21	3775-3782	control	_	
19-22	3783-3789	system	_	
19-23	3789-3790	.	_	

#Text=Through learning, the control network allows individuals to resist immediate attraction to rewards in favor of longer-term, advantageous outcomes.
20-1	3791-3798	Through	_	
20-2	3799-3807	learning	_	
20-3	3807-3808	,	_	
20-4	3809-3812	the	_	
20-5	3813-3820	control	_	
20-6	3821-3828	network	_	
20-7	3829-3835	allows	_	
20-8	3836-3847	individuals	_	
20-9	3848-3850	to	_	
20-10	3851-3857	resist	_	
20-11	3858-3867	immediate	_	
20-12	3868-3878	attraction	_	
20-13	3879-3881	to	_	
20-14	3882-3889	rewards	_	
20-15	3890-3892	in	_	
20-16	3893-3898	favor	_	
20-17	3899-3901	of	_	
20-18	3902-3913	longer-term	_	
20-19	3913-3914	,	_	
20-20	3915-3927	advantageous	_	
20-21	3928-3936	outcomes	_	
20-22	3936-3937	.	_	

#Text=In SUD, biobehavioral indices of risk-taking suggest an underlying imbalance between the control and impulsive systems.
21-1	3938-3940	In	_	
21-2	3941-3944	SUD	_	
21-3	3944-3945	,	_	
21-4	3946-3959	biobehavioral	_	
21-5	3960-3967	indices	_	
21-6	3968-3970	of	_	
21-7	3971-3982	risk-taking	_	
21-8	3983-3990	suggest	_	
21-9	3991-3993	an	_	
21-10	3994-4004	underlying	_	
21-11	4005-4014	imbalance	_	
21-12	4015-4022	between	_	
21-13	4023-4026	the	_	
21-14	4027-4034	control	_	
21-15	4035-4038	and	_	
21-16	4039-4048	impulsive	_	
21-17	4049-4056	systems	_	
21-18	4056-4057	.	_	

#Text=The control system integral to decision making comprises prefrontal cortex (PFC), theorized as responsible for learning the relationship between stimuli and outcome, working memory and inhibiting behavior.
22-1	4058-4061	The	_	
22-2	4062-4069	control	_	
22-3	4070-4076	system	_	
22-4	4077-4085	integral	_	
22-5	4086-4088	to	_	
22-6	4089-4097	decision	_	
22-7	4098-4104	making	_	
22-8	4105-4114	comprises	_	
22-9	4115-4125	prefrontal	_	
22-10	4126-4132	cortex	_	
22-11	4133-4134	(	_	
22-12	4134-4137	PFC	_	
22-13	4137-4138	)	_	
22-14	4138-4139	,	_	
22-15	4140-4149	theorized	_	
22-16	4150-4152	as	_	
22-17	4153-4164	responsible	_	
22-18	4165-4168	for	_	
22-19	4169-4177	learning	_	
22-20	4178-4181	the	_	
22-21	4182-4194	relationship	_	
22-22	4195-4202	between	_	
22-23	4203-4210	stimuli	_	
22-24	4211-4214	and	_	
22-25	4215-4222	outcome	_	
22-26	4222-4223	,	_	
22-27	4224-4231	working	_	
22-28	4232-4238	memory	_	
22-29	4239-4242	and	_	
22-30	4243-4253	inhibiting	_	
22-31	4254-4262	behavior	_	
22-32	4262-4263	.	_	

#Text=SUD samples exhibit frontal lobe impairments associated with compromised decision making and increased risk behavior.
23-1	4264-4267	SUD	_	
23-2	4268-4275	samples	_	
23-3	4276-4283	exhibit	_	
23-4	4284-4291	frontal	_	
23-5	4292-4296	lobe	_	
23-6	4297-4308	impairments	_	
23-7	4309-4319	associated	_	
23-8	4320-4324	with	_	
23-9	4325-4336	compromised	_	
23-10	4337-4345	decision	_	
23-11	4346-4352	making	_	
23-12	4353-4356	and	_	
23-13	4357-4366	increased	_	
23-14	4367-4371	risk	_	
23-15	4372-4380	behavior	_	
23-16	4380-4381	.	_	

#Text=For example, cocaine abusers exhibit dorsolateral PFC (DLPFC) hypoactivation during response inhibition and prediction of uncertain outcomes; in cocaine dependence, orbitofrontal cortex (OFC) and DLPFC attenuation are linked to reduced ability to differentiate between variable monetary gains.
24-1	4382-4385	For	_	
24-2	4386-4393	example	_	
24-3	4393-4394	,	_	
24-4	4395-4402	cocaine	_	
24-5	4403-4410	abusers	_	
24-6	4411-4418	exhibit	_	
24-7	4419-4431	dorsolateral	_	
24-8	4432-4435	PFC	_	
24-9	4436-4437	(	_	
24-10	4437-4442	DLPFC	_	
24-11	4442-4443	)	_	
24-12	4444-4458	hypoactivation	_	
24-13	4459-4465	during	_	
24-14	4466-4474	response	_	
24-15	4475-4485	inhibition	_	
24-16	4486-4489	and	_	
24-17	4490-4500	prediction	_	
24-18	4501-4503	of	_	
24-19	4504-4513	uncertain	_	
24-20	4514-4522	outcomes	_	
24-21	4522-4523	;	_	
24-22	4524-4526	in	_	
24-23	4527-4534	cocaine	_	
24-24	4535-4545	dependence	_	
24-25	4545-4546	,	_	
24-26	4547-4560	orbitofrontal	_	
24-27	4561-4567	cortex	_	
24-28	4568-4569	(	_	
24-29	4569-4572	OFC	_	
24-30	4572-4573	)	_	
24-31	4574-4577	and	_	
24-32	4578-4583	DLPFC	_	
24-33	4584-4595	attenuation	_	
24-34	4596-4599	are	_	
24-35	4600-4606	linked	_	
24-36	4607-4609	to	_	
24-37	4610-4617	reduced	_	
24-38	4618-4625	ability	_	
24-39	4626-4628	to	_	
24-40	4629-4642	differentiate	_	
24-41	4643-4650	between	_	
24-42	4651-4659	variable	_	
24-43	4660-4668	monetary	_	
24-44	4669-4674	gains	_	
24-45	4674-4675	.	_	

#Text=Similarly, methamphetamine users inaccurately process success or failure of available options, a pattern associated with OFC/DLPFC hypoactivation.
25-1	4676-4685	Similarly	_	
25-2	4685-4686	,	_	
25-3	4687-4702	methamphetamine	_	
25-4	4703-4708	users	_	
25-5	4709-4721	inaccurately	_	
25-6	4722-4729	process	_	
25-7	4730-4737	success	_	
25-8	4738-4740	or	_	
25-9	4741-4748	failure	_	
25-10	4749-4751	of	_	
25-11	4752-4761	available	_	
25-12	4762-4769	options	_	
25-13	4769-4770	,	_	
25-14	4771-4772	a	_	
25-15	4773-4780	pattern	_	
25-16	4781-4791	associated	_	
25-17	4792-4796	with	_	
25-18	4797-4800	OFC	_	
25-19	4800-4801	/	_	
25-20	4801-4806	DLPFC	_	
25-21	4807-4821	hypoactivation	_	
25-22	4821-4822	.	_	

#Text=Working in conjunction with frontal regions is striatum, an area associated with reward processing, selecting and initiating actions, and learning.
26-1	4823-4830	Working	_	
26-2	4831-4833	in	_	
26-3	4834-4845	conjunction	_	
26-4	4846-4850	with	_	
26-5	4851-4858	frontal	_	
26-6	4859-4866	regions	_	
26-7	4867-4869	is	_	
26-8	4870-4878	striatum	_	
26-9	4878-4879	,	_	
26-10	4880-4882	an	_	
26-11	4883-4887	area	_	
26-12	4888-4898	associated	_	
26-13	4899-4903	with	_	
26-14	4904-4910	reward	_	
26-15	4911-4921	processing	_	
26-16	4921-4922	,	_	
26-17	4923-4932	selecting	_	
26-18	4933-4936	and	_	
26-19	4937-4947	initiating	_	
26-20	4948-4955	actions	_	
26-21	4955-4956	,	_	
26-22	4957-4960	and	_	
26-23	4961-4969	learning	_	
26-24	4969-4970	.	_	

#Text=During the Iowa Gambling Task (IGT), healthy individuals show stronger striatal activation to wins than losses, but amphetamine dependent individuals demonstrate hypersensitive striatal responses to rewards.
27-1	4971-4977	During	_	
27-2	4978-4981	the	_	
27-3	4982-4986	Iowa	_	
27-4	4987-4995	Gambling	_	
27-5	4996-5000	Task	_	
27-6	5001-5002	(	_	
27-7	5002-5005	IGT	_	
27-8	5005-5006	)	_	
27-9	5006-5007	,	_	
27-10	5008-5015	healthy	_	
27-11	5016-5027	individuals	_	
27-12	5028-5032	show	_	
27-13	5033-5041	stronger	_	
27-14	5042-5050	striatal	_	
27-15	5051-5061	activation	_	
27-16	5062-5064	to	_	
27-17	5065-5069	wins	_	
27-18	5070-5074	than	_	
27-19	5075-5081	losses	_	
27-20	5081-5082	,	_	
27-21	5083-5086	but	_	
27-22	5087-5098	amphetamine	_	
27-23	5099-5108	dependent	_	
27-24	5109-5120	individuals	_	
27-25	5121-5132	demonstrate	_	
27-26	5133-5147	hypersensitive	_	
27-27	5148-5156	striatal	_	
27-28	5157-5166	responses	_	
27-29	5167-5169	to	_	
27-30	5170-5177	rewards	_	
27-31	5177-5178	.	_	

#Text=Cocaine and methamphetamine users also exhibit striatal hyperactivation but frontal hypoactivation during risky decision making tasks such as the IGT and the Balloon Analogue Risk Task (BART) that is linked to riskier behavioral performance.
28-1	5179-5186	Cocaine	_	
28-2	5187-5190	and	_	
28-3	5191-5206	methamphetamine	_	
28-4	5207-5212	users	_	
28-5	5213-5217	also	_	
28-6	5218-5225	exhibit	_	
28-7	5226-5234	striatal	_	
28-8	5235-5250	hyperactivation	_	
28-9	5251-5254	but	_	
28-10	5255-5262	frontal	_	
28-11	5263-5277	hypoactivation	_	
28-12	5278-5284	during	_	
28-13	5285-5290	risky	_	
28-14	5291-5299	decision	_	
28-15	5300-5306	making	_	
28-16	5307-5312	tasks	_	
28-17	5313-5317	such	_	
28-18	5318-5320	as	_	
28-19	5321-5324	the	_	
28-20	5325-5328	IGT	_	
28-21	5329-5332	and	_	
28-22	5333-5336	the	_	
28-23	5337-5344	Balloon	_	
28-24	5345-5353	Analogue	_	
28-25	5354-5358	Risk	_	
28-26	5359-5363	Task	_	
28-27	5364-5365	(	_	
28-28	5365-5369	BART	_	
28-29	5369-5370	)	_	
28-30	5371-5375	that	_	
28-31	5376-5378	is	_	
28-32	5379-5385	linked	_	
28-33	5386-5388	to	_	
28-34	5389-5396	riskier	_	
28-35	5397-5407	behavioral	_	
28-36	5408-5419	performance	_	
28-37	5419-5420	.	_	

#Text=This suggests that such neural patterns during decision making promotes favoring of risky incentives.
29-1	5421-5425	This	_	
29-2	5426-5434	suggests	_	
29-3	5435-5439	that	_	
29-4	5440-5444	such	_	
29-5	5445-5451	neural	_	
29-6	5452-5460	patterns	_	
29-7	5461-5467	during	_	
29-8	5468-5476	decision	_	
29-9	5477-5483	making	_	
29-10	5484-5492	promotes	_	
29-11	5493-5501	favoring	_	
29-12	5502-5504	of	_	
29-13	5505-5510	risky	_	
29-14	5511-5521	incentives	_	
29-15	5521-5522	.	_	

#Text=Evidence from functional MRI studies have led researchers to theorize that the frontal lobe and striatum form a functional circuit with insular cortex and anterior cingulate cortex (ACC); these regions coordinate to integrate emotional and autonomic information about rewards into goal-oriented behavior.
30-1	5523-5531	Evidence	_	
30-2	5532-5536	from	_	
30-3	5537-5547	functional	_	
30-4	5548-5551	MRI	_	
30-5	5552-5559	studies	_	
30-6	5560-5564	have	_	
30-7	5565-5568	led	_	
30-8	5569-5580	researchers	_	
30-9	5581-5583	to	_	
30-10	5584-5592	theorize	_	
30-11	5593-5597	that	_	
30-12	5598-5601	the	_	
30-13	5602-5609	frontal	_	
30-14	5610-5614	lobe	_	
30-15	5615-5618	and	_	
30-16	5619-5627	striatum	_	
30-17	5628-5632	form	_	
30-18	5633-5634	a	_	
30-19	5635-5645	functional	_	
30-20	5646-5653	circuit	_	
30-21	5654-5658	with	_	
30-22	5659-5666	insular	_	
30-23	5667-5673	cortex	_	
30-24	5674-5677	and	_	
30-25	5678-5686	anterior	_	
30-26	5687-5696	cingulate	_	
30-27	5697-5703	cortex	_	
30-28	5704-5705	(	_	
30-29	5705-5708	ACC	_	
30-30	5708-5709	)	_	
30-31	5709-5710	;	_	
30-32	5711-5716	these	_	
30-33	5717-5724	regions	_	
30-34	5725-5735	coordinate	_	
30-35	5736-5738	to	_	
30-36	5739-5748	integrate	_	
30-37	5749-5758	emotional	_	
30-38	5759-5762	and	_	
30-39	5763-5772	autonomic	_	
30-40	5773-5784	information	_	
30-41	5785-5790	about	_	
30-42	5791-5798	rewards	_	
30-43	5799-5803	into	_	
30-44	5804-5817	goal-oriented	_	
30-45	5818-5826	behavior	_	
30-46	5826-5827	.	_	

#Text=ACC is proposed to be involved in emotion and behavior management based on its neural connections to both the emotion-processing limbic system and the cognitive control center, PFC.
31-1	5828-5831	ACC	_	
31-2	5832-5834	is	_	
31-3	5835-5843	proposed	_	
31-4	5844-5846	to	_	
31-5	5847-5849	be	_	
31-6	5850-5858	involved	_	
31-7	5859-5861	in	_	
31-8	5862-5869	emotion	_	
31-9	5870-5873	and	_	
31-10	5874-5882	behavior	_	
31-11	5883-5893	management	_	
31-12	5894-5899	based	_	
31-13	5900-5902	on	_	
31-14	5903-5906	its	_	
31-15	5907-5913	neural	_	
31-16	5914-5925	connections	_	
31-17	5926-5928	to	_	
31-18	5929-5933	both	_	
31-19	5934-5937	the	_	
31-20	5938-5956	emotion-processing	_	
31-21	5957-5963	limbic	_	
31-22	5964-5970	system	_	
31-23	5971-5974	and	_	
31-24	5975-5978	the	_	
31-25	5979-5988	cognitive	_	
31-26	5989-5996	control	_	
31-27	5997-6003	center	_	
31-28	6003-6004	,	_	
31-29	6005-6008	PFC	_	
31-30	6008-6009	.	_	

#Text=Insula is proposed to play a role in interoceptive processing, wherein individuals integrate physiological cues to differentiate between risky and safe decisions, and transform these cues into conscious feelings and behaviors.
32-1	6010-6016	Insula	_	
32-2	6017-6019	is	_	
32-3	6020-6028	proposed	_	
32-4	6029-6031	to	_	
32-5	6032-6036	play	_	
32-6	6037-6038	a	_	
32-7	6039-6043	role	_	
32-8	6044-6046	in	_	
32-9	6047-6060	interoceptive	_	
32-10	6061-6071	processing	_	
32-11	6071-6072	,	_	
32-12	6073-6080	wherein	_	
32-13	6081-6092	individuals	_	
32-14	6093-6102	integrate	_	
32-15	6103-6116	physiological	_	
32-16	6117-6121	cues	_	
32-17	6122-6124	to	_	
32-18	6125-6138	differentiate	_	
32-19	6139-6146	between	_	
32-20	6147-6152	risky	_	
32-21	6153-6156	and	_	
32-22	6157-6161	safe	_	
32-23	6162-6171	decisions	_	
32-24	6171-6172	,	_	
32-25	6173-6176	and	_	
32-26	6177-6186	transform	_	
32-27	6187-6192	these	_	
32-28	6193-6197	cues	_	
32-29	6198-6202	into	_	
32-30	6203-6212	conscious	_	
32-31	6213-6221	feelings	_	
32-32	6222-6225	and	_	
32-33	6226-6235	behaviors	_	
32-34	6235-6236	.	_	

#Text=ACC and insula hypoactivation is evident in chronic stimulant users during response inhibition and error monitoring during decision making.
33-1	6237-6240	ACC	_	
33-2	6241-6244	and	_	
33-3	6245-6251	insula	_	
33-4	6252-6266	hypoactivation	_	
33-5	6267-6269	is	_	
33-6	6270-6277	evident	_	
33-7	6278-6280	in	_	
33-8	6281-6288	chronic	_	
33-9	6289-6298	stimulant	_	
33-10	6299-6304	users	_	
33-11	6305-6311	during	_	
33-12	6312-6320	response	_	
33-13	6321-6331	inhibition	_	
33-14	6332-6335	and	_	
33-15	6336-6341	error	_	
33-16	6342-6352	monitoring	_	
33-17	6353-6359	during	_	
33-18	6360-6368	decision	_	
33-19	6369-6375	making	_	
33-20	6375-6376	.	_	

#Text=Evidence for aberrant activity in key components of the PFC-limbic network has led researchers to suggest that weakened ability to accurately process information about options and control behaviors leads to favoring choices that offer immediate, rather than delayed, rewards.
34-1	6377-6385	Evidence	_	
34-2	6386-6389	for	_	
34-3	6390-6398	aberrant	_	
34-4	6399-6407	activity	_	
34-5	6408-6410	in	_	
34-6	6411-6414	key	_	
34-7	6415-6425	components	_	
34-8	6426-6428	of	_	
34-9	6429-6432	the	_	
34-10	6433-6443	PFC-limbic	_	
34-11	6444-6451	network	_	
34-12	6452-6455	has	_	
34-13	6456-6459	led	_	
34-14	6460-6471	researchers	_	
34-15	6472-6474	to	_	
34-16	6475-6482	suggest	_	
34-17	6483-6487	that	_	
34-18	6488-6496	weakened	_	
34-19	6497-6504	ability	_	
34-20	6505-6507	to	_	
34-21	6508-6518	accurately	_	
34-22	6519-6526	process	_	
34-23	6527-6538	information	_	
34-24	6539-6544	about	_	
34-25	6545-6552	options	_	
34-26	6553-6556	and	_	
34-27	6557-6564	control	_	
34-28	6565-6574	behaviors	_	
34-29	6575-6580	leads	_	
34-30	6581-6583	to	_	
34-31	6584-6592	favoring	_	
34-32	6593-6600	choices	_	
34-33	6601-6605	that	_	
34-34	6606-6611	offer	_	
34-35	6612-6621	immediate	_	
34-36	6621-6622	,	_	
34-37	6623-6629	rather	_	
34-38	6630-6634	than	_	
34-39	6635-6642	delayed	_	
34-40	6642-6643	,	_	
34-41	6644-6651	rewards	_	
34-42	6651-6652	.	_	

#Text=Cross-sectional studies of OSU report decision making impairments that parallel findings in stimulant dependent individuals, including: 1) weakened inhibitory control and reduced cognitive flexibility; 2) neuropsychological impairments in executive functions (e.g. attention, set-shifting); and 3) frontal, striatal, and insular attenuation during a Risky Gains Task (RGT) paired with reduced ability to differentiate between safe and risky decisions.
35-1	6653-6668	Cross-sectional	_	
35-2	6669-6676	studies	_	
35-3	6677-6679	of	_	
35-4	6680-6683	OSU	_	
35-5	6684-6690	report	_	
35-6	6691-6699	decision	_	
35-7	6700-6706	making	_	
35-8	6707-6718	impairments	_	
35-9	6719-6723	that	_	
35-10	6724-6732	parallel	_	
35-11	6733-6741	findings	_	
35-12	6742-6744	in	_	
35-13	6745-6754	stimulant	_	
35-14	6755-6764	dependent	_	
35-15	6765-6776	individuals	_	
35-16	6776-6777	,	_	
35-17	6778-6787	including	_	
35-18	6787-6788	:	_	
35-19	6789-6790	1	_	
35-20	6790-6791	)	_	
35-21	6792-6800	weakened	_	
35-22	6801-6811	inhibitory	_	
35-23	6812-6819	control	_	
35-24	6820-6823	and	_	
35-25	6824-6831	reduced	_	
35-26	6832-6841	cognitive	_	
35-27	6842-6853	flexibility	_	
35-28	6853-6854	;	_	
35-29	6855-6856	2	_	
35-30	6856-6857	)	_	
35-31	6858-6876	neuropsychological	_	
35-32	6877-6888	impairments	_	
35-33	6889-6891	in	_	
35-34	6892-6901	executive	_	
35-35	6902-6911	functions	_	
35-36	6912-6913	(	_	
35-37	6913-6916	e.g	_	
35-38	6916-6917	.	_	
35-39	6918-6927	attention	_	
35-40	6927-6928	,	_	
35-41	6929-6941	set-shifting	_	
35-42	6941-6942	)	_	
35-43	6942-6943	;	_	
35-44	6944-6947	and	_	
35-45	6948-6949	3	_	
35-46	6949-6950	)	_	
35-47	6951-6958	frontal	_	
35-48	6958-6959	,	_	
35-49	6960-6968	striatal	_	
35-50	6968-6969	,	_	
35-51	6970-6973	and	_	
35-52	6974-6981	insular	_	
35-53	6982-6993	attenuation	_	
35-54	6994-7000	during	_	
35-55	7001-7002	a	_	
35-56	7003-7008	Risky	_	
35-57	7009-7014	Gains	_	
35-58	7015-7019	Task	_	
35-59	7020-7021	(	_	
35-60	7021-7024	RGT	_	
35-61	7024-7025	)	_	
35-62	7026-7032	paired	_	
35-63	7033-7037	with	_	
35-64	7038-7045	reduced	_	
35-65	7046-7053	ability	_	
35-66	7054-7056	to	_	
35-67	7057-7070	differentiate	_	
35-68	7071-7078	between	_	
35-69	7079-7083	safe	_	
35-70	7084-7087	and	_	
35-71	7088-7093	risky	_	
35-72	7094-7103	decisions	_	
35-73	7103-7104	.	_	

#Text=Several research groups have recognized limitations of cross-sectional addiction research and have shifted towards a longitudinal approach to understand the transition to problematic substance use.
36-1	7105-7112	Several	_	
36-2	7113-7121	research	_	
36-3	7122-7128	groups	_	
36-4	7129-7133	have	_	
36-5	7134-7144	recognized	_	
36-6	7145-7156	limitations	_	
36-7	7157-7159	of	_	
36-8	7160-7175	cross-sectional	_	
36-9	7176-7185	addiction	_	
36-10	7186-7194	research	_	
36-11	7195-7198	and	_	
36-12	7199-7203	have	_	
36-13	7204-7211	shifted	_	
36-14	7212-7219	towards	_	
36-15	7220-7221	a	_	
36-16	7222-7234	longitudinal	_	
36-17	7235-7243	approach	_	
36-18	7244-7246	to	_	
36-19	7247-7257	understand	_	
36-20	7258-7261	the	_	
36-21	7262-7272	transition	_	
36-22	7273-7275	to	_	
36-23	7276-7287	problematic	_	
36-24	7288-7297	substance	_	
36-25	7298-7301	use	_	
36-26	7301-7302	.	_	

#Text=Structural MRI studies show that decreased brain volume in: 1) frontocentral regions at age 14 predict binge drinking at age 16; and 2) frontostriatal regions is linked to heightened stimulant use in OSU 1–2 years later.
37-1	7303-7313	Structural	_	
37-2	7314-7317	MRI	_	
37-3	7318-7325	studies	_	
37-4	7326-7330	show	_	
37-5	7331-7335	that	_	
37-6	7336-7345	decreased	_	
37-7	7346-7351	brain	_	
37-8	7352-7358	volume	_	
37-9	7359-7361	in	_	
37-10	7361-7362	:	_	
37-11	7363-7364	1	_	
37-12	7364-7365	)	_	
37-13	7366-7379	frontocentral	_	
37-14	7380-7387	regions	_	
37-15	7388-7390	at	_	
37-16	7391-7394	age	_	
37-17	7395-7397	14	_	
37-18	7398-7405	predict	_	
37-19	7406-7411	binge	_	
37-20	7412-7420	drinking	_	
37-21	7421-7423	at	_	
37-22	7424-7427	age	_	
37-23	7428-7430	16	_	
37-24	7430-7431	;	_	
37-25	7432-7435	and	_	
37-26	7436-7437	2	_	
37-27	7437-7438	)	_	
37-28	7439-7453	frontostriatal	_	
37-29	7454-7461	regions	_	
37-30	7462-7464	is	_	
37-31	7465-7471	linked	_	
37-32	7472-7474	to	_	
37-33	7475-7485	heightened	_	
37-34	7486-7495	stimulant	_	
37-35	7496-7499	use	_	
37-36	7500-7502	in	_	
37-37	7503-7506	OSU	_	
37-38	7507-7508	1	_	
37-39	7508-7509	–	_	
37-40	7509-7510	2	_	
37-41	7511-7516	years	_	
37-42	7517-7522	later	_	
37-43	7522-7523	.	_	

#Text=However, functional MRI has been less applied to predict the development of SUD.
38-1	7524-7531	However	_	
38-2	7531-7532	,	_	
38-3	7533-7543	functional	_	
38-4	7544-7547	MRI	_	
38-5	7548-7551	has	_	
38-6	7552-7556	been	_	
38-7	7557-7561	less	_	
38-8	7562-7569	applied	_	
38-9	7570-7572	to	_	
38-10	7573-7580	predict	_	
38-11	7581-7584	the	_	
38-12	7585-7596	development	_	
38-13	7597-7599	of	_	
38-14	7600-7603	SUD	_	
38-15	7603-7604	.	_	

#Text=The present longitudinal study utilized follow-up clinical and drug use data from OSU (n=144) three years after a fMRI scan to determine whether baseline behavioral and blood oxygen level dependent (BOLD) responses during the RGT: 1) differentiated young adults who became problem stimulant users (PSU; n=35) from those who desisted stimulant use (DSU; n=75) in the three-year interim (categorical approach); and 2) predicted cumulative baseline and follow-up stimulant and marijuana use across OSU, regardless of clinical status (dimensional approach; n=144), to address concerns regarding significant rates of marijuana and stimulant co-use.
39-1	7605-7608	The	_	
39-2	7609-7616	present	_	
39-3	7617-7629	longitudinal	_	
39-4	7630-7635	study	_	
39-5	7636-7644	utilized	_	
39-6	7645-7654	follow-up	_	
39-7	7655-7663	clinical	_	
39-8	7664-7667	and	_	
39-9	7668-7672	drug	_	
39-10	7673-7676	use	_	
39-11	7677-7681	data	_	
39-12	7682-7686	from	_	
39-13	7687-7690	OSU	_	
39-14	7691-7692	(	_	
39-15	7692-7693	n	_	
39-16	7693-7694	=	_	
39-17	7694-7697	144	_	
39-18	7697-7698	)	_	
39-19	7699-7704	three	_	
39-20	7705-7710	years	_	
39-21	7711-7716	after	_	
39-22	7717-7718	a	_	
39-23	7719-7723	fMRI	_	
39-24	7724-7728	scan	_	
39-25	7729-7731	to	_	
39-26	7732-7741	determine	_	
39-27	7742-7749	whether	_	
39-28	7750-7758	baseline	_	
39-29	7759-7769	behavioral	_	
39-30	7770-7773	and	_	
39-31	7774-7779	blood	_	
39-32	7780-7786	oxygen	_	
39-33	7787-7792	level	_	
39-34	7793-7802	dependent	_	
39-35	7803-7804	(	_	
39-36	7804-7808	BOLD	_	
39-37	7808-7809	)	_	
39-38	7810-7819	responses	_	
39-39	7820-7826	during	_	
39-40	7827-7830	the	_	
39-41	7831-7834	RGT	_	
39-42	7834-7835	:	_	
39-43	7836-7837	1	_	
39-44	7837-7838	)	_	
39-45	7839-7853	differentiated	_	
39-46	7854-7859	young	_	
39-47	7860-7866	adults	_	
39-48	7867-7870	who	_	
39-49	7871-7877	became	_	
39-50	7878-7885	problem	_	
39-51	7886-7895	stimulant	_	
39-52	7896-7901	users	_	
39-53	7902-7903	(	_	
39-54	7903-7906	PSU	_	
39-55	7906-7907	;	_	
39-56	7908-7909	n	_	
39-57	7909-7910	=	_	
39-58	7910-7912	35	_	
39-59	7912-7913	)	_	
39-60	7914-7918	from	_	
39-61	7919-7924	those	_	
39-62	7925-7928	who	_	
39-63	7929-7937	desisted	_	
39-64	7938-7947	stimulant	_	
39-65	7948-7951	use	_	
39-66	7952-7953	(	_	
39-67	7953-7956	DSU	_	
39-68	7956-7957	;	_	
39-69	7958-7959	n	_	
39-70	7959-7960	=	_	
39-71	7960-7962	75	_	
39-72	7962-7963	)	_	
39-73	7964-7966	in	_	
39-74	7967-7970	the	_	
39-75	7971-7981	three-year	_	
39-76	7982-7989	interim	_	
39-77	7990-7991	(	_	
39-78	7991-8002	categorical	_	
39-79	8003-8011	approach	_	
39-80	8011-8012	)	_	
39-81	8012-8013	;	_	
39-82	8014-8017	and	_	
39-83	8018-8019	2	_	
39-84	8019-8020	)	_	
39-85	8021-8030	predicted	_	
39-86	8031-8041	cumulative	_	
39-87	8042-8050	baseline	_	
39-88	8051-8054	and	_	
39-89	8055-8064	follow-up	_	
39-90	8065-8074	stimulant	_	
39-91	8075-8078	and	_	
39-92	8079-8088	marijuana	_	
39-93	8089-8092	use	_	
39-94	8093-8099	across	_	
39-95	8100-8103	OSU	_	
39-96	8103-8104	,	_	
39-97	8105-8115	regardless	_	
39-98	8116-8118	of	_	
39-99	8119-8127	clinical	_	
39-100	8128-8134	status	_	
39-101	8135-8136	(	_	
39-102	8136-8147	dimensional	_	
39-103	8148-8156	approach	_	
39-104	8156-8157	;	_	
39-105	8158-8159	n	_	
39-106	8159-8160	=	_	
39-107	8160-8163	144	_	
39-108	8163-8164	)	_	
39-109	8164-8165	,	_	
39-110	8166-8168	to	_	
39-111	8169-8176	address	_	
39-112	8177-8185	concerns	_	
39-113	8186-8195	regarding	_	
39-114	8196-8207	significant	_	
39-115	8208-8213	rates	_	
39-116	8214-8216	of	_	
39-117	8217-8226	marijuana	_	
39-118	8227-8230	and	_	
39-119	8231-8240	stimulant	_	
39-120	8241-8247	co-use	_	
39-121	8247-8248	.	_	

#Text=Analyses compared BOLD activity related to specific task requirements: decision contrasts compared BOLD activity during risk-taking choice trials versus safe choice trials; outcome contrasts compared BOLD activity on trials wherein each subject took a risk and subsequently earned a win or a loss.
40-1	8249-8257	Analyses	_	
40-2	8258-8266	compared	_	
40-3	8267-8271	BOLD	_	
40-4	8272-8280	activity	_	
40-5	8281-8288	related	_	
40-6	8289-8291	to	_	
40-7	8292-8300	specific	_	
40-8	8301-8305	task	_	
40-9	8306-8318	requirements	_	
40-10	8318-8319	:	_	
40-11	8320-8328	decision	_	
40-12	8329-8338	contrasts	_	
40-13	8339-8347	compared	_	
40-14	8348-8352	BOLD	_	
40-15	8353-8361	activity	_	
40-16	8362-8368	during	_	
40-17	8369-8380	risk-taking	_	
40-18	8381-8387	choice	_	
40-19	8388-8394	trials	_	
40-20	8395-8401	versus	_	
40-21	8402-8406	safe	_	
40-22	8407-8413	choice	_	
40-23	8414-8420	trials	_	
40-24	8420-8421	;	_	
40-25	8422-8429	outcome	_	
40-26	8430-8439	contrasts	_	
40-27	8440-8448	compared	_	
40-28	8449-8453	BOLD	_	
40-29	8454-8462	activity	_	
40-30	8463-8465	on	_	
40-31	8466-8472	trials	_	
40-32	8473-8480	wherein	_	
40-33	8481-8485	each	_	
40-34	8486-8493	subject	_	
40-35	8494-8498	took	_	
40-36	8499-8500	a	_	
40-37	8501-8505	risk	_	
40-38	8506-8509	and	_	
40-39	8510-8522	subsequently	_	
40-40	8523-8529	earned	_	
40-41	8530-8531	a	_	
40-42	8532-8535	win	_	
40-43	8536-8538	or	_	
40-44	8539-8540	a	_	
40-45	8541-8545	loss	_	
40-46	8545-8546	.	_	

#Text=Categorical hypotheses were tested based on prior biobehavioral findings in stimulant dependent individuals: 1) PSU would exhibit riskier task performance than DSU; 2) PSU would show greater striatal BOLD signal than DSU to outcomes, particularly in response to risky wins; and 3) PSU would exhibit lower PFC, insular, and cingulate BOLD signal during decision making.
41-1	8547-8558	Categorical	_	
41-2	8559-8569	hypotheses	_	
41-3	8570-8574	were	_	
41-4	8575-8581	tested	_	
41-5	8582-8587	based	_	
41-6	8588-8590	on	_	
41-7	8591-8596	prior	_	
41-8	8597-8610	biobehavioral	_	
41-9	8611-8619	findings	_	
41-10	8620-8622	in	_	
41-11	8623-8632	stimulant	_	
41-12	8633-8642	dependent	_	
41-13	8643-8654	individuals	_	
41-14	8654-8655	:	_	
41-15	8656-8657	1	_	
41-16	8657-8658	)	_	
41-17	8659-8662	PSU	_	
41-18	8663-8668	would	_	
41-19	8669-8676	exhibit	_	
41-20	8677-8684	riskier	_	
41-21	8685-8689	task	_	
41-22	8690-8701	performance	_	
41-23	8702-8706	than	_	
41-24	8707-8710	DSU	_	
41-25	8710-8711	;	_	
41-26	8712-8713	2	_	
41-27	8713-8714	)	_	
41-28	8715-8718	PSU	_	
41-29	8719-8724	would	_	
41-30	8725-8729	show	_	
41-31	8730-8737	greater	_	
41-32	8738-8746	striatal	_	
41-33	8747-8751	BOLD	_	
41-34	8752-8758	signal	_	
41-35	8759-8763	than	_	
41-36	8764-8767	DSU	_	
41-37	8768-8770	to	_	
41-38	8771-8779	outcomes	_	
41-39	8779-8780	,	_	
41-40	8781-8793	particularly	_	
41-41	8794-8796	in	_	
41-42	8797-8805	response	_	
41-43	8806-8808	to	_	
41-44	8809-8814	risky	_	
41-45	8815-8819	wins	_	
41-46	8819-8820	;	_	
41-47	8821-8824	and	_	
41-48	8825-8826	3	_	
41-49	8826-8827	)	_	
41-50	8828-8831	PSU	_	
41-51	8832-8837	would	_	
41-52	8838-8845	exhibit	_	
41-53	8846-8851	lower	_	
41-54	8852-8855	PFC	_	
41-55	8855-8856	,	_	
41-56	8857-8864	insular	_	
41-57	8864-8865	,	_	
41-58	8866-8869	and	_	
41-59	8870-8879	cingulate	_	
41-60	8880-8884	BOLD	_	
41-61	8885-8891	signal	_	
41-62	8892-8898	during	_	
41-63	8899-8907	decision	_	
41-64	8908-8914	making	_	
41-65	8914-8915	.	_	

#Text=As dimensional analyses were exploratory, no apriori hypotheses were tested.
42-1	8916-8918	As	_	
42-2	8919-8930	dimensional	_	
42-3	8931-8939	analyses	_	
42-4	8940-8944	were	_	
42-5	8945-8956	exploratory	_	
42-6	8956-8957	,	_	
42-7	8958-8960	no	_	
42-8	8961-8968	apriori	_	
42-9	8969-8979	hypotheses	_	
42-10	8980-8984	were	_	
42-11	8985-8991	tested	_	
42-12	8991-8992	.	_	

#Text=Methods and Materials
#Text=Participants
#Text=The University of California, San Diego Human Subjects Review Board approved the study protocol.
43-1	8993-9000	Methods	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
43-2	9001-9004	and	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
43-3	9005-9014	Materials	http://www.case.edu/ProvCaRe/provcare#StudyMethod[2]	
43-4	9015-9027	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-5	9028-9031	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-6	9032-9042	University	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-7	9043-9045	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-8	9046-9056	California	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-9	9056-9057	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-10	9058-9061	San	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-11	9062-9067	Diego	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-12	9068-9073	Human	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-13	9074-9082	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-14	9083-9089	Review	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-15	9090-9095	Board	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-16	9096-9104	approved	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-17	9105-9108	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-18	9109-9114	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-19	9115-9123	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
43-20	9123-9124	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=Participants were recruited through newspapers, internet ads and fliers mailed to college students.
44-1	9125-9137	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-2	9138-9142	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-3	9143-9152	recruited	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-4	9153-9160	through	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-5	9161-9171	newspapers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-6	9171-9172	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-7	9173-9181	internet	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-8	9182-9185	ads	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-9	9186-9189	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-10	9190-9196	fliers	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-11	9197-9203	mailed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-12	9204-9206	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-13	9207-9214	college	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-14	9215-9223	students	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
44-15	9223-9224	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	

#Text=Figure 1 demonstrates participant recruitment and categorical/dimensional data analysis protocol.
45-1	9225-9231	Figure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-2	9232-9233	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-3	9234-9246	demonstrates	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-4	9247-9258	participant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-5	9259-9270	recruitment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-6	9271-9274	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-7	9275-9286	categorical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-8	9286-9287	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-9	9287-9298	dimensional	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-10	9299-9303	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-11	9304-9312	analysis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-12	9313-9321	protocol	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[3]	
45-13	9321-9322	.	_	

#Text=A total of 1025 individuals were phone-screened and 184 OSU meeting study criteria provided written informed consent to participate.
46-1	9323-9324	A	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-2	9325-9330	total	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-3	9331-9333	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-4	9334-9338	1025	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-5	9339-9350	individuals	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-6	9351-9355	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-7	9356-9370	phone-screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-8	9371-9374	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-9	9375-9378	184	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-10	9379-9382	OSU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-11	9383-9390	meeting	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-12	9391-9396	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-13	9397-9405	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-14	9406-9414	provided	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-15	9415-9422	written	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-16	9423-9431	informed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-17	9432-9439	consent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-18	9440-9442	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-19	9443-9454	participate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
46-20	9454-9455	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=OSU inclusionary criteria were: 1) within the last 6 months, 2+ separate occasions cocaine or prescription amphetamines (e.g. methylphenidate (Adderall), dextroamphetamine (Ritalin) used without a prescribed purpose; 2) no lifetime stimulant dependence; 3) no lifetime stimulant use for medical reasons; and 4) no drug treatment interest.
47-1	9456-9459	OSU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-2	9460-9472	inclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-3	9473-9481	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-4	9482-9486	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-5	9486-9487	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-6	9488-9489	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-7	9489-9490	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-8	9491-9497	within	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-9	9498-9501	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-10	9502-9506	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-11	9507-9508	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-12	9509-9515	months	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-13	9515-9516	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-14	9517-9518	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-15	9518-9519	+	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-16	9520-9528	separate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-17	9529-9538	occasions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-18	9539-9546	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-19	9547-9549	or	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-20	9550-9562	prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-21	9563-9575	amphetamines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-22	9576-9577	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-23	9577-9580	e.g	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-24	9580-9581	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-25	9582-9597	methylphenidate	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-26	9598-9599	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-27	9599-9607	Adderall	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-28	9607-9608	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-29	9608-9609	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-30	9610-9627	dextroamphetamine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-31	9628-9629	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-32	9629-9636	Ritalin	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-33	9636-9637	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-34	9638-9642	used	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-35	9643-9650	without	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-36	9651-9652	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-37	9653-9663	prescribed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-38	9664-9671	purpose	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-39	9671-9672	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-40	9673-9674	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-41	9674-9675	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-42	9676-9678	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-43	9679-9687	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-44	9688-9697	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-45	9698-9708	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-46	9708-9709	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-47	9710-9711	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-48	9711-9712	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-49	9713-9715	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-50	9716-9724	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-51	9725-9734	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-52	9735-9738	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-53	9739-9742	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-54	9743-9750	medical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-55	9751-9758	reasons	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-56	9758-9759	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-57	9760-9763	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-58	9764-9765	4	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-59	9765-9766	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-60	9767-9769	no	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-61	9770-9774	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-62	9775-9784	treatment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-63	9785-9793	interest	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
47-64	9793-9794	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Participants completed three sessions: 1) a baseline diagnostic interview to determine lifetime psychiatric diagnoses and current drug use patterns (n=184); 2) a neuroimaging session completing the RGT (n=161), and 3) a follow-up interview session three years later to determine changes in drug use and clinical diagnoses (n=144).
48-1	9795-9807	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-2	9808-9817	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-3	9818-9823	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-4	9824-9832	sessions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-5	9832-9833	:	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-6	9834-9835	1	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-7	9835-9836	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-8	9837-9838	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-9	9839-9847	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-10	9848-9858	diagnostic	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-11	9859-9868	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-12	9869-9871	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-13	9872-9881	determine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-14	9882-9890	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-15	9891-9902	psychiatric	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-16	9903-9912	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-17	9913-9916	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-18	9917-9924	current	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-19	9925-9929	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-20	9930-9933	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-21	9934-9942	patterns	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-22	9943-9944	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-23	9944-9945	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-24	9945-9946	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-25	9946-9949	184	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-26	9949-9950	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-27	9950-9951	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-28	9952-9953	2	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-29	9953-9954	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-30	9955-9956	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-31	9957-9969	neuroimaging	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-32	9970-9977	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-33	9978-9988	completing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-34	9989-9992	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-35	9993-9996	RGT	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-36	9997-9998	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-37	9998-9999	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-38	9999-10000	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-39	10000-10003	161	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-40	10003-10004	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-41	10004-10005	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-42	10006-10009	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-43	10010-10011	3	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-44	10011-10012	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-45	10013-10014	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-46	10015-10024	follow-up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-47	10025-10034	interview	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-48	10035-10042	session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-49	10043-10048	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-50	10049-10054	years	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-51	10055-10060	later	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-52	10061-10063	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-53	10064-10073	determine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-54	10074-10081	changes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-55	10082-10084	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-56	10085-10089	drug	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-57	10090-10093	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-58	10094-10097	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-59	10098-10106	clinical	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-60	10107-10116	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-61	10117-10118	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-62	10118-10119	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-63	10119-10120	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-64	10120-10123	144	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-65	10123-10124	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
48-66	10124-10125	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=The present study includes data from OSU who completed all three sessions (n=144).
49-1	10126-10129	The	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-2	10130-10137	present	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-3	10138-10143	study	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-4	10144-10152	includes	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-5	10153-10157	data	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-6	10158-10162	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-7	10163-10166	OSU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-8	10167-10170	who	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-9	10171-10180	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-10	10181-10184	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-11	10185-10190	three	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-12	10191-10199	sessions	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-13	10200-10201	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-14	10201-10202	n	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-15	10202-10203	=	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-16	10203-10206	144	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-17	10206-10207	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
49-18	10207-10208	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=No OSU reported using methamphetamines at baseline; all baseline stimulant use was of cocaine and prescription stimulants.
50-1	10209-10211	No	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-2	10212-10215	OSU	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-3	10216-10224	reported	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-4	10225-10230	using	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-5	10231-10247	methamphetamines	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-6	10248-10250	at	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-7	10251-10259	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-8	10259-10260	;	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-9	10261-10264	all	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-10	10265-10273	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-11	10274-10283	stimulant	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-12	10284-10287	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-13	10288-10291	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-14	10292-10294	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-15	10295-10302	cocaine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-16	10303-10306	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-17	10307-10319	prescription	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-18	10320-10330	stimulants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
50-19	10330-10331	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Baseline Session
#Text=Participants were screened for lifetime DSM-IV Axis I diagnoses (including attention deficit hyperactivity disorder (ADHD), and substance abuse/dependence) and Axis II antisocial personality disorder by the Semi-Structured Assessment for the Genetics of Alcoholism II, and administered the Wechsler Test of Adult Reading, a verbal intelligence measure (IQ).
51-1	10332-10340	Baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-2	10341-10348	Session	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-3	10349-10361	Participants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-4	10362-10366	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-5	10367-10375	screened	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-6	10376-10379	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-7	10380-10388	lifetime	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-8	10389-10395	DSM-IV	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-9	10396-10400	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-10	10401-10402	I	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-11	10403-10412	diagnoses	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-12	10413-10414	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-13	10414-10423	including	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-14	10424-10433	attention	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[5]	
51-15	10434-10441	deficit	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[5]	
51-16	10442-10455	hyperactivity	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[5]	
51-17	10456-10464	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[5]	
51-18	10465-10466	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[5]	
51-19	10466-10470	ADHD	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[5]	
51-20	10470-10471	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]|http://maven.renci.org/NeuroBridge/neurobridge#AttentionDeficitHyperactivityDisorder[5]	
51-21	10471-10472	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-22	10473-10476	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-23	10477-10486	substance	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-24	10487-10492	abuse	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-25	10492-10493	/	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-26	10493-10503	dependence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-27	10503-10504	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-28	10505-10508	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-29	10509-10513	Axis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-30	10514-10516	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-31	10517-10527	antisocial	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-32	10528-10539	personality	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-33	10540-10548	disorder	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-34	10549-10551	by	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-35	10552-10555	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-36	10556-10571	Semi-Structured	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-37	10572-10582	Assessment	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-38	10583-10586	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-39	10587-10590	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-40	10591-10599	Genetics	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-41	10600-10602	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-42	10603-10613	Alcoholism	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-43	10614-10616	II	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-44	10616-10617	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-45	10618-10621	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-46	10622-10634	administered	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-47	10635-10638	the	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-48	10639-10647	Wechsler	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-49	10648-10652	Test	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-50	10653-10655	of	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-51	10656-10661	Adult	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-52	10662-10669	Reading	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-53	10669-10670	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-54	10671-10672	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-55	10673-10679	verbal	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-56	10680-10692	intelligence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-57	10693-10700	measure	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-58	10701-10702	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-59	10702-10704	IQ	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-60	10704-10705	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
51-61	10705-10706	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Exclusion criteria is outlined in Stewart et al. and is included as supplemental information.
52-1	10707-10716	Exclusion	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-2	10717-10725	criteria	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-3	10726-10728	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-4	10729-10737	outlined	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-5	10738-10740	in	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-6	10741-10748	Stewart	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-7	10749-10751	et	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-8	10752-10754	al	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-9	10754-10755	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-10	10756-10759	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-11	10760-10762	is	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-12	10763-10771	included	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-13	10772-10774	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-14	10775-10787	supplemental	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-15	10788-10799	information	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
52-16	10799-10800	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Subjects completed a baseline urine toxicology screen and were excluded if they tested positive for stimulants (thereby avoiding confounding effects from recent use).
53-1	10801-10809	Subjects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-2	10810-10819	completed	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-3	10820-10821	a	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-4	10822-10830	baseline	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-5	10831-10836	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-6	10837-10847	toxicology	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-7	10848-10854	screen	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-8	10855-10858	and	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-9	10859-10863	were	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-10	10864-10872	excluded	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-11	10873-10875	if	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-12	10876-10880	they	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-13	10881-10887	tested	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-14	10888-10896	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-15	10897-10900	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-16	10901-10911	stimulants	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-17	10912-10913	(	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-18	10913-10920	thereby	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-19	10921-10929	avoiding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-20	10930-10941	confounding	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-21	10942-10949	effects	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-22	10950-10954	from	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-23	10955-10961	recent	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-24	10962-10965	use	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-25	10965-10966	)	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
53-26	10966-10967	.	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	

#Text=Testing positive for cannabis was not exclusionary, as its urine presence may last up to 6 weeks.
54-1	10968-10975	Testing	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-2	10976-10984	positive	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-3	10985-10988	for	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-4	10989-10997	cannabis	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-5	10998-11001	was	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-6	11002-11005	not	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-7	11006-11018	exclusionary	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-8	11018-11019	,	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-9	11020-11022	as	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-10	11023-11026	its	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-11	11027-11032	urine	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-12	11033-11041	presence	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-13	11042-11045	may	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-14	11046-11050	last	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-15	11051-11053	up	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-16	11054-11056	to	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-17	11057-11058	6	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-18	11059-11064	weeks	http://maven.renci.org/NeuroBridge/neurobridge#RecruitmentProtocol[4]	
54-19	11064-11065	.	_	

#Text=Risky Gains Task (RGT)
#Text=The RGT (illustrated in Figure 2) has been previously described by our experimental group.
55-1	11066-11071	Risky	_	
55-2	11072-11077	Gains	_	
55-3	11078-11082	Task	_	
55-4	11083-11084	(	_	
55-5	11084-11087	RGT	_	
55-6	11087-11088	)	_	
55-7	11089-11092	The	_	
55-8	11093-11096	RGT	_	
55-9	11097-11098	(	_	
55-10	11098-11109	illustrated	_	
55-11	11110-11112	in	_	
55-12	11113-11119	Figure	_	
55-13	11120-11121	2	_	
55-14	11121-11122	)	_	
55-15	11123-11126	has	_	
55-16	11127-11131	been	_	
55-17	11132-11142	previously	_	
55-18	11143-11152	described	_	
55-19	11153-11155	by	_	
55-20	11156-11159	our	_	
55-21	11160-11172	experimental	_	
55-22	11173-11178	group	_	
55-23	11178-11179	.	_	

#Text=On each trial, participants were shown the numbers 20, 40, and 80 in increasing order, which represented the number of cents to be added to their total.
56-1	11180-11182	On	_	
56-2	11183-11187	each	_	
56-3	11188-11193	trial	_	
56-4	11193-11194	,	_	
56-5	11195-11207	participants	_	
56-6	11208-11212	were	_	
56-7	11213-11218	shown	_	
56-8	11219-11222	the	_	
56-9	11223-11230	numbers	_	
56-10	11231-11233	20	_	
56-11	11233-11234	,	_	
56-12	11235-11237	40	_	
56-13	11237-11238	,	_	
56-14	11239-11242	and	_	
56-15	11243-11245	80	_	
56-16	11246-11248	in	_	
56-17	11249-11259	increasing	_	
56-18	11260-11265	order	_	
56-19	11265-11266	,	_	
56-20	11267-11272	which	_	
56-21	11273-11284	represented	_	
56-22	11285-11288	the	_	
56-23	11289-11295	number	_	
56-24	11296-11298	of	_	
56-25	11299-11304	cents	_	
56-26	11305-11307	to	_	
56-27	11308-11310	be	_	
56-28	11311-11316	added	_	
56-29	11317-11319	to	_	
56-30	11320-11325	their	_	
56-31	11326-11331	total	_	
56-32	11331-11332	.	_	

#Text=Participants were informed that 20 was always the “safe option” but that they had the option to wait 1s to receive 40 cents or wait an additional second to receive 80 cents.
57-1	11333-11345	Participants	_	
57-2	11346-11350	were	_	
57-3	11351-11359	informed	_	
57-4	11360-11364	that	_	
57-5	11365-11367	20	_	
57-6	11368-11371	was	_	
57-7	11372-11378	always	_	
57-8	11379-11382	the	_	
57-9	11383-11384	“	_	
57-10	11384-11388	safe	_	
57-11	11389-11395	option	_	
57-12	11395-11396	”	_	
57-13	11397-11400	but	_	
57-14	11401-11405	that	_	
57-15	11406-11410	they	_	
57-16	11411-11414	had	_	
57-17	11415-11418	the	_	
57-18	11419-11425	option	_	
57-19	11426-11428	to	_	
57-20	11429-11433	wait	_	
57-21	11434-11436	1s	_	
57-22	11437-11439	to	_	
57-23	11440-11447	receive	_	
57-24	11448-11450	40	_	
57-25	11451-11456	cents	_	
57-26	11457-11459	or	_	
57-27	11460-11464	wait	_	
57-28	11465-11467	an	_	
57-29	11468-11478	additional	_	
57-30	11479-11485	second	_	
57-31	11486-11488	to	_	
57-32	11489-11496	receive	_	
57-33	11497-11499	80	_	
57-34	11500-11505	cents	_	
57-35	11505-11506	.	_	

#Text=They were also informed of the potential that 40 or 80 would appear in red font, denoting actual losses of money (-40 or -80) from the total score; 40 and 80 were explicitly called “risky options.”
58-1	11507-11511	They	_	
58-2	11512-11516	were	_	
58-3	11517-11521	also	_	
58-4	11522-11530	informed	_	
58-5	11531-11533	of	_	
58-6	11534-11537	the	_	
58-7	11538-11547	potential	_	
58-8	11548-11552	that	_	
58-9	11553-11555	40	_	
58-10	11556-11558	or	_	
58-11	11559-11561	80	_	
58-12	11562-11567	would	_	
58-13	11568-11574	appear	_	
58-14	11575-11577	in	_	
58-15	11578-11581	red	_	
58-16	11582-11586	font	_	
58-17	11586-11587	,	_	
58-18	11588-11596	denoting	_	
58-19	11597-11603	actual	_	
58-20	11604-11610	losses	_	
58-21	11611-11613	of	_	
58-22	11614-11619	money	_	
58-23	11620-11621	(	_	
58-24	11621-11622	-	_	
58-25	11622-11624	40	_	
58-26	11625-11627	or	_	
58-27	11628-11629	-	_	
58-28	11629-11631	80	_	
58-29	11631-11632	)	_	
58-30	11633-11637	from	_	
58-31	11638-11641	the	_	
58-32	11642-11647	total	_	
58-33	11648-11653	score	_	
58-34	11653-11654	;	_	
58-35	11655-11657	40	_	
58-36	11658-11661	and	_	
58-37	11662-11664	80	_	
58-38	11665-11669	were	_	
58-39	11670-11680	explicitly	_	
58-40	11681-11687	called	_	
58-41	11688-11689	“	_	
58-42	11689-11694	risky	_	
58-43	11695-11702	options	_	
58-44	11702-11703	.	_	
58-45	11703-11704	”	_	

#Text=Unknown to subjects, −40 and −80 outcome frequencies were predefined so that the final gain was identical regardless of whether they selected 20, 40, or 80 cents.
59-1	11705-11712	Unknown	_	
59-2	11713-11715	to	_	
59-3	11716-11724	subjects	_	
59-4	11724-11725	,	_	
59-5	11726-11727	−	_	
59-6	11727-11729	40	_	
59-7	11730-11733	and	_	
59-8	11734-11735	−	_	
59-9	11735-11737	80	_	
59-10	11738-11745	outcome	_	
59-11	11746-11757	frequencies	_	
59-12	11758-11762	were	_	
59-13	11763-11773	predefined	_	
59-14	11774-11776	so	_	
59-15	11777-11781	that	_	
59-16	11782-11785	the	_	
59-17	11786-11791	final	_	
59-18	11792-11796	gain	_	
59-19	11797-11800	was	_	
59-20	11801-11810	identical	_	
59-21	11811-11821	regardless	_	
59-22	11822-11824	of	_	
59-23	11825-11832	whether	_	
59-24	11833-11837	they	_	
59-25	11838-11846	selected	_	
59-26	11847-11849	20	_	
59-27	11849-11850	,	_	
59-28	11851-11853	40	_	
59-29	11853-11854	,	_	
59-30	11855-11857	or	_	
59-31	11858-11860	80	_	
59-32	11861-11866	cents	_	
59-33	11866-11867	.	_	

#Text=That is, there was no actual advantage of selecting risky compared to safe options.
60-1	11868-11872	That	_	
60-2	11873-11875	is	_	
60-3	11875-11876	,	_	
60-4	11877-11882	there	_	
60-5	11883-11886	was	_	
60-6	11887-11889	no	_	
60-7	11890-11896	actual	_	
60-8	11897-11906	advantage	_	
60-9	11907-11909	of	_	
60-10	11910-11919	selecting	_	
60-11	11920-11925	risky	_	
60-12	11926-11934	compared	_	
60-13	11935-11937	to	_	
60-14	11938-11942	safe	_	
60-15	11943-11950	options	_	
60-16	11950-11951	.	_	

#Text=Participants were told that a positive value had to be collected via an index finger button press within a subsequent 1s window.
61-1	11952-11964	Participants	_	
61-2	11965-11969	were	_	
61-3	11970-11974	told	_	
61-4	11975-11979	that	_	
61-5	11980-11981	a	_	
61-6	11982-11990	positive	_	
61-7	11991-11996	value	_	
61-8	11997-12000	had	_	
61-9	12001-12003	to	_	
61-10	12004-12006	be	_	
61-11	12007-12016	collected	_	
61-12	12017-12020	via	_	
61-13	12021-12023	an	_	
61-14	12024-12029	index	_	
61-15	12030-12036	finger	_	
61-16	12037-12043	button	_	
61-17	12044-12049	press	_	
61-18	12050-12056	within	_	
61-19	12057-12058	a	_	
61-20	12059-12069	subsequent	_	
61-21	12070-12072	1s	_	
61-22	12073-12079	window	_	
61-23	12079-12080	.	_	

#Text=A press outside of that timeframe would result in a loss.
62-1	12081-12082	A	_	
62-2	12083-12088	press	_	
62-3	12089-12096	outside	_	
62-4	12097-12099	of	_	
62-5	12100-12104	that	_	
62-6	12105-12114	timeframe	_	
62-7	12115-12120	would	_	
62-8	12121-12127	result	_	
62-9	12128-12130	in	_	
62-10	12131-12132	a	_	
62-11	12133-12137	loss	_	
62-12	12137-12138	.	_	

#Text=The 1s length was chosen to allow slow-responding individuals to collect an option.
63-1	12139-12142	The	_	
63-2	12143-12145	1s	_	
63-3	12146-12152	length	_	
63-4	12153-12156	was	_	
63-5	12157-12163	chosen	_	
63-6	12164-12166	to	_	
63-7	12167-12172	allow	_	
63-8	12173-12188	slow-responding	_	
63-9	12189-12200	individuals	_	
63-10	12201-12203	to	_	
63-11	12204-12211	collect	_	
63-12	12212-12214	an	_	
63-13	12215-12221	option	_	
63-14	12221-12222	.	_	

#Text=Auditory and visual feedback (“yay”/“You win” for wins and “yuck”/“You lose” for losses) followed each choice.
64-1	12223-12231	Auditory	_	
64-2	12232-12235	and	_	
64-3	12236-12242	visual	_	
64-4	12243-12251	feedback	_	
64-5	12252-12253	(	_	
64-6	12253-12254	“	_	
64-7	12254-12257	yay	_	
64-8	12257-12258	”	_	
64-9	12258-12259	/	_	
64-10	12259-12260	“	_	
64-11	12260-12263	You	_	
64-12	12264-12267	win	_	
64-13	12267-12268	”	_	
64-14	12269-12272	for	_	
64-15	12273-12277	wins	_	
64-16	12278-12281	and	_	
64-17	12282-12283	“	_	
64-18	12283-12287	yuck	_	
64-19	12287-12288	”	_	
64-20	12288-12289	/	_	
64-21	12289-12290	“	_	
64-22	12290-12293	You	_	
64-23	12294-12298	lose	_	
64-24	12298-12299	”	_	
64-25	12300-12303	for	_	
64-26	12304-12310	losses	_	
64-27	12310-12311	)	_	
64-28	12312-12320	followed	_	
64-29	12321-12325	each	_	
64-30	12326-12332	choice	_	
64-31	12332-12333	.	_	

#Text=Cumulative total (in dollars) was displayed after trial completion to allow performance monitoring.
65-1	12334-12344	Cumulative	_	
65-2	12345-12350	total	_	
65-3	12351-12352	(	_	
65-4	12352-12354	in	_	
65-5	12355-12362	dollars	_	
65-6	12362-12363	)	_	
65-7	12364-12367	was	_	
65-8	12368-12377	displayed	_	
65-9	12378-12383	after	_	
65-10	12384-12389	trial	_	
65-11	12390-12400	completion	_	
65-12	12401-12403	to	_	
65-13	12404-12409	allow	_	
65-14	12410-12421	performance	_	
65-15	12422-12432	monitoring	_	
65-16	12432-12433	.	_	

#Text=The task consisted of 96 trials lasting 3.5s each.
66-1	12434-12437	The	_	
66-2	12438-12442	task	_	
66-3	12443-12452	consisted	_	
66-4	12453-12455	of	_	
66-5	12456-12458	96	_	
66-6	12459-12465	trials	_	
66-7	12466-12473	lasting	_	
66-8	12474-12478	3.5s	_	
66-9	12479-12483	each	_	
66-10	12483-12484	.	_	

#Text=Three trial types were presented in a pre-set randomized order: 54 rewarded (+20, +40, +80), 24 punished −40, and 18 punished −80 trials.
67-1	12485-12490	Three	_	
67-2	12491-12496	trial	_	
67-3	12497-12502	types	_	
67-4	12503-12507	were	_	
67-5	12508-12517	presented	_	
67-6	12518-12520	in	_	
67-7	12521-12522	a	_	
67-8	12523-12530	pre-set	_	
67-9	12531-12541	randomized	_	
67-10	12542-12547	order	_	
67-11	12547-12548	:	_	
67-12	12549-12551	54	_	
67-13	12552-12560	rewarded	_	
67-14	12561-12562	(	_	
67-15	12562-12563	+	_	
67-16	12563-12565	20	_	
67-17	12565-12566	,	_	
67-18	12567-12568	+	_	
67-19	12568-12570	40	_	
67-20	12570-12571	,	_	
67-21	12572-12573	+	_	
67-22	12573-12575	80	_	
67-23	12575-12576	)	_	
67-24	12576-12577	,	_	
67-25	12578-12580	24	_	
67-26	12581-12589	punished	_	
67-27	12590-12591	−	_	
67-28	12591-12593	40	_	
67-29	12593-12594	,	_	
67-30	12595-12598	and	_	
67-31	12599-12601	18	_	
67-32	12602-12610	punished	_	
67-33	12611-12612	−	_	
67-34	12612-12614	80	_	
67-35	12615-12621	trials	_	
67-36	12621-12622	.	_	

#Text=In addition to potential losses due to slow or non-responses on rewarded trials, the RGT design led to each participant receiving a different amount of −40 and −80 trials.
68-1	12623-12625	In	_	
68-2	12626-12634	addition	_	
68-3	12635-12637	to	_	
68-4	12638-12647	potential	_	
68-5	12648-12654	losses	_	
68-6	12655-12658	due	_	
68-7	12659-12661	to	_	
68-8	12662-12666	slow	_	
68-9	12667-12669	or	_	
68-10	12670-12683	non-responses	_	
68-11	12684-12686	on	_	
68-12	12687-12695	rewarded	_	
68-13	12696-12702	trials	_	
68-14	12702-12703	,	_	
68-15	12704-12707	the	_	
68-16	12708-12711	RGT	_	
68-17	12712-12718	design	_	
68-18	12719-12722	led	_	
68-19	12723-12725	to	_	
68-20	12726-12730	each	_	
68-21	12731-12742	participant	_	
68-22	12743-12752	receiving	_	
68-23	12753-12754	a	_	
68-24	12755-12764	different	_	
68-25	12765-12771	amount	_	
68-26	12772-12774	of	_	
68-27	12775-12776	−	_	
68-28	12776-12778	40	_	
68-29	12779-12782	and	_	
68-30	12783-12784	−	_	
68-31	12784-12786	80	_	
68-32	12787-12793	trials	_	
68-33	12793-12794	.	_	

#Text=If a participant pressed to collect 20 on a trial meant to be a −40 trial, or tried to collect 20 or 40 on a dedicated −80 trial, the subject received the collected amount, therein reducing the number of punished trials.
69-1	12795-12797	If	_	
69-2	12798-12799	a	_	
69-3	12800-12811	participant	_	
69-4	12812-12819	pressed	_	
69-5	12820-12822	to	_	
69-6	12823-12830	collect	_	
69-7	12831-12833	20	_	
69-8	12834-12836	on	_	
69-9	12837-12838	a	_	
69-10	12839-12844	trial	_	
69-11	12845-12850	meant	_	
69-12	12851-12853	to	_	
69-13	12854-12856	be	_	
69-14	12857-12858	a	_	
69-15	12859-12860	−	_	
69-16	12860-12862	40	_	
69-17	12863-12868	trial	_	
69-18	12868-12869	,	_	
69-19	12870-12872	or	_	
69-20	12873-12878	tried	_	
69-21	12879-12881	to	_	
69-22	12882-12889	collect	_	
69-23	12890-12892	20	_	
69-24	12893-12895	or	_	
69-25	12896-12898	40	_	
69-26	12899-12901	on	_	
69-27	12902-12903	a	_	
69-28	12904-12913	dedicated	_	
69-29	12914-12915	−	_	
69-30	12915-12917	80	_	
69-31	12918-12923	trial	_	
69-32	12923-12924	,	_	
69-33	12925-12928	the	_	
69-34	12929-12936	subject	_	
69-35	12937-12945	received	_	
69-36	12946-12949	the	_	
69-37	12950-12959	collected	_	
69-38	12960-12966	amount	_	
69-39	12966-12967	,	_	
69-40	12968-12975	therein	_	
69-41	12976-12984	reducing	_	
69-42	12985-12988	the	_	
69-43	12989-12995	number	_	
69-44	12996-12998	of	_	
69-45	12999-13007	punished	_	
69-46	13008-13014	trials	_	
69-47	13014-13015	.	_	

#Text=Image Acquisition
#Text=The scanning session lasted approximately 60m and included an anatomical scan as well as four functional tasks: Stop-Signal, Paper Rock Scissors, two choice prediction, and RGT.
70-1	13016-13021	Image	_	
70-2	13022-13033	Acquisition	_	
70-3	13034-13037	The	_	
70-4	13038-13046	scanning	_	
70-5	13047-13054	session	_	
70-6	13055-13061	lasted	_	
70-7	13062-13075	approximately	_	
70-8	13076-13079	60m	_	
70-9	13080-13083	and	_	
70-10	13084-13092	included	_	
70-11	13093-13095	an	_	
70-12	13096-13106	anatomical	_	
70-13	13107-13111	scan	_	
70-14	13112-13114	as	_	
70-15	13115-13119	well	_	
70-16	13120-13122	as	_	
70-17	13123-13127	four	_	
70-18	13128-13138	functional	_	
70-19	13139-13144	tasks	_	
70-20	13144-13145	:	_	
70-21	13146-13157	Stop-Signal	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-22	13157-13158	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-23	13159-13164	Paper	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-24	13165-13169	Rock	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-25	13170-13178	Scissors	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-26	13178-13179	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-27	13180-13183	two	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-28	13184-13190	choice	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-29	13191-13201	prediction	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-30	13201-13202	,	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-31	13203-13206	and	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-32	13207-13210	RGT	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging[6]	
70-33	13210-13211	.	_	

#Text=Prior to scanner entry, a brief RGT training session was conducted.
71-1	13212-13217	Prior	_	
71-2	13218-13220	to	_	
71-3	13221-13228	scanner	_	
71-4	13229-13234	entry	_	
71-5	13234-13235	,	_	
71-6	13236-13237	a	_	
71-7	13238-13243	brief	_	
71-8	13244-13247	RGT	_	
71-9	13248-13256	training	_	
71-10	13257-13264	session	_	
71-11	13265-13268	was	_	
71-12	13269-13278	conducted	_	
71-13	13278-13279	.	_	

#Text=The RGT was administered as a randomized fast-event related design, time-locked to the onset of 256 whole brain acquisitions (T2*-weighted EPI on a Signa EXCITE, GE Healthcare, Milwaukee, Wisconsin, 3T scanner; TR = 2000 ms, TE = 32ms, FoV = 230x230 mm2, 64x64 matrix, 30 2.6-mm axial slices, 1.4 mm gap, flip angle= 90°, duration: 8m, 32s).
72-1	13280-13283	The	_	
72-2	13284-13287	RGT	_	
72-3	13288-13291	was	_	
72-4	13292-13304	administered	_	
72-5	13305-13307	as	_	
72-6	13308-13309	a	_	
72-7	13310-13320	randomized	_	
72-8	13321-13331	fast-event	_	
72-9	13332-13339	related	_	
72-10	13340-13346	design	_	
72-11	13346-13347	,	_	
72-12	13348-13359	time-locked	_	
72-13	13360-13362	to	_	
72-14	13363-13366	the	_	
72-15	13367-13372	onset	_	
72-16	13373-13375	of	_	
72-17	13376-13379	256	_	
72-18	13380-13385	whole	_	
72-19	13386-13391	brain	_	
72-20	13392-13404	acquisitions	_	
72-21	13405-13406	(	_	
72-22	13406-13408	T2	_	
72-23	13408-13409	*	_	
72-24	13409-13410	-	_	
72-25	13410-13418	weighted	_	
72-26	13419-13422	EPI	_	
72-27	13423-13425	on	_	
72-28	13426-13427	a	_	
72-29	13428-13433	Signa	_	
72-30	13434-13440	EXCITE	_	
72-31	13440-13441	,	_	
72-32	13442-13444	GE	_	
72-33	13445-13455	Healthcare	_	
72-34	13455-13456	,	_	
72-35	13457-13466	Milwaukee	_	
72-36	13466-13467	,	_	
72-37	13468-13477	Wisconsin	_	
72-38	13477-13478	,	_	
72-39	13479-13481	3T	_	
72-40	13482-13489	scanner	_	
72-41	13489-13490	;	_	
72-42	13491-13493	TR	_	
72-43	13494-13495	=	_	
72-44	13496-13500	2000	_	
72-45	13501-13503	ms	_	
72-46	13503-13504	,	_	
72-47	13505-13507	TE	_	
72-48	13508-13509	=	_	
72-49	13510-13514	32ms	_	
72-50	13514-13515	,	_	
72-51	13516-13519	FoV	_	
72-52	13520-13521	=	_	
72-53	13522-13529	230x230	_	
72-54	13530-13533	mm2	_	
72-55	13533-13534	,	_	
72-56	13535-13540	64x64	_	
72-57	13541-13547	matrix	_	
72-58	13547-13548	,	_	
72-59	13549-13551	30	_	
72-60	13552-13555	2.6	_	
72-61	13555-13556	-	_	
72-62	13556-13558	mm	_	
72-63	13559-13564	axial	_	
72-64	13565-13571	slices	_	
72-65	13571-13572	,	_	
72-66	13573-13576	1.4	_	
72-67	13577-13579	mm	_	
72-68	13580-13583	gap	_	
72-69	13583-13584	,	_	
72-70	13585-13589	flip	_	
72-71	13590-13595	angle	_	
72-72	13595-13596	=	_	
72-73	13597-13599	90	_	
72-74	13599-13600	°	_	
72-75	13600-13601	,	_	
72-76	13602-13610	duration	_	
72-77	13610-13611	:	_	
72-78	13612-13614	8m	_	
72-79	13614-13615	,	_	
72-80	13616-13619	32s	_	
72-81	13619-13620	)	_	
72-82	13620-13621	.	_	

#Text=Six resting-state trials were intermixed throughout the 96 trials and were not used in analysis.
73-1	13622-13625	Six	_	
73-2	13626-13639	resting-state	_	
73-3	13640-13646	trials	_	
73-4	13647-13651	were	_	
73-5	13652-13662	intermixed	_	
73-6	13663-13673	throughout	_	
73-7	13674-13677	the	_	
73-8	13678-13680	96	_	
73-9	13681-13687	trials	_	
73-10	13688-13691	and	_	
73-11	13692-13696	were	_	
73-12	13697-13700	not	_	
73-13	13701-13705	used	_	
73-14	13706-13708	in	_	
73-15	13709-13717	analysis	_	
73-16	13717-13718	.	_	

#Text=A high-resolution T1-weight image (TR = 8ms, TE =3msec, FoV = 250x250 mm2, 192x256 matrix interpolated to a 256x256 matrix, flip angle= 12°, 172 sagittally acquired slices, .97x.97x1 mm3 voxels) was also obtained as a reference.
74-1	13719-13720	A	_	
74-2	13721-13736	high-resolution	_	
74-3	13737-13739	T1	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[7]	
74-4	13739-13740	-	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[7]	
74-5	13740-13746	weight	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging[7]	
74-6	13747-13752	image	_	
74-7	13753-13754	(	_	
74-8	13754-13756	TR	_	
74-9	13757-13758	=	_	
74-10	13759-13762	8ms	_	
74-11	13762-13763	,	_	
74-12	13764-13766	TE	_	
74-13	13767-13768	=	_	
74-14	13768-13773	3msec	_	
74-15	13773-13774	,	_	
74-16	13775-13778	FoV	_	
74-17	13779-13780	=	_	
74-18	13781-13788	250x250	_	
74-19	13789-13792	mm2	_	
74-20	13792-13793	,	_	
74-21	13794-13801	192x256	_	
74-22	13802-13808	matrix	_	
74-23	13809-13821	interpolated	_	
74-24	13822-13824	to	_	
74-25	13825-13826	a	_	
74-26	13827-13834	256x256	_	
74-27	13835-13841	matrix	_	
74-28	13841-13842	,	_	
74-29	13843-13847	flip	_	
74-30	13848-13853	angle	_	
74-31	13853-13854	=	_	
74-32	13855-13857	12	_	
74-33	13857-13858	°	_	
74-34	13858-13859	,	_	
74-35	13860-13863	172	_	
74-36	13864-13874	sagittally	_	
74-37	13875-13883	acquired	_	
74-38	13884-13890	slices	_	
74-39	13890-13891	,	_	
74-40	13892-13896	.97x	_	
74-41	13896-13901	.97x1	_	
74-42	13902-13905	mm3	_	
74-43	13906-13912	voxels	_	
74-44	13912-13913	)	_	
74-45	13914-13917	was	_	
74-46	13918-13922	also	_	
74-47	13923-13931	obtained	_	
74-48	13932-13934	as	_	
74-49	13935-13936	a	_	
74-50	13937-13946	reference	_	
74-51	13946-13947	.	_	

#Text=Three Year Follow-Up Interview
#Text=OSU participated in another standardized interview three years after their baseline sessions (Figure 1), by phone or in-person, to assess drug use severity in the interim period.
75-1	13948-13953	Three	_	
75-2	13954-13958	Year	_	
75-3	13959-13968	Follow-Up	_	
75-4	13969-13978	Interview	_	
75-5	13979-13982	OSU	_	
75-6	13983-13995	participated	_	
75-7	13996-13998	in	_	
75-8	13999-14006	another	_	
75-9	14007-14019	standardized	_	
75-10	14020-14029	interview	_	
75-11	14030-14035	three	_	
75-12	14036-14041	years	_	
75-13	14042-14047	after	_	
75-14	14048-14053	their	_	
75-15	14054-14062	baseline	_	
75-16	14063-14071	sessions	_	
75-17	14072-14073	(	_	
75-18	14073-14079	Figure	_	
75-19	14080-14081	1	_	
75-20	14081-14082	)	_	
75-21	14082-14083	,	_	
75-22	14084-14086	by	_	
75-23	14087-14092	phone	_	
75-24	14093-14095	or	_	
75-25	14096-14105	in-person	_	
75-26	14105-14106	,	_	
75-27	14107-14109	to	_	
75-28	14110-14116	assess	_	
75-29	14117-14121	drug	_	
75-30	14122-14125	use	_	
75-31	14126-14134	severity	_	
75-32	14135-14137	in	_	
75-33	14138-14141	the	_	
75-34	14142-14149	interim	_	
75-35	14150-14156	period	_	
75-36	14156-14157	.	_	

#Text=Analyses were conducted using both categorical and dimensional definitions of interim stimulant use as recommended by Rabin and Moeller.
76-1	14158-14166	Analyses	_	
76-2	14167-14171	were	_	
76-3	14172-14181	conducted	_	
76-4	14182-14187	using	_	
76-5	14188-14192	both	_	
76-6	14193-14204	categorical	_	
76-7	14205-14208	and	_	
76-8	14209-14220	dimensional	_	
76-9	14221-14232	definitions	_	
76-10	14233-14235	of	_	
76-11	14236-14243	interim	_	
76-12	14244-14253	stimulant	_	
76-13	14254-14257	use	_	
76-14	14258-14260	as	_	
76-15	14261-14272	recommended	_	
76-16	14273-14275	by	_	
76-17	14276-14281	Rabin	_	
76-18	14282-14285	and	_	
76-19	14286-14293	Moeller	_	
76-20	14293-14294	.	_	

#Text=For categorical analyses, participants were grouped into two categories: PSU or DSU.
77-1	14295-14298	For	_	
77-2	14299-14310	categorical	_	
77-3	14311-14319	analyses	_	
77-4	14319-14320	,	_	
77-5	14321-14333	participants	_	
77-6	14334-14338	were	_	
77-7	14339-14346	grouped	_	
77-8	14347-14351	into	_	
77-9	14352-14355	two	_	
77-10	14356-14366	categories	_	
77-11	14366-14367	:	_	
77-12	14368-14371	PSU	_	
77-13	14372-14374	or	_	
77-14	14375-14378	DSU	_	
77-15	14378-14379	.	_	

#Text=PSU (n=35) were a priori defined based on the current DSM-V criteria for SUD: 1) continued stimulant use since baseline; and 2) endorsement of 2+ DSM-IV symptoms of stimulant abuse or dependence occurring together for 6+ consecutive interim months.
78-1	14380-14383	PSU	_	
78-2	14384-14385	(	_	
78-3	14385-14386	n	_	
78-4	14386-14387	=	_	
78-5	14387-14389	35	_	
78-6	14389-14390	)	_	
78-7	14391-14395	were	_	
78-8	14396-14397	a	_	
78-9	14398-14404	priori	_	
78-10	14405-14412	defined	_	
78-11	14413-14418	based	_	
78-12	14419-14421	on	_	
78-13	14422-14425	the	_	
78-14	14426-14433	current	_	
78-15	14434-14439	DSM-V	_	
78-16	14440-14448	criteria	_	
78-17	14449-14452	for	_	
78-18	14453-14456	SUD	_	
78-19	14456-14457	:	_	
78-20	14458-14459	1	_	
78-21	14459-14460	)	_	
78-22	14461-14470	continued	_	
78-23	14471-14480	stimulant	_	
78-24	14481-14484	use	_	
78-25	14485-14490	since	_	
78-26	14491-14499	baseline	_	
78-27	14499-14500	;	_	
78-28	14501-14504	and	_	
78-29	14505-14506	2	_	
78-30	14506-14507	)	_	
78-31	14508-14519	endorsement	_	
78-32	14520-14522	of	_	
78-33	14523-14524	2	_	
78-34	14524-14525	+	_	
78-35	14526-14532	DSM-IV	_	
78-36	14533-14541	symptoms	_	
78-37	14542-14544	of	_	
78-38	14545-14554	stimulant	_	
78-39	14555-14560	abuse	_	
78-40	14561-14563	or	_	
78-41	14564-14574	dependence	_	
78-42	14575-14584	occurring	_	
78-43	14585-14593	together	_	
78-44	14594-14597	for	_	
78-45	14598-14599	6	_	
78-46	14599-14600	+	_	
78-47	14601-14612	consecutive	_	
78-48	14613-14620	interim	_	
78-49	14621-14627	months	_	
78-50	14627-14628	.	_	

#Text=Within PSU, 51% met criteria for cocaine abuse, 23% met criteria for cocaine dependence, 46% met criteria for amphetamine abuse and 17% met criteria for amphetamine dependence.
79-1	14629-14635	Within	_	
79-2	14636-14639	PSU	_	
79-3	14639-14640	,	_	
79-4	14641-14644	51%	_	
79-5	14645-14648	met	_	
79-6	14649-14657	criteria	_	
79-7	14658-14661	for	_	
79-8	14662-14669	cocaine	_	
79-9	14670-14675	abuse	_	
79-10	14675-14676	,	_	
79-11	14677-14680	23%	_	
79-12	14681-14684	met	_	
79-13	14685-14693	criteria	_	
79-14	14694-14697	for	_	
79-15	14698-14705	cocaine	_	
79-16	14706-14716	dependence	_	
79-17	14716-14717	,	_	
79-18	14718-14721	46%	_	
79-19	14722-14725	met	_	
79-20	14726-14734	criteria	_	
79-21	14735-14738	for	_	
79-22	14739-14750	amphetamine	_	
79-23	14751-14756	abuse	_	
79-24	14757-14760	and	_	
79-25	14761-14764	17%	_	
79-26	14765-14768	met	_	
79-27	14769-14777	criteria	_	
79-28	14778-14781	for	_	
79-29	14782-14793	amphetamine	_	
79-30	14794-14804	dependence	_	
79-31	14804-14805	.	_	

#Text=DSU (n=75) were defined based on the emphasis of the choice to desist as a critical part of addiction recovery models and in the prevention of transition to SUD: 1) no 6-month periods of 3+ stimulant uses; and 2) no endorsement of interim SUD symptoms.
80-1	14806-14809	DSU	_	
80-2	14810-14811	(	_	
80-3	14811-14812	n	_	
80-4	14812-14813	=	_	
80-5	14813-14815	75	_	
80-6	14815-14816	)	_	
80-7	14817-14821	were	_	
80-8	14822-14829	defined	_	
80-9	14830-14835	based	_	
80-10	14836-14838	on	_	
80-11	14839-14842	the	_	
80-12	14843-14851	emphasis	_	
80-13	14852-14854	of	_	
80-14	14855-14858	the	_	
80-15	14859-14865	choice	_	
80-16	14866-14868	to	_	
80-17	14869-14875	desist	_	
80-18	14876-14878	as	_	
80-19	14879-14880	a	_	
80-20	14881-14889	critical	_	
80-21	14890-14894	part	_	
80-22	14895-14897	of	_	
80-23	14898-14907	addiction	_	
80-24	14908-14916	recovery	_	
80-25	14917-14923	models	_	
80-26	14924-14927	and	_	
80-27	14928-14930	in	_	
80-28	14931-14934	the	_	
80-29	14935-14945	prevention	_	
80-30	14946-14948	of	_	
80-31	14949-14959	transition	_	
80-32	14960-14962	to	_	
80-33	14963-14966	SUD	_	
80-34	14966-14967	:	_	
80-35	14968-14969	1	_	
80-36	14969-14970	)	_	
80-37	14971-14973	no	_	
80-38	14974-14975	6	_	
80-39	14975-14976	-	_	
80-40	14976-14981	month	_	
80-41	14982-14989	periods	_	
80-42	14990-14992	of	_	
80-43	14993-14994	3	_	
80-44	14994-14995	+	_	
80-45	14996-15005	stimulant	_	
80-46	15006-15010	uses	_	
80-47	15010-15011	;	_	
80-48	15012-15015	and	_	
80-49	15016-15017	2	_	
80-50	15017-15018	)	_	
80-51	15019-15021	no	_	
80-52	15022-15033	endorsement	_	
80-53	15034-15036	of	_	
80-54	15037-15044	interim	_	
80-55	15045-15048	SUD	_	
80-56	15049-15057	symptoms	_	
80-57	15057-15058	.	_	

#Text=OSU who did not meet criteria for either PSU or DSU (n=34) were excluded from categorical analyses because of the highly variable nature of those who did not fit either category (e.g. met only 1 abuse/dependence criteria, used too many times in interim but no accompanying symptoms, etc.).Dimensional analyses were conducted using all OSU (n=144), wherein RGT BOLD signals were correlated with baseline and interim stimulant and marijuana uses (quantified as total sessions).
81-1	15059-15062	OSU	_	
81-2	15063-15066	who	_	
81-3	15067-15070	did	_	
81-4	15071-15074	not	_	
81-5	15075-15079	meet	_	
81-6	15080-15088	criteria	_	
81-7	15089-15092	for	_	
81-8	15093-15099	either	_	
81-9	15100-15103	PSU	_	
81-10	15104-15106	or	_	
81-11	15107-15110	DSU	_	
81-12	15111-15112	(	_	
81-13	15112-15113	n	_	
81-14	15113-15114	=	_	
81-15	15114-15116	34	_	
81-16	15116-15117	)	_	
81-17	15118-15122	were	_	
81-18	15123-15131	excluded	_	
81-19	15132-15136	from	_	
81-20	15137-15148	categorical	_	
81-21	15149-15157	analyses	_	
81-22	15158-15165	because	_	
81-23	15166-15168	of	_	
81-24	15169-15172	the	_	
81-25	15173-15179	highly	_	
81-26	15180-15188	variable	_	
81-27	15189-15195	nature	_	
81-28	15196-15198	of	_	
81-29	15199-15204	those	_	
81-30	15205-15208	who	_	
81-31	15209-15212	did	_	
81-32	15213-15216	not	_	
81-33	15217-15220	fit	_	
81-34	15221-15227	either	_	
81-35	15228-15236	category	_	
81-36	15237-15238	(	_	
81-37	15238-15241	e.g	_	
81-38	15241-15242	.	_	
81-39	15243-15246	met	_	
81-40	15247-15251	only	_	
81-41	15252-15253	1	_	
81-42	15254-15259	abuse	_	
81-43	15259-15260	/	_	
81-44	15260-15270	dependence	_	
81-45	15271-15279	criteria	_	
81-46	15279-15280	,	_	
81-47	15281-15285	used	_	
81-48	15286-15289	too	_	
81-49	15290-15294	many	_	
81-50	15295-15300	times	_	
81-51	15301-15303	in	_	
81-52	15304-15311	interim	_	
81-53	15312-15315	but	_	
81-54	15316-15318	no	_	
81-55	15319-15331	accompanying	_	
81-56	15332-15340	symptoms	_	
81-57	15340-15341	,	_	
81-58	15342-15345	etc	_	
81-59	15345-15346	.	_	
81-60	15346-15347	)	_	
81-61	15347-15348	.	_	
81-62	15348-15359	Dimensional	_	
81-63	15360-15368	analyses	_	
81-64	15369-15373	were	_	
81-65	15374-15383	conducted	_	
81-66	15384-15389	using	_	
81-67	15390-15393	all	_	
81-68	15394-15397	OSU	_	
81-69	15398-15399	(	_	
81-70	15399-15400	n	_	
81-71	15400-15401	=	_	
81-72	15401-15404	144	_	
81-73	15404-15405	)	_	
81-74	15405-15406	,	_	
81-75	15407-15414	wherein	_	
81-76	15415-15418	RGT	_	
81-77	15419-15423	BOLD	_	
81-78	15424-15431	signals	_	
81-79	15432-15436	were	_	
81-80	15437-15447	correlated	_	
81-81	15448-15452	with	_	
81-82	15453-15461	baseline	_	
81-83	15462-15465	and	_	
81-84	15466-15473	interim	_	
81-85	15474-15483	stimulant	_	
81-86	15484-15487	and	_	
81-87	15488-15497	marijuana	_	
81-88	15498-15502	uses	_	
81-89	15503-15504	(	_	
81-90	15504-15514	quantified	_	
81-91	15515-15517	as	_	
81-92	15518-15523	total	_	
81-93	15524-15532	sessions	_	
81-94	15532-15533	)	_	
81-95	15533-15534	.	_	

#Text=Data Analysis
#Text=Baseline Characteristics and Behavior
#Text=Group differences in age, IQ, education, drug use, and RGT behavior were compared in SPSS by independent samples t-tests, whereas differences in gender, race/ethnicity, and handedness were analyzed using chi-square tests (Table 1).
82-1	15535-15539	Data	_	
82-2	15540-15548	Analysis	_	
82-3	15549-15557	Baseline	_	
82-4	15558-15573	Characteristics	_	
82-5	15574-15577	and	_	
82-6	15578-15586	Behavior	_	
82-7	15587-15592	Group	_	
82-8	15593-15604	differences	_	
82-9	15605-15607	in	_	
82-10	15608-15611	age	_	
82-11	15611-15612	,	_	
82-12	15613-15615	IQ	_	
82-13	15615-15616	,	_	
82-14	15617-15626	education	_	
82-15	15626-15627	,	_	
82-16	15628-15632	drug	_	
82-17	15633-15636	use	_	
82-18	15636-15637	,	_	
82-19	15638-15641	and	_	
82-20	15642-15645	RGT	_	
82-21	15646-15654	behavior	_	
82-22	15655-15659	were	_	
82-23	15660-15668	compared	_	
82-24	15669-15671	in	_	
82-25	15672-15676	SPSS	_	
82-26	15677-15679	by	_	
82-27	15680-15691	independent	_	
82-28	15692-15699	samples	_	
82-29	15700-15707	t-tests	_	
82-30	15707-15708	,	_	
82-31	15709-15716	whereas	_	
82-32	15717-15728	differences	_	
82-33	15729-15731	in	_	
82-34	15732-15738	gender	_	
82-35	15738-15739	,	_	
82-36	15740-15744	race	_	
82-37	15744-15745	/	_	
82-38	15745-15754	ethnicity	_	
82-39	15754-15755	,	_	
82-40	15756-15759	and	_	
82-41	15760-15770	handedness	_	
82-42	15771-15775	were	_	
82-43	15776-15784	analyzed	_	
82-44	15785-15790	using	_	
82-45	15791-15801	chi-square	_	
82-46	15802-15807	tests	_	
82-47	15808-15809	(	_	
82-48	15809-15814	Table	_	
82-49	15815-15816	1	_	
82-50	15816-15817	)	_	
82-51	15817-15818	.	_	

#Text=To evaluate whether follow-up status differed as a function of baseline preferred stimulant type (cocaine versus prescription amphetamines) or in relation to the history of/presence of comorbid alcohol and marijuana abuse or dependence, chi-square analyses were performed.
83-1	15819-15821	To	_	
83-2	15822-15830	evaluate	_	
83-3	15831-15838	whether	_	
83-4	15839-15848	follow-up	_	
83-5	15849-15855	status	_	
83-6	15856-15864	differed	_	
83-7	15865-15867	as	_	
83-8	15868-15869	a	_	
83-9	15870-15878	function	_	
83-10	15879-15881	of	_	
83-11	15882-15890	baseline	_	
83-12	15891-15900	preferred	_	
83-13	15901-15910	stimulant	_	
83-14	15911-15915	type	_	
83-15	15916-15917	(	_	
83-16	15917-15924	cocaine	_	
83-17	15925-15931	versus	_	
83-18	15932-15944	prescription	_	
83-19	15945-15957	amphetamines	_	
83-20	15957-15958	)	_	
83-21	15959-15961	or	_	
83-22	15962-15964	in	_	
83-23	15965-15973	relation	_	
83-24	15974-15976	to	_	
83-25	15977-15980	the	_	
83-26	15981-15988	history	_	
83-27	15989-15991	of	_	
83-28	15991-15992	/	_	
83-29	15992-16000	presence	_	
83-30	16001-16003	of	_	
83-31	16004-16012	comorbid	_	
83-32	16013-16020	alcohol	_	
83-33	16021-16024	and	_	
83-34	16025-16034	marijuana	_	
83-35	16035-16040	abuse	_	
83-36	16041-16043	or	_	
83-37	16044-16054	dependence	_	
83-38	16054-16055	,	_	
83-39	16056-16066	chi-square	_	
83-40	16067-16075	analyses	_	
83-41	16076-16080	were	_	
83-42	16081-16090	performed	_	
83-43	16090-16091	.	_	

#Text=RGT
#Text=The RGT was analyzed in two stages.
84-1	16092-16095	RGT	_	
84-2	16096-16099	The	_	
84-3	16100-16103	RGT	_	
84-4	16104-16107	was	_	
84-5	16108-16116	analyzed	_	
84-6	16117-16119	in	_	
84-7	16120-16123	two	_	
84-8	16124-16130	stages	_	
84-9	16130-16131	.	_	

#Text=First, decision contrasts evaluated differences between groups when individuals made a “risky” (+/− 40; +/−80) versus “safe” (+20) decision.
85-1	16132-16137	First	_	
85-2	16137-16138	,	_	
85-3	16139-16147	decision	_	
85-4	16148-16157	contrasts	_	
85-5	16158-16167	evaluated	_	
85-6	16168-16179	differences	_	
85-7	16180-16187	between	_	
85-8	16188-16194	groups	_	
85-9	16195-16199	when	_	
85-10	16200-16211	individuals	_	
85-11	16212-16216	made	_	
85-12	16217-16218	a	_	
85-13	16219-16220	“	_	
85-14	16220-16225	risky	_	
85-15	16225-16226	”	_	
85-16	16227-16228	(	_	
85-17	16228-16229	+	_	
85-18	16229-16230	/	_	
85-19	16230-16231	−	_	
85-20	16232-16234	40	_	
85-21	16234-16235	;	_	
85-22	16236-16237	+	_	
85-23	16237-16238	/	_	
85-24	16238-16239	−	_	
85-25	16239-16241	80	_	
85-26	16241-16242	)	_	
85-27	16243-16249	versus	_	
85-28	16250-16251	“	_	
85-29	16251-16255	safe	_	
85-30	16255-16256	”	_	
85-31	16257-16258	(	_	
85-32	16258-16259	+	_	
85-33	16259-16261	20	_	
85-34	16261-16262	)	_	
85-35	16263-16271	decision	_	
85-36	16271-16272	.	_	

#Text=All risky responses were combined to create a relatively even split between risky and safe decisions.
86-1	16273-16276	All	_	
86-2	16277-16282	risky	_	
86-3	16283-16292	responses	_	
86-4	16293-16297	were	_	
86-5	16298-16306	combined	_	
86-6	16307-16309	to	_	
86-7	16310-16316	create	_	
86-8	16317-16318	a	_	
86-9	16319-16329	relatively	_	
86-10	16330-16334	even	_	
86-11	16335-16340	split	_	
86-12	16341-16348	between	_	
86-13	16349-16354	risky	_	
86-14	16355-16358	and	_	
86-15	16359-16363	safe	_	
86-16	16364-16373	decisions	_	
86-17	16373-16374	.	_	

#Text=Second, outcome contrasts evaluated differences in response after wins (+40; +80) versus losses (−40; −80) on risky trials; participants without 5 of each trial type (safe versus risky (40 or 80)) were excluded from analysis.
87-1	16375-16381	Second	_	
87-2	16381-16382	,	_	
87-3	16383-16390	outcome	_	
87-4	16391-16400	contrasts	_	
87-5	16401-16410	evaluated	_	
87-6	16411-16422	differences	_	
87-7	16423-16425	in	_	
87-8	16426-16434	response	_	
87-9	16435-16440	after	_	
87-10	16441-16445	wins	_	
87-11	16446-16447	(	_	
87-12	16447-16448	+	_	
87-13	16448-16450	40	_	
87-14	16450-16451	;	_	
87-15	16452-16453	+	_	
87-16	16453-16455	80	_	
87-17	16455-16456	)	_	
87-18	16457-16463	versus	_	
87-19	16464-16470	losses	_	
87-20	16471-16472	(	_	
87-21	16472-16473	−	_	
87-22	16473-16475	40	_	
87-23	16475-16476	;	_	
87-24	16477-16478	−	_	
87-25	16478-16480	80	_	
87-26	16480-16481	)	_	
87-27	16482-16484	on	_	
87-28	16485-16490	risky	_	
87-29	16491-16497	trials	_	
87-30	16497-16498	;	_	
87-31	16499-16511	participants	_	
87-32	16512-16519	without	_	
87-33	16520-16521	5	_	
87-34	16522-16524	of	_	
87-35	16525-16529	each	_	
87-36	16530-16535	trial	_	
87-37	16536-16540	type	_	
87-38	16541-16542	(	_	
87-39	16542-16546	safe	_	
87-40	16547-16553	versus	_	
87-41	16554-16559	risky	_	
87-42	16560-16561	(	_	
87-43	16561-16563	40	_	
87-44	16564-16566	or	_	
87-45	16567-16569	80	_	
87-46	16569-16570	)	_	
87-47	16570-16571	)	_	
87-48	16572-16576	were	_	
87-49	16577-16585	excluded	_	
87-50	16586-16590	from	_	
87-51	16591-16599	analysis	_	
87-52	16599-16600	.	_	

#Text=Neuroimaging
#Text=MRI data were analyzed using Analysis of Functional Neuroimages (AFNI).
88-1	16601-16613	Neuroimaging	_	
88-2	16614-16617	MRI	_	
88-3	16618-16622	data	_	
88-4	16623-16627	were	_	
88-5	16628-16636	analyzed	_	
88-6	16637-16642	using	_	
88-7	16643-16651	Analysis	_	
88-8	16652-16654	of	_	
88-9	16655-16665	Functional	_	
88-10	16666-16677	Neuroimages	_	
88-11	16678-16679	(	_	
88-12	16679-16683	AFNI	_	
88-13	16683-16684	)	_	
88-14	16684-16685	.	_	

#Text=Single subject data preprocessing procedures are outlined in Reske et al..
89-1	16686-16692	Single	_	
89-2	16693-16700	subject	_	
89-3	16701-16705	data	_	
89-4	16706-16719	preprocessing	_	
89-5	16720-16730	procedures	_	
89-6	16731-16734	are	_	
89-7	16735-16743	outlined	_	
89-8	16744-16746	in	_	
89-9	16747-16752	Reske	_	
89-10	16753-16755	et	_	
89-11	16756-16758	al	_	
89-12	16758-16759	.	_	
89-13	16759-16760	.	_	

#Text=Multiple regressor analysis and individual linear contrasts were computed in 3dDeconvolve, including six motion regressors as well as baseline and linear drift.
90-1	16761-16769	Multiple	_	
90-2	16770-16779	regressor	_	
90-3	16780-16788	analysis	_	
90-4	16789-16792	and	_	
90-5	16793-16803	individual	_	
90-6	16804-16810	linear	_	
90-7	16811-16820	contrasts	_	
90-8	16821-16825	were	_	
90-9	16826-16834	computed	_	
90-10	16835-16837	in	_	
90-11	16838-16850	3dDeconvolve	_	
90-12	16850-16851	,	_	
90-13	16852-16861	including	_	
90-14	16862-16865	six	_	
90-15	16866-16872	motion	_	
90-16	16873-16883	regressors	_	
90-17	16884-16886	as	_	
90-18	16887-16891	well	_	
90-19	16892-16894	as	_	
90-20	16895-16903	baseline	_	
90-21	16904-16907	and	_	
90-22	16908-16914	linear	_	
90-23	16915-16920	drift	_	
90-24	16920-16921	.	_	

#Text=Deconvolution was performed to examine the decision contrast (risky = +/−40, +/−80; safe = +20) and outcome contrast (risky wins = +40, +80; risky losses = −40, −80).
91-1	16922-16935	Deconvolution	_	
91-2	16936-16939	was	_	
91-3	16940-16949	performed	_	
91-4	16950-16952	to	_	
91-5	16953-16960	examine	_	
91-6	16961-16964	the	_	
91-7	16965-16973	decision	_	
91-8	16974-16982	contrast	_	
91-9	16983-16984	(	_	
91-10	16984-16989	risky	_	
91-11	16990-16991	=	_	
91-12	16992-16993	+	_	
91-13	16993-16994	/	_	
91-14	16994-16995	−	_	
91-15	16995-16997	40	_	
91-16	16997-16998	,	_	
91-17	16999-17000	+	_	
91-18	17000-17001	/	_	
91-19	17001-17002	−	_	
91-20	17002-17004	80	_	
91-21	17004-17005	;	_	
91-22	17006-17010	safe	_	
91-23	17011-17012	=	_	
91-24	17013-17014	+	_	
91-25	17014-17016	20	_	
91-26	17016-17017	)	_	
91-27	17018-17021	and	_	
91-28	17022-17029	outcome	_	
91-29	17030-17038	contrast	_	
91-30	17039-17040	(	_	
91-31	17040-17045	risky	_	
91-32	17046-17050	wins	_	
91-33	17051-17052	=	_	
91-34	17053-17054	+	_	
91-35	17054-17056	40	_	
91-36	17056-17057	,	_	
91-37	17058-17059	+	_	
91-38	17059-17061	80	_	
91-39	17061-17062	;	_	
91-40	17063-17068	risky	_	
91-41	17069-17075	losses	_	
91-42	17076-17077	=	_	
91-43	17078-17079	−	_	
91-44	17079-17081	40	_	
91-45	17081-17082	,	_	
91-46	17083-17084	−	_	
91-47	17084-17086	80	_	
91-48	17086-17087	)	_	
91-49	17087-17088	.	_	

#Text=Voxels were resampled into 4×4×4-mm3 space and whole-brain voxel-wise normalized percent signal change, the main dependent measure, was determined by dividing the beta coefficient for each of the predictors of interest (BOLD signal for risky versus safe decisions and risky wins versus risky losses) by the beta coefficient for the baseline regressor and multiplying by 100.
92-1	17089-17095	Voxels	_	
92-2	17096-17100	were	_	
92-3	17101-17110	resampled	_	
92-4	17111-17115	into	_	
92-5	17116-17117	4	_	
92-6	17117-17118	×	_	
92-7	17118-17119	4	_	
92-8	17119-17120	×	_	
92-9	17120-17121	4	_	
92-10	17121-17122	-	_	
92-11	17122-17125	mm3	_	
92-12	17126-17131	space	_	
92-13	17132-17135	and	_	
92-14	17136-17147	whole-brain	_	
92-15	17148-17158	voxel-wise	_	
92-16	17159-17169	normalized	_	
92-17	17170-17177	percent	_	
92-18	17178-17184	signal	_	
92-19	17185-17191	change	_	
92-20	17191-17192	,	_	
92-21	17193-17196	the	_	
92-22	17197-17201	main	_	
92-23	17202-17211	dependent	_	
92-24	17212-17219	measure	_	
92-25	17219-17220	,	_	
92-26	17221-17224	was	_	
92-27	17225-17235	determined	_	
92-28	17236-17238	by	_	
92-29	17239-17247	dividing	_	
92-30	17248-17251	the	_	
92-31	17252-17256	beta	_	
92-32	17257-17268	coefficient	_	
92-33	17269-17272	for	_	
92-34	17273-17277	each	_	
92-35	17278-17280	of	_	
92-36	17281-17284	the	_	
92-37	17285-17295	predictors	_	
92-38	17296-17298	of	_	
92-39	17299-17307	interest	_	
92-40	17308-17309	(	_	
92-41	17309-17313	BOLD	_	
92-42	17314-17320	signal	_	
92-43	17321-17324	for	_	
92-44	17325-17330	risky	_	
92-45	17331-17337	versus	_	
92-46	17338-17342	safe	_	
92-47	17343-17352	decisions	_	
92-48	17353-17356	and	_	
92-49	17357-17362	risky	_	
92-50	17363-17367	wins	_	
92-51	17368-17374	versus	_	
92-52	17375-17380	risky	_	
92-53	17381-17387	losses	_	
92-54	17387-17388	)	_	
92-55	17389-17391	by	_	
92-56	17392-17395	the	_	
92-57	17396-17400	beta	_	
92-58	17401-17412	coefficient	_	
92-59	17413-17416	for	_	
92-60	17417-17420	the	_	
92-61	17421-17429	baseline	_	
92-62	17430-17439	regressor	_	
92-63	17440-17443	and	_	
92-64	17444-17455	multiplying	_	
92-65	17456-17458	by	_	
92-66	17459-17462	100	_	
92-67	17462-17463	.	_	

#Text=A Gaussian spatial filter (4 mm full-width half-maximum; FWHM) blurred percent signal change values, which were then normalized to AFNI Talairach coordinates (40×48×38 voxel coverage).
93-1	17464-17465	A	_	
93-2	17466-17474	Gaussian	_	
93-3	17475-17482	spatial	_	
93-4	17483-17489	filter	_	
93-5	17490-17491	(	_	
93-6	17491-17492	4	_	
93-7	17493-17495	mm	_	
93-8	17496-17506	full-width	_	
93-9	17507-17519	half-maximum	_	
93-10	17519-17520	;	_	
93-11	17521-17525	FWHM	_	
93-12	17525-17526	)	_	
93-13	17527-17534	blurred	_	
93-14	17535-17542	percent	_	
93-15	17543-17549	signal	_	
93-16	17550-17556	change	_	
93-17	17557-17563	values	_	
93-18	17563-17564	,	_	
93-19	17565-17570	which	_	
93-20	17571-17575	were	_	
93-21	17576-17580	then	_	
93-22	17581-17591	normalized	_	
93-23	17592-17594	to	_	
93-24	17595-17599	AFNI	_	
93-25	17600-17609	Talairach	_	
93-26	17610-17621	coordinates	_	
93-27	17622-17623	(	_	
93-28	17623-17625	40	_	
93-29	17625-17626	×	_	
93-30	17626-17628	48	_	
93-31	17628-17629	×	_	
93-32	17629-17631	38	_	
93-33	17632-17637	voxel	_	
93-34	17638-17646	coverage	_	
93-35	17646-17647	)	_	
93-36	17647-17648	.	_	

#Text=Individual-subject values for risky decisions, safe decisions, risky win outcomes, and risky loss outcomes for each voxel included in a whole-brain mask were extracted for statistical analyses.
94-1	17649-17667	Individual-subject	_	
94-2	17668-17674	values	_	
94-3	17675-17678	for	_	
94-4	17679-17684	risky	_	
94-5	17685-17694	decisions	_	
94-6	17694-17695	,	_	
94-7	17696-17700	safe	_	
94-8	17701-17710	decisions	_	
94-9	17710-17711	,	_	
94-10	17712-17717	risky	_	
94-11	17718-17721	win	_	
94-12	17722-17730	outcomes	_	
94-13	17730-17731	,	_	
94-14	17732-17735	and	_	
94-15	17736-17741	risky	_	
94-16	17742-17746	loss	_	
94-17	17747-17755	outcomes	_	
94-18	17756-17759	for	_	
94-19	17760-17764	each	_	
94-20	17765-17770	voxel	_	
94-21	17771-17779	included	_	
94-22	17780-17782	in	_	
94-23	17783-17784	a	_	
94-24	17785-17796	whole-brain	_	
94-25	17797-17801	mask	_	
94-26	17802-17806	were	_	
94-27	17807-17816	extracted	_	
94-28	17817-17820	for	_	
94-29	17821-17832	statistical	_	
94-30	17833-17841	analyses	_	
94-31	17841-17842	.	_	

#Text=Individual voxels meeting a p< 0.01 significance criterion as a result of statistical tests outlined below were evaluated further to determine whether they comprised a significant brain cluster after correction for multiple comparisons.
95-1	17843-17853	Individual	_	
95-2	17854-17860	voxels	_	
95-3	17861-17868	meeting	_	
95-4	17869-17870	a	_	
95-5	17871-17872	p	_	
95-6	17872-17873	<	_	
95-7	17874-17878	0.01	_	
95-8	17879-17891	significance	_	
95-9	17892-17901	criterion	_	
95-10	17902-17904	as	_	
95-11	17905-17906	a	_	
95-12	17907-17913	result	_	
95-13	17914-17916	of	_	
95-14	17917-17928	statistical	_	
95-15	17929-17934	tests	_	
95-16	17935-17943	outlined	_	
95-17	17944-17949	below	_	
95-18	17950-17954	were	_	
95-19	17955-17964	evaluated	_	
95-20	17965-17972	further	_	
95-21	17973-17975	to	_	
95-22	17976-17985	determine	_	
95-23	17986-17993	whether	_	
95-24	17994-17998	they	_	
95-25	17999-18008	comprised	_	
95-26	18009-18010	a	_	
95-27	18011-18022	significant	_	
95-28	18023-18028	brain	_	
95-29	18029-18036	cluster	_	
95-30	18037-18042	after	_	
95-31	18043-18053	correction	_	
95-32	18054-18057	for	_	
95-33	18058-18066	multiple	_	
95-34	18067-18078	comparisons	_	
95-35	18078-18079	.	_	

#Text=Categorical analyses
#Text=For each voxel, a linear mixed effects (LME) model was performed in R to identify significant regions of percent signal change between PSU and DSU, for decision and outcome analyses separately.
96-1	18080-18091	Categorical	_	
96-2	18092-18100	analyses	_	
96-3	18101-18104	For	_	
96-4	18105-18109	each	_	
96-5	18110-18115	voxel	_	
96-6	18115-18116	,	_	
96-7	18117-18118	a	_	
96-8	18119-18125	linear	_	
96-9	18126-18131	mixed	_	
96-10	18132-18139	effects	_	
96-11	18140-18141	(	_	
96-12	18141-18144	LME	_	
96-13	18144-18145	)	_	
96-14	18146-18151	model	_	
96-15	18152-18155	was	_	
96-16	18156-18165	performed	_	
96-17	18166-18168	in	_	
96-18	18169-18170	R	_	
96-19	18171-18173	to	_	
96-20	18174-18182	identify	_	
96-21	18183-18194	significant	_	
96-22	18195-18202	regions	_	
96-23	18203-18205	of	_	
96-24	18206-18213	percent	_	
96-25	18214-18220	signal	_	
96-26	18221-18227	change	_	
96-27	18228-18235	between	_	
96-28	18236-18239	PSU	_	
96-29	18240-18243	and	_	
96-30	18244-18247	DSU	_	
96-31	18247-18248	,	_	
96-32	18249-18252	for	_	
96-33	18253-18261	decision	_	
96-34	18262-18265	and	_	
96-35	18266-18273	outcome	_	
96-36	18274-18282	analyses	_	
96-37	18283-18293	separately	_	
96-38	18293-18294	.	_	

#Text=Group was the between-subjects variable and subject was a random variable.
97-1	18295-18300	Group	_	
97-2	18301-18304	was	_	
97-3	18305-18308	the	_	
97-4	18309-18325	between-subjects	_	
97-5	18326-18334	variable	_	
97-6	18335-18338	and	_	
97-7	18339-18346	subject	_	
97-8	18347-18350	was	_	
97-9	18351-18352	a	_	
97-10	18353-18359	random	_	
97-11	18360-18368	variable	_	
97-12	18368-18369	.	_	

#Text=Within-subject variables were decision type (risky versus safe) and outcome type (risky wins versus risky losses).
98-1	18370-18384	Within-subject	_	
98-2	18385-18394	variables	_	
98-3	18395-18399	were	_	
98-4	18400-18408	decision	_	
98-5	18409-18413	type	_	
98-6	18414-18415	(	_	
98-7	18415-18420	risky	_	
98-8	18421-18427	versus	_	
98-9	18428-18432	safe	_	
98-10	18432-18433	)	_	
98-11	18434-18437	and	_	
98-12	18438-18445	outcome	_	
98-13	18446-18450	type	_	
98-14	18451-18452	(	_	
98-15	18452-18457	risky	_	
98-16	18458-18462	wins	_	
98-17	18463-18469	versus	_	
98-18	18470-18475	risky	_	
98-19	18476-18482	losses	_	
98-20	18482-18483	)	_	
98-21	18483-18484	.	_	

#Text=Cohen’s d was calculated to determine effect sizes.
99-1	18485-18490	Cohen	_	
99-2	18490-18491	’	_	
99-3	18491-18492	s	_	
99-4	18493-18494	d	_	
99-5	18495-18498	was	_	
99-6	18499-18509	calculated	_	
99-7	18510-18512	to	_	
99-8	18513-18522	determine	_	
99-9	18523-18529	effect	_	
99-10	18530-18535	sizes	_	
99-11	18535-18536	.	_	

#Text=Dimensional analyses
#Text=Multiple regressions were computed for each brain voxel, with two separate dependent variables: 1) percent signal change for risky minus safe decisions; and 2) percent signal change for risky wins minus losses.
100-1	18537-18548	Dimensional	_	
100-2	18549-18557	analyses	_	
100-3	18558-18566	Multiple	_	
100-4	18567-18578	regressions	_	
100-5	18579-18583	were	_	
100-6	18584-18592	computed	_	
100-7	18593-18596	for	_	
100-8	18597-18601	each	_	
100-9	18602-18607	brain	_	
100-10	18608-18613	voxel	_	
100-11	18613-18614	,	_	
100-12	18615-18619	with	_	
100-13	18620-18623	two	_	
100-14	18624-18632	separate	_	
100-15	18633-18642	dependent	_	
100-16	18643-18652	variables	_	
100-17	18652-18653	:	_	
100-18	18654-18655	1	_	
100-19	18655-18656	)	_	
100-20	18657-18664	percent	_	
100-21	18665-18671	signal	_	
100-22	18672-18678	change	_	
100-23	18679-18682	for	_	
100-24	18683-18688	risky	_	
100-25	18689-18694	minus	_	
100-26	18695-18699	safe	_	
100-27	18700-18709	decisions	_	
100-28	18709-18710	;	_	
100-29	18711-18714	and	_	
100-30	18715-18716	2	_	
100-31	18716-18717	)	_	
100-32	18718-18725	percent	_	
100-33	18726-18732	signal	_	
100-34	18733-18739	change	_	
100-35	18740-18743	for	_	
100-36	18744-18749	risky	_	
100-37	18750-18754	wins	_	
100-38	18755-18760	minus	_	
100-39	18761-18767	losses	_	
100-40	18767-18768	.	_	

#Text=Predictors in each regression were the following: 1) baseline stimulant uses; 2) interim stimulant uses; 3) baseline marijuana uses; and 4) interim marijuana uses.
101-1	18769-18779	Predictors	_	
101-2	18780-18782	in	_	
101-3	18783-18787	each	_	
101-4	18788-18798	regression	_	
101-5	18799-18803	were	_	
101-6	18804-18807	the	_	
101-7	18808-18817	following	_	
101-8	18817-18818	:	_	
101-9	18819-18820	1	_	
101-10	18820-18821	)	_	
101-11	18822-18830	baseline	_	
101-12	18831-18840	stimulant	_	
101-13	18841-18845	uses	_	
101-14	18845-18846	;	_	
101-15	18847-18848	2	_	
101-16	18848-18849	)	_	
101-17	18850-18857	interim	_	
101-18	18858-18867	stimulant	_	
101-19	18868-18872	uses	_	
101-20	18872-18873	;	_	
101-21	18874-18875	3	_	
101-22	18875-18876	)	_	
101-23	18877-18885	baseline	_	
101-24	18886-18895	marijuana	_	
101-25	18896-18900	uses	_	
101-26	18900-18901	;	_	
101-27	18902-18905	and	_	
101-28	18906-18907	4	_	
101-29	18907-18908	)	_	
101-30	18909-18916	interim	_	
101-31	18917-18926	marijuana	_	
101-32	18927-18931	uses	_	
101-33	18931-18932	.	_	

#Text=All predictors were log-transformed due to non-normality and z-scored prior to regression entry.
102-1	18933-18936	All	_	
102-2	18937-18947	predictors	_	
102-3	18948-18952	were	_	
102-4	18953-18968	log-transformed	_	
102-5	18969-18972	due	_	
102-6	18973-18975	to	_	
102-7	18976-18989	non-normality	_	
102-8	18990-18993	and	_	
102-9	18994-19002	z-scored	_	
102-10	19003-19008	prior	_	
102-11	19009-19011	to	_	
102-12	19012-19022	regression	_	
102-13	19023-19028	entry	_	
102-14	19028-19029	.	_	

#Text=Extracting significant whole-brain clusters
#Text=Neuroimaging analysis software has been criticized for underestimating spatial autocorrelation, leading to insufficient multiple comparison corrections.
103-1	19030-19040	Extracting	_	
103-2	19041-19052	significant	_	
103-3	19053-19064	whole-brain	_	
103-4	19065-19073	clusters	_	
103-5	19074-19086	Neuroimaging	_	
103-6	19087-19095	analysis	_	
103-7	19096-19104	software	_	
103-8	19105-19108	has	_	
103-9	19109-19113	been	_	
103-10	19114-19124	criticized	_	
103-11	19125-19128	for	_	
103-12	19129-19144	underestimating	_	
103-13	19145-19152	spatial	_	
103-14	19153-19168	autocorrelation	_	
103-15	19168-19169	,	_	
103-16	19170-19177	leading	_	
103-17	19178-19180	to	_	
103-18	19181-19193	insufficient	_	
103-19	19194-19202	multiple	_	
103-20	19203-19213	comparison	_	
103-21	19214-19225	corrections	_	
103-22	19225-19226	.	_	

#Text=In response to these concerns: 1) the updated 3dFWHMx program was employed to more reliably estimate true autocorrelation and smoothness present following blurring (5 mm); and 2) an updated version of 3dClustSim was run to account for autocorrelation given our voxel/whole-brain mask size, 10,000 Monte Carlo simulations and two-sided thresholding with an overall voxel p statistical threshold of 0.01 and a corrected clusterwise alpha value of 0.01.
104-1	19227-19229	In	_	
104-2	19230-19238	response	_	
104-3	19239-19241	to	_	
104-4	19242-19247	these	_	
104-5	19248-19256	concerns	_	
104-6	19256-19257	:	_	
104-7	19258-19259	1	_	
104-8	19259-19260	)	_	
104-9	19261-19264	the	_	
104-10	19265-19272	updated	_	
104-11	19273-19280	3dFWHMx	_	
104-12	19281-19288	program	_	
104-13	19289-19292	was	_	
104-14	19293-19301	employed	_	
104-15	19302-19304	to	_	
104-16	19305-19309	more	_	
104-17	19310-19318	reliably	_	
104-18	19319-19327	estimate	_	
104-19	19328-19332	true	_	
104-20	19333-19348	autocorrelation	_	
104-21	19349-19352	and	_	
104-22	19353-19363	smoothness	_	
104-23	19364-19371	present	_	
104-24	19372-19381	following	_	
104-25	19382-19390	blurring	_	
104-26	19391-19392	(	_	
104-27	19392-19393	5	_	
104-28	19394-19396	mm	_	
104-29	19396-19397	)	_	
104-30	19397-19398	;	_	
104-31	19399-19402	and	_	
104-32	19403-19404	2	_	
104-33	19404-19405	)	_	
104-34	19406-19408	an	_	
104-35	19409-19416	updated	_	
104-36	19417-19424	version	_	
104-37	19425-19427	of	_	
104-38	19428-19438	3dClustSim	_	
104-39	19439-19442	was	_	
104-40	19443-19446	run	_	
104-41	19447-19449	to	_	
104-42	19450-19457	account	_	
104-43	19458-19461	for	_	
104-44	19462-19477	autocorrelation	_	
104-45	19478-19483	given	_	
104-46	19484-19487	our	_	
104-47	19488-19493	voxel	_	
104-48	19493-19494	/	_	
104-49	19494-19505	whole-brain	_	
104-50	19506-19510	mask	_	
104-51	19511-19515	size	_	
104-52	19515-19516	,	_	
104-53	19517-19523	10,000	_	
104-54	19524-19529	Monte	_	
104-55	19530-19535	Carlo	_	
104-56	19536-19547	simulations	_	
104-57	19548-19551	and	_	
104-58	19552-19561	two-sided	_	
104-59	19562-19574	thresholding	_	
104-60	19575-19579	with	_	
104-61	19580-19582	an	_	
104-62	19583-19590	overall	_	
104-63	19591-19596	voxel	_	
104-64	19597-19598	p	_	
104-65	19599-19610	statistical	_	
104-66	19611-19620	threshold	_	
104-67	19621-19623	of	_	
104-68	19624-19628	0.01	_	
104-69	19629-19632	and	_	
104-70	19633-19634	a	_	
104-71	19635-19644	corrected	_	
104-72	19645-19656	clusterwise	_	
104-73	19657-19662	alpha	_	
104-74	19663-19668	value	_	
104-75	19669-19671	of	_	
104-76	19672-19676	0.01	_	
104-77	19676-19677	.	_	

#Text=Data smoothness was approximately 6 mm and > 19 neighboring voxels (or > 1216 μL) comprised a significant brain cluster.
105-1	19678-19682	Data	_	
105-2	19683-19693	smoothness	_	
105-3	19694-19697	was	_	
105-4	19698-19711	approximately	_	
105-5	19712-19713	6	_	
105-6	19714-19716	mm	_	
105-7	19717-19720	and	_	
105-8	19721-19722	>	_	
105-9	19723-19725	19	_	
105-10	19726-19737	neighboring	_	
105-11	19738-19744	voxels	_	
105-12	19745-19746	(	_	
105-13	19746-19748	or	_	
105-14	19749-19750	>	_	
105-15	19751-19755	1216	_	
105-16	19756-19758	μL	_	
105-17	19758-19759	)	_	
105-18	19760-19769	comprised	_	
105-19	19770-19771	a	_	
105-20	19772-19783	significant	_	
105-21	19784-19789	brain	_	
105-22	19790-19797	cluster	_	
105-23	19797-19798	.	_	

#Text=Results
#Text=Demographic and Behavioral Characteristics
#Text=Although groups did not differ in baseline stimulant use (Table 1), PSU used amphetamines more recently prior to the fMRI scan than DSU.
106-1	19799-19806	Results	_	
106-2	19807-19818	Demographic	_	
106-3	19819-19822	and	_	
106-4	19823-19833	Behavioral	_	
106-5	19834-19849	Characteristics	_	
106-6	19850-19858	Although	_	
106-7	19859-19865	groups	_	
106-8	19866-19869	did	_	
106-9	19870-19873	not	_	
106-10	19874-19880	differ	_	
106-11	19881-19883	in	_	
106-12	19884-19892	baseline	_	
106-13	19893-19902	stimulant	_	
106-14	19903-19906	use	_	
106-15	19907-19908	(	_	
106-16	19908-19913	Table	_	
106-17	19914-19915	1	_	
106-18	19915-19916	)	_	
106-19	19916-19917	,	_	
106-20	19918-19921	PSU	_	
106-21	19922-19926	used	_	
106-22	19927-19939	amphetamines	_	
106-23	19940-19944	more	_	
106-24	19945-19953	recently	_	
106-25	19954-19959	prior	_	
106-26	19960-19962	to	_	
106-27	19963-19966	the	_	
106-28	19967-19971	fMRI	_	
106-29	19972-19976	scan	_	
106-30	19977-19981	than	_	
106-31	19982-19985	DSU	_	
106-32	19985-19986	.	_	

#Text=Groups did not differ on baseline or interim marijuana uses, nor on frequency of baseline/interim cannabis abuse or dependence diagnoses.
107-1	19987-19993	Groups	_	
107-2	19994-19997	did	_	
107-3	19998-20001	not	_	
107-4	20002-20008	differ	_	
107-5	20009-20011	on	_	
107-6	20012-20020	baseline	_	
107-7	20021-20023	or	_	
107-8	20024-20031	interim	_	
107-9	20032-20041	marijuana	_	
107-10	20042-20046	uses	_	
107-11	20046-20047	,	_	
107-12	20048-20051	nor	_	
107-13	20052-20054	on	_	
107-14	20055-20064	frequency	_	
107-15	20065-20067	of	_	
107-16	20068-20076	baseline	_	
107-17	20076-20077	/	_	
107-18	20077-20084	interim	_	
107-19	20085-20093	cannabis	_	
107-20	20094-20099	abuse	_	
107-21	20100-20102	or	_	
107-22	20103-20113	dependence	_	
107-23	20114-20123	diagnoses	_	
107-24	20123-20124	.	_	

#Text=DSU endorsed higher depression scores than PSU, although they were not clinically elevated.
108-1	20125-20128	DSU	_	
108-2	20129-20137	endorsed	_	
108-3	20138-20144	higher	_	
108-4	20145-20155	depression	_	
108-5	20156-20162	scores	_	
108-6	20163-20167	than	_	
108-7	20168-20171	PSU	_	
108-8	20171-20172	,	_	
108-9	20173-20181	although	_	
108-10	20182-20186	they	_	
108-11	20187-20191	were	_	
108-12	20192-20195	not	_	
108-13	20196-20206	clinically	_	
108-14	20207-20215	elevated	_	
108-15	20215-20216	.	_	

#Text=Preferred stimulant type at baseline was not related to follow-up group (Table 2).
109-1	20217-20226	Preferred	_	
109-2	20227-20236	stimulant	_	
109-3	20237-20241	type	_	
109-4	20242-20244	at	_	
109-5	20245-20253	baseline	_	
109-6	20254-20257	was	_	
109-7	20258-20261	not	_	
109-8	20262-20269	related	_	
109-9	20270-20272	to	_	
109-10	20273-20282	follow-up	_	
109-11	20283-20288	group	_	
109-12	20289-20290	(	_	
109-13	20290-20295	Table	_	
109-14	20296-20297	2	_	
109-15	20297-20298	)	_	
109-16	20298-20299	.	_	

#Text=Although groups did not differ in frequency of type of trial chosen (20, 40, or 80), rewarded/punished trials, or risky losses followed by a risky loss (Table 3), PSU made a greater number of risky decisions after a win than DSU, while DSU made more safe decisions following a win.
110-1	20300-20308	Although	_	
110-2	20309-20315	groups	_	
110-3	20316-20319	did	_	
110-4	20320-20323	not	_	
110-5	20324-20330	differ	_	
110-6	20331-20333	in	_	
110-7	20334-20343	frequency	_	
110-8	20344-20346	of	_	
110-9	20347-20351	type	_	
110-10	20352-20354	of	_	
110-11	20355-20360	trial	_	
110-12	20361-20367	chosen	_	
110-13	20368-20369	(	_	
110-14	20369-20371	20	_	
110-15	20371-20372	,	_	
110-16	20373-20375	40	_	
110-17	20375-20376	,	_	
110-18	20377-20379	or	_	
110-19	20380-20382	80	_	
110-20	20382-20383	)	_	
110-21	20383-20384	,	_	
110-22	20385-20393	rewarded	_	
110-23	20393-20394	/	_	
110-24	20394-20402	punished	_	
110-25	20403-20409	trials	_	
110-26	20409-20410	,	_	
110-27	20411-20413	or	_	
110-28	20414-20419	risky	_	
110-29	20420-20426	losses	_	
110-30	20427-20435	followed	_	
110-31	20436-20438	by	_	
110-32	20439-20440	a	_	
110-33	20441-20446	risky	_	
110-34	20447-20451	loss	_	
110-35	20452-20453	(	_	
110-36	20453-20458	Table	_	
110-37	20459-20460	3	_	
110-38	20460-20461	)	_	
110-39	20461-20462	,	_	
110-40	20463-20466	PSU	_	
110-41	20467-20471	made	_	
110-42	20472-20473	a	_	
110-43	20474-20481	greater	_	
110-44	20482-20488	number	_	
110-45	20489-20491	of	_	
110-46	20492-20497	risky	_	
110-47	20498-20507	decisions	_	
110-48	20508-20513	after	_	
110-49	20514-20515	a	_	
110-50	20516-20519	win	_	
110-51	20520-20524	than	_	
110-52	20525-20528	DSU	_	
110-53	20528-20529	,	_	
110-54	20530-20535	while	_	
110-55	20536-20539	DSU	_	
110-56	20540-20544	made	_	
110-57	20545-20549	more	_	
110-58	20550-20554	safe	_	
110-59	20555-20564	decisions	_	
110-60	20565-20574	following	_	
110-61	20575-20576	a	_	
110-62	20577-20580	win	_	
110-63	20580-20581	.	_	

#Text=Neuroimaging: Categorical Analyses (Table 4)
#Text=For purposes of illustration, interaction effects are graphed as difference scores.
111-1	20582-20594	Neuroimaging	_	
111-2	20594-20595	:	_	
111-3	20596-20607	Categorical	_	
111-4	20608-20616	Analyses	_	
111-5	20617-20618	(	_	
111-6	20618-20623	Table	_	
111-7	20624-20625	4	_	
111-8	20625-20626	)	_	
111-9	20627-20630	For	_	
111-10	20631-20639	purposes	_	
111-11	20640-20642	of	_	
111-12	20643-20655	illustration	_	
111-13	20655-20656	,	_	
111-14	20657-20668	interaction	_	
111-15	20669-20676	effects	_	
111-16	20677-20680	are	_	
111-17	20681-20688	graphed	_	
111-18	20689-20691	as	_	
111-19	20692-20702	difference	_	
111-20	20703-20709	scores	_	
111-21	20709-20710	.	_	

#Text=Decision contrast
#Text=No group main effect emerged.
112-1	20711-20719	Decision	_	
112-2	20720-20728	contrast	_	
112-3	20729-20731	No	_	
112-4	20732-20737	group	_	
112-5	20738-20742	main	_	
112-6	20743-20749	effect	_	
112-7	20750-20757	emerged	_	
112-8	20757-20758	.	_	

#Text=The group by decision interaction indicated that PSU exhibited greater cingulate and precuneus BOLD signal to risky than safe decisions when compared to DSU (Figure 3).
113-1	20759-20762	The	_	
113-2	20763-20768	group	_	
113-3	20769-20771	by	_	
113-4	20772-20780	decision	_	
113-5	20781-20792	interaction	_	
113-6	20793-20802	indicated	_	
113-7	20803-20807	that	_	
113-8	20808-20811	PSU	_	
113-9	20812-20821	exhibited	_	
113-10	20822-20829	greater	_	
113-11	20830-20839	cingulate	_	
113-12	20840-20843	and	_	
113-13	20844-20853	precuneus	_	
113-14	20854-20858	BOLD	_	
113-15	20859-20865	signal	_	
113-16	20866-20868	to	_	
113-17	20869-20874	risky	_	
113-18	20875-20879	than	_	
113-19	20880-20884	safe	_	
113-20	20885-20894	decisions	_	
113-21	20895-20899	when	_	
113-22	20900-20908	compared	_	
113-23	20909-20911	to	_	
113-24	20912-20915	DSU	_	
113-25	20916-20917	(	_	
113-26	20917-20923	Figure	_	
113-27	20924-20925	3	_	
113-28	20925-20926	)	_	
113-29	20926-20927	.	_	

#Text=Outcome contrast
#Text=The group main effect demonstrated that across risky wins and losses, PSU displayed weaker superior/middle frontal, cingulate, insula, striatum (putamen, lentiform nucleus) and posterior cingulate BOLD signal than DSU (Figure 4).
114-1	20928-20935	Outcome	_	
114-2	20936-20944	contrast	_	
114-3	20945-20948	The	_	
114-4	20949-20954	group	_	
114-5	20955-20959	main	_	
114-6	20960-20966	effect	_	
114-7	20967-20979	demonstrated	_	
114-8	20980-20984	that	_	
114-9	20985-20991	across	_	
114-10	20992-20997	risky	_	
114-11	20998-21002	wins	_	
114-12	21003-21006	and	_	
114-13	21007-21013	losses	_	
114-14	21013-21014	,	_	
114-15	21015-21018	PSU	_	
114-16	21019-21028	displayed	_	
114-17	21029-21035	weaker	_	
114-18	21036-21044	superior	_	
114-19	21044-21045	/	_	
114-20	21045-21051	middle	_	
114-21	21052-21059	frontal	_	
114-22	21059-21060	,	_	
114-23	21061-21070	cingulate	_	
114-24	21070-21071	,	_	
114-25	21072-21078	insula	_	
114-26	21078-21079	,	_	
114-27	21080-21088	striatum	_	
114-28	21089-21090	(	_	
114-29	21090-21097	putamen	_	
114-30	21097-21098	,	_	
114-31	21099-21108	lentiform	_	
114-32	21109-21116	nucleus	_	
114-33	21116-21117	)	_	
114-34	21118-21121	and	_	
114-35	21122-21131	posterior	_	
114-36	21132-21141	cingulate	_	
114-37	21142-21146	BOLD	_	
114-38	21147-21153	signal	_	
114-39	21154-21158	than	_	
114-40	21159-21162	DSU	_	
114-41	21163-21164	(	_	
114-42	21164-21170	Figure	_	
114-43	21171-21172	4	_	
114-44	21172-21173	)	_	
114-45	21173-21174	.	_	

#Text=The group by outcome interaction showed that PSU exhibited greater thalamic, inferior/middle temporal and occipital BOLD signal to win risky than lose risky feedback than DSU (Figure 5).
115-1	21175-21178	The	_	
115-2	21179-21184	group	_	
115-3	21185-21187	by	_	
115-4	21188-21195	outcome	_	
115-5	21196-21207	interaction	_	
115-6	21208-21214	showed	_	
115-7	21215-21219	that	_	
115-8	21220-21223	PSU	_	
115-9	21224-21233	exhibited	_	
115-10	21234-21241	greater	_	
115-11	21242-21250	thalamic	_	
115-12	21250-21251	,	_	
115-13	21252-21260	inferior	_	
115-14	21260-21261	/	_	
115-15	21261-21267	middle	_	
115-16	21268-21276	temporal	_	
115-17	21277-21280	and	_	
115-18	21281-21290	occipital	_	
115-19	21291-21295	BOLD	_	
115-20	21296-21302	signal	_	
115-21	21303-21305	to	_	
115-22	21306-21309	win	_	
115-23	21310-21315	risky	_	
115-24	21316-21320	than	_	
115-25	21321-21325	lose	_	
115-26	21326-21331	risky	_	
115-27	21332-21340	feedback	_	
115-28	21341-21345	than	_	
115-29	21346-21349	DSU	_	
115-30	21350-21351	(	_	
115-31	21351-21357	Figure	_	
115-32	21358-21359	5	_	
115-33	21359-21360	)	_	
115-34	21360-21361	.	_	

#Text=Neuroimaging: Dimensional analyses (Table 5)
#Text=Higher interim marijuana use was linked to lower superior/middle/inferior frontal, inferior parietal, superior/middle temporal, thalamus, and precuneus activation for risky compared to safe decisions (Figure 6).
116-1	21362-21374	Neuroimaging	_	
116-2	21374-21375	:	_	
116-3	21376-21387	Dimensional	_	
116-4	21388-21396	analyses	_	
116-5	21397-21398	(	_	
116-6	21398-21403	Table	_	
116-7	21404-21405	5	_	
116-8	21405-21406	)	_	
116-9	21407-21413	Higher	_	
116-10	21414-21421	interim	_	
116-11	21422-21431	marijuana	_	
116-12	21432-21435	use	_	
116-13	21436-21439	was	_	
116-14	21440-21446	linked	_	
116-15	21447-21449	to	_	
116-16	21450-21455	lower	_	
116-17	21456-21464	superior	_	
116-18	21464-21465	/	_	
116-19	21465-21471	middle	_	
116-20	21471-21472	/	_	
116-21	21472-21480	inferior	_	
116-22	21481-21488	frontal	_	
116-23	21488-21489	,	_	
116-24	21490-21498	inferior	_	
116-25	21499-21507	parietal	_	
116-26	21507-21508	,	_	
116-27	21509-21517	superior	_	
116-28	21517-21518	/	_	
116-29	21518-21524	middle	_	
116-30	21525-21533	temporal	_	
116-31	21533-21534	,	_	
116-32	21535-21543	thalamus	_	
116-33	21543-21544	,	_	
116-34	21545-21548	and	_	
116-35	21549-21558	precuneus	_	
116-36	21559-21569	activation	_	
116-37	21570-21573	for	_	
116-38	21574-21579	risky	_	
116-39	21580-21588	compared	_	
116-40	21589-21591	to	_	
116-41	21592-21596	safe	_	
116-42	21597-21606	decisions	_	
116-43	21607-21608	(	_	
116-44	21608-21614	Figure	_	
116-45	21615-21616	6	_	
116-46	21616-21617	)	_	
116-47	21617-21618	.	_	

#Text=No significant clusters emerged for baseline marijuana uses or baseline/interim stimulant uses.
117-1	21619-21621	No	_	
117-2	21622-21633	significant	_	
117-3	21634-21642	clusters	_	
117-4	21643-21650	emerged	_	
117-5	21651-21654	for	_	
117-6	21655-21663	baseline	_	
117-7	21664-21673	marijuana	_	
117-8	21674-21678	uses	_	
117-9	21679-21681	or	_	
117-10	21682-21690	baseline	_	
117-11	21690-21691	/	_	
117-12	21691-21698	interim	_	
117-13	21699-21708	stimulant	_	
117-14	21709-21713	uses	_	
117-15	21713-21714	.	_	

#Text=Discussion
#Text=This study employed categorical and dimensional analysis strategies in OSU to determine whether baseline biobehavioral RGT responses predicted future stimulant use.
118-1	21715-21725	Discussion	_	
118-2	21726-21730	This	_	
118-3	21731-21736	study	_	
118-4	21737-21745	employed	_	
118-5	21746-21757	categorical	_	
118-6	21758-21761	and	_	
118-7	21762-21773	dimensional	_	
118-8	21774-21782	analysis	_	
118-9	21783-21793	strategies	_	
118-10	21794-21796	in	_	
118-11	21797-21800	OSU	_	
118-12	21801-21803	to	_	
118-13	21804-21813	determine	_	
118-14	21814-21821	whether	_	
118-15	21822-21830	baseline	_	
118-16	21831-21844	biobehavioral	_	
118-17	21845-21848	RGT	_	
118-18	21849-21858	responses	_	
118-19	21859-21868	predicted	_	
118-20	21869-21875	future	_	
118-21	21876-21885	stimulant	_	
118-22	21886-21889	use	_	
118-23	21889-21890	.	_	

#Text=Categorical Analyses: PSU versus DSU
#Text=Three hypotheses were tested.
119-1	21891-21902	Categorical	_	
119-2	21903-21911	Analyses	_	
119-3	21911-21912	:	_	
119-4	21913-21916	PSU	_	
119-5	21917-21923	versus	_	
119-6	21924-21927	DSU	_	
119-7	21928-21933	Three	_	
119-8	21934-21944	hypotheses	_	
119-9	21945-21949	were	_	
119-10	21950-21956	tested	_	
119-11	21956-21957	.	_	

#Text=First, consistent with the prediction that PSU would exhibit riskier task performance than DSU, PSU more frequently made a risky decision following a win compared to DSU, while DSU more frequently made a safe decision following a risky win.
120-1	21958-21963	First	_	
120-2	21963-21964	,	_	
120-3	21965-21975	consistent	_	
120-4	21976-21980	with	_	
120-5	21981-21984	the	_	
120-6	21985-21995	prediction	_	
120-7	21996-22000	that	_	
120-8	22001-22004	PSU	_	
120-9	22005-22010	would	_	
120-10	22011-22018	exhibit	_	
120-11	22019-22026	riskier	_	
120-12	22027-22031	task	_	
120-13	22032-22043	performance	_	
120-14	22044-22048	than	_	
120-15	22049-22052	DSU	_	
120-16	22052-22053	,	_	
120-17	22054-22057	PSU	_	
120-18	22058-22062	more	_	
120-19	22063-22073	frequently	_	
120-20	22074-22078	made	_	
120-21	22079-22080	a	_	
120-22	22081-22086	risky	_	
120-23	22087-22095	decision	_	
120-24	22096-22105	following	_	
120-25	22106-22107	a	_	
120-26	22108-22111	win	_	
120-27	22112-22120	compared	_	
120-28	22121-22123	to	_	
120-29	22124-22127	DSU	_	
120-30	22127-22128	,	_	
120-31	22129-22134	while	_	
120-32	22135-22138	DSU	_	
120-33	22139-22143	more	_	
120-34	22144-22154	frequently	_	
120-35	22155-22159	made	_	
120-36	22160-22161	a	_	
120-37	22162-22166	safe	_	
120-38	22167-22175	decision	_	
120-39	22176-22185	following	_	
120-40	22186-22187	a	_	
120-41	22188-22193	risky	_	
120-42	22194-22197	win	_	
120-43	22197-22198	.	_	

#Text=This pattern supports previous findings that PSU are more reactive to rewards.
121-1	22199-22203	This	_	
121-2	22204-22211	pattern	_	
121-3	22212-22220	supports	_	
121-4	22221-22229	previous	_	
121-5	22230-22238	findings	_	
121-6	22239-22243	that	_	
121-7	22244-22247	PSU	_	
121-8	22248-22251	are	_	
121-9	22252-22256	more	_	
121-10	22257-22265	reactive	_	
121-11	22266-22268	to	_	
121-12	22269-22276	rewards	_	
121-13	22276-22277	.	_	

#Text=Second, although it was predicted that PSU would show greater activation in reward-processing striatal regions to risky wins than losses when compared to DSU, our results demonstrated the opposite effect, wherein PSU exhibited lower striatal BOLD signal across outcomes than DSU.
122-1	22278-22284	Second	_	
122-2	22284-22285	,	_	
122-3	22286-22294	although	_	
122-4	22295-22297	it	_	
122-5	22298-22301	was	_	
122-6	22302-22311	predicted	_	
122-7	22312-22316	that	_	
122-8	22317-22320	PSU	_	
122-9	22321-22326	would	_	
122-10	22327-22331	show	_	
122-11	22332-22339	greater	_	
122-12	22340-22350	activation	_	
122-13	22351-22353	in	_	
122-14	22354-22371	reward-processing	_	
122-15	22372-22380	striatal	_	
122-16	22381-22388	regions	_	
122-17	22389-22391	to	_	
122-18	22392-22397	risky	_	
122-19	22398-22402	wins	_	
122-20	22403-22407	than	_	
122-21	22408-22414	losses	_	
122-22	22415-22419	when	_	
122-23	22420-22428	compared	_	
122-24	22429-22431	to	_	
122-25	22432-22435	DSU	_	
122-26	22435-22436	,	_	
122-27	22437-22440	our	_	
122-28	22441-22448	results	_	
122-29	22449-22461	demonstrated	_	
122-30	22462-22465	the	_	
122-31	22466-22474	opposite	_	
122-32	22475-22481	effect	_	
122-33	22481-22482	,	_	
122-34	22483-22490	wherein	_	
122-35	22491-22494	PSU	_	
122-36	22495-22504	exhibited	_	
122-37	22505-22510	lower	_	
122-38	22511-22519	striatal	_	
122-39	22520-22524	BOLD	_	
122-40	22525-22531	signal	_	
122-41	22532-22538	across	_	
122-42	22539-22547	outcomes	_	
122-43	22548-22552	than	_	
122-44	22553-22556	DSU	_	
122-45	22556-22557	.	_	

#Text=However, this finding is consistent with a longitudinal study of sensation-seeking adolescents, wherein striatal hypoactivation predicted future problematic drug use; authors theorized that lower striatal activity may lead to a compensatory mechanism in which one seeks out increased risk to gain greater stimulation, thereby balancing reward center hypoactivation.
123-1	22558-22565	However	_	
123-2	22565-22566	,	_	
123-3	22567-22571	this	_	
123-4	22572-22579	finding	_	
123-5	22580-22582	is	_	
123-6	22583-22593	consistent	_	
123-7	22594-22598	with	_	
123-8	22599-22600	a	_	
123-9	22601-22613	longitudinal	_	
123-10	22614-22619	study	_	
123-11	22620-22622	of	_	
123-12	22623-22640	sensation-seeking	_	
123-13	22641-22652	adolescents	_	
123-14	22652-22653	,	_	
123-15	22654-22661	wherein	_	
123-16	22662-22670	striatal	_	
123-17	22671-22685	hypoactivation	_	
123-18	22686-22695	predicted	_	
123-19	22696-22702	future	_	
123-20	22703-22714	problematic	_	
123-21	22715-22719	drug	_	
123-22	22720-22723	use	_	
123-23	22723-22724	;	_	
123-24	22725-22732	authors	_	
123-25	22733-22742	theorized	_	
123-26	22743-22747	that	_	
123-27	22748-22753	lower	_	
123-28	22754-22762	striatal	_	
123-29	22763-22771	activity	_	
123-30	22772-22775	may	_	
123-31	22776-22780	lead	_	
123-32	22781-22783	to	_	
123-33	22784-22785	a	_	
123-34	22786-22798	compensatory	_	
123-35	22799-22808	mechanism	_	
123-36	22809-22811	in	_	
123-37	22812-22817	which	_	
123-38	22818-22821	one	_	
123-39	22822-22827	seeks	_	
123-40	22828-22831	out	_	
123-41	22832-22841	increased	_	
123-42	22842-22846	risk	_	
123-43	22847-22849	to	_	
123-44	22850-22854	gain	_	
123-45	22855-22862	greater	_	
123-46	22863-22874	stimulation	_	
123-47	22874-22875	,	_	
123-48	22876-22883	thereby	_	
123-49	22884-22893	balancing	_	
123-50	22894-22900	reward	_	
123-51	22901-22907	center	_	
123-52	22908-22922	hypoactivation	_	
123-53	22922-22923	.	_	

#Text=PSU exhibited greater temporo-occipital BOLD signal to wins than losses, findings consistent with a recent meta-analysis reporting that 86% of addiction-related neuroimaging studies demonstrate significant visual cortex activity to drug cues.
124-1	22924-22927	PSU	_	
124-2	22928-22937	exhibited	_	
124-3	22938-22945	greater	_	
124-4	22946-22963	temporo-occipital	_	
124-5	22964-22968	BOLD	_	
124-6	22969-22975	signal	_	
124-7	22976-22978	to	_	
124-8	22979-22983	wins	_	
124-9	22984-22988	than	_	
124-10	22989-22995	losses	_	
124-11	22995-22996	,	_	
124-12	22997-23005	findings	_	
124-13	23006-23016	consistent	_	
124-14	23017-23021	with	_	
124-15	23022-23023	a	_	
124-16	23024-23030	recent	_	
124-17	23031-23044	meta-analysis	_	
124-18	23045-23054	reporting	_	
124-19	23055-23059	that	_	
124-20	23060-23063	86%	_	
124-21	23064-23066	of	_	
124-22	23067-23084	addiction-related	_	
124-23	23085-23097	neuroimaging	_	
124-24	23098-23105	studies	_	
124-25	23106-23117	demonstrate	_	
124-26	23118-23129	significant	_	
124-27	23130-23136	visual	_	
124-28	23137-23143	cortex	_	
124-29	23144-23152	activity	_	
124-30	23153-23155	to	_	
124-31	23156-23160	drug	_	
124-32	23161-23165	cues	_	
124-33	23165-23166	.	_	

#Text=Although the RGT did not test drug-related responses, our results demonstrate an analogous relationship to general reward cues, suggesting that PSU may allocate greater visual attention towards risky rewards than losses.
125-1	23167-23175	Although	_	
125-2	23176-23179	the	_	
125-3	23180-23183	RGT	_	
125-4	23184-23187	did	_	
125-5	23188-23191	not	_	
125-6	23192-23196	test	_	
125-7	23197-23209	drug-related	_	
125-8	23210-23219	responses	_	
125-9	23219-23220	,	_	
125-10	23221-23224	our	_	
125-11	23225-23232	results	_	
125-12	23233-23244	demonstrate	_	
125-13	23245-23247	an	_	
125-14	23248-23257	analogous	_	
125-15	23258-23270	relationship	_	
125-16	23271-23273	to	_	
125-17	23274-23281	general	_	
125-18	23282-23288	reward	_	
125-19	23289-23293	cues	_	
125-20	23293-23294	,	_	
125-21	23295-23305	suggesting	_	
125-22	23306-23310	that	_	
125-23	23311-23314	PSU	_	
125-24	23315-23318	may	_	
125-25	23319-23327	allocate	_	
125-26	23328-23335	greater	_	
125-27	23336-23342	visual	_	
125-28	23343-23352	attention	_	
125-29	23353-23360	towards	_	
125-30	23361-23366	risky	_	
125-31	23367-23374	rewards	_	
125-32	23375-23379	than	_	
125-33	23380-23386	losses	_	
125-34	23386-23387	.	_	

#Text=Middle temporal lobe is involved in memory of reward-based information critical for future-oriented decision making, suggesting that PSU may be less able to consolidate information about outcomes differently.
126-1	23388-23394	Middle	_	
126-2	23395-23403	temporal	_	
126-3	23404-23408	lobe	_	
126-4	23409-23411	is	_	
126-5	23412-23420	involved	_	
126-6	23421-23423	in	_	
126-7	23424-23430	memory	_	
126-8	23431-23433	of	_	
126-9	23434-23446	reward-based	_	
126-10	23447-23458	information	_	
126-11	23459-23467	critical	_	
126-12	23468-23471	for	_	
126-13	23472-23487	future-oriented	_	
126-14	23488-23496	decision	_	
126-15	23497-23503	making	_	
126-16	23503-23504	,	_	
126-17	23505-23515	suggesting	_	
126-18	23516-23520	that	_	
126-19	23521-23524	PSU	_	
126-20	23525-23528	may	_	
126-21	23529-23531	be	_	
126-22	23532-23536	less	_	
126-23	23537-23541	able	_	
126-24	23542-23544	to	_	
126-25	23545-23556	consolidate	_	
126-26	23557-23568	information	_	
126-27	23569-23574	about	_	
126-28	23575-23583	outcomes	_	
126-29	23584-23595	differently	_	
126-30	23595-23596	.	_	

#Text=Together, PSU are characterized by visual attention and memory activation during risky rewards, but blunted responsivity to loss outcomes.
127-1	23597-23605	Together	_	
127-2	23605-23606	,	_	
127-3	23607-23610	PSU	_	
127-4	23611-23614	are	_	
127-5	23615-23628	characterized	_	
127-6	23629-23631	by	_	
127-7	23632-23638	visual	_	
127-8	23639-23648	attention	_	
127-9	23649-23652	and	_	
127-10	23653-23659	memory	_	
127-11	23660-23670	activation	_	
127-12	23671-23677	during	_	
127-13	23678-23683	risky	_	
127-14	23684-23691	rewards	_	
127-15	23691-23692	,	_	
127-16	23693-23696	but	_	
127-17	23697-23704	blunted	_	
127-18	23705-23717	responsivity	_	
127-19	23718-23720	to	_	
127-20	23721-23725	loss	_	
127-21	23726-23734	outcomes	_	
127-22	23734-23735	.	_	

#Text=Our third prediction was supported in that PSU exhibited lower PFC, insula, and cingulate BOLD signal than DSU during risky feedback.
128-1	23736-23739	Our	_	
128-2	23740-23745	third	_	
128-3	23746-23756	prediction	_	
128-4	23757-23760	was	_	
128-5	23761-23770	supported	_	
128-6	23771-23773	in	_	
128-7	23774-23778	that	_	
128-8	23779-23782	PSU	_	
128-9	23783-23792	exhibited	_	
128-10	23793-23798	lower	_	
128-11	23799-23802	PFC	_	
128-12	23802-23803	,	_	
128-13	23804-23810	insula	_	
128-14	23810-23811	,	_	
128-15	23812-23815	and	_	
128-16	23816-23825	cingulate	_	
128-17	23826-23830	BOLD	_	
128-18	23831-23837	signal	_	
128-19	23838-23842	than	_	
128-20	23843-23846	DSU	_	
128-21	23847-23853	during	_	
128-22	23854-23859	risky	_	
128-23	23860-23868	feedback	_	
128-24	23868-23869	.	_	

#Text=These findings align with a recent study conducted by our research group demonstrating that during a task evaluating how individuals learn to make decisions, PSU exhibited lower insula and ACC activation across all available outcomes (win, loss, tie) than DSU.
129-1	23870-23875	These	_	
129-2	23876-23884	findings	_	
129-3	23885-23890	align	_	
129-4	23891-23895	with	_	
129-5	23896-23897	a	_	
129-6	23898-23904	recent	_	
129-7	23905-23910	study	_	
129-8	23911-23920	conducted	_	
129-9	23921-23923	by	_	
129-10	23924-23927	our	_	
129-11	23928-23936	research	_	
129-12	23937-23942	group	_	
129-13	23943-23956	demonstrating	_	
129-14	23957-23961	that	_	
129-15	23962-23968	during	_	
129-16	23969-23970	a	_	
129-17	23971-23975	task	_	
129-18	23976-23986	evaluating	_	
129-19	23987-23990	how	_	
129-20	23991-24002	individuals	_	
129-21	24003-24008	learn	_	
129-22	24009-24011	to	_	
129-23	24012-24016	make	_	
129-24	24017-24026	decisions	_	
129-25	24026-24027	,	_	
129-26	24028-24031	PSU	_	
129-27	24032-24041	exhibited	_	
129-28	24042-24047	lower	_	
129-29	24048-24054	insula	_	
129-30	24055-24058	and	_	
129-31	24059-24062	ACC	_	
129-32	24063-24073	activation	_	
129-33	24074-24080	across	_	
129-34	24081-24084	all	_	
129-35	24085-24094	available	_	
129-36	24095-24103	outcomes	_	
129-37	24104-24105	(	_	
129-38	24105-24108	win	_	
129-39	24108-24109	,	_	
129-40	24110-24114	loss	_	
129-41	24114-24115	,	_	
129-42	24116-24119	tie	_	
129-43	24119-24120	)	_	
129-44	24121-24125	than	_	
129-45	24126-24129	DSU	_	
129-46	24129-24130	.	_	

#Text=Such patterns are consistent with previous reports of PFC, insula, and ACC attenuations in chronic stimulant users which are, respectively, linked with decreased ability to adapt behavior using prior experiences/reduced inhibitory control, interoceptive awareness and conflict monitoring.
130-1	24131-24135	Such	_	
130-2	24136-24144	patterns	_	
130-3	24145-24148	are	_	
130-4	24149-24159	consistent	_	
130-5	24160-24164	with	_	
130-6	24165-24173	previous	_	
130-7	24174-24181	reports	_	
130-8	24182-24184	of	_	
130-9	24185-24188	PFC	_	
130-10	24188-24189	,	_	
130-11	24190-24196	insula	_	
130-12	24196-24197	,	_	
130-13	24198-24201	and	_	
130-14	24202-24205	ACC	_	
130-15	24206-24218	attenuations	_	
130-16	24219-24221	in	_	
130-17	24222-24229	chronic	_	
130-18	24230-24239	stimulant	_	
130-19	24240-24245	users	_	
130-20	24246-24251	which	_	
130-21	24252-24255	are	_	
130-22	24255-24256	,	_	
130-23	24257-24269	respectively	_	
130-24	24269-24270	,	_	
130-25	24271-24277	linked	_	
130-26	24278-24282	with	_	
130-27	24283-24292	decreased	_	
130-28	24293-24300	ability	_	
130-29	24301-24303	to	_	
130-30	24304-24309	adapt	_	
130-31	24310-24318	behavior	_	
130-32	24319-24324	using	_	
130-33	24325-24330	prior	_	
130-34	24331-24342	experiences	_	
130-35	24342-24343	/	_	
130-36	24343-24350	reduced	_	
130-37	24351-24361	inhibitory	_	
130-38	24362-24369	control	_	
130-39	24369-24370	,	_	
130-40	24371-24384	interoceptive	_	
130-41	24385-24394	awareness	_	
130-42	24395-24398	and	_	
130-43	24399-24407	conflict	_	
130-44	24408-24418	monitoring	_	
130-45	24418-24419	.	_	

#Text=Thus, young adults predisposed to SUD may have prior deficits recruiting neural effort toward critical decision making processes.
131-1	24420-24424	Thus	_	
131-2	24424-24425	,	_	
131-3	24426-24431	young	_	
131-4	24432-24438	adults	_	
131-5	24439-24450	predisposed	_	
131-6	24451-24453	to	_	
131-7	24454-24457	SUD	_	
131-8	24458-24461	may	_	
131-9	24462-24466	have	_	
131-10	24467-24472	prior	_	
131-11	24473-24481	deficits	_	
131-12	24482-24492	recruiting	_	
131-13	24493-24499	neural	_	
131-14	24500-24506	effort	_	
131-15	24507-24513	toward	_	
131-16	24514-24522	critical	_	
131-17	24523-24531	decision	_	
131-18	24532-24538	making	_	
131-19	24539-24548	processes	_	
131-20	24548-24549	.	_	

#Text=Non-hypothesized group differences also emerged in thalamic, precuneus, and posterior cingulate regions that warrant discussion.
132-1	24550-24566	Non-hypothesized	_	
132-2	24567-24572	group	_	
132-3	24573-24584	differences	_	
132-4	24585-24589	also	_	
132-5	24590-24597	emerged	_	
132-6	24598-24600	in	_	
132-7	24601-24609	thalamic	_	
132-8	24609-24610	,	_	
132-9	24611-24620	precuneus	_	
132-10	24620-24621	,	_	
132-11	24622-24625	and	_	
132-12	24626-24635	posterior	_	
132-13	24636-24645	cingulate	_	
132-14	24646-24653	regions	_	
132-15	24654-24658	that	_	
132-16	24659-24666	warrant	_	
132-17	24667-24677	discussion	_	
132-18	24677-24678	.	_	

#Text=PSU showed relatively greater precuneus and posterior cingulate BOLD signal when making risky than safe decisions when compared to DSU.
133-1	24679-24682	PSU	_	
133-2	24683-24689	showed	_	
133-3	24690-24700	relatively	_	
133-4	24701-24708	greater	_	
133-5	24709-24718	precuneus	_	
133-6	24719-24722	and	_	
133-7	24723-24732	posterior	_	
133-8	24733-24742	cingulate	_	
133-9	24743-24747	BOLD	_	
133-10	24748-24754	signal	_	
133-11	24755-24759	when	_	
133-12	24760-24766	making	_	
133-13	24767-24772	risky	_	
133-14	24773-24777	than	_	
133-15	24778-24782	safe	_	
133-16	24783-24792	decisions	_	
133-17	24793-24797	when	_	
133-18	24798-24806	compared	_	
133-19	24807-24809	to	_	
133-20	24810-24813	DSU	_	
133-21	24813-24814	.	_	

#Text=Such differences are consistent with previous findings in SUD samples that heightened activation of these areas during exteroceptive awareness (evaluative processing of external stimuli) may underlie the maintenance and exacerbation of substance use.
134-1	24815-24819	Such	_	
134-2	24820-24831	differences	_	
134-3	24832-24835	are	_	
134-4	24836-24846	consistent	_	
134-5	24847-24851	with	_	
134-6	24852-24860	previous	_	
134-7	24861-24869	findings	_	
134-8	24870-24872	in	_	
134-9	24873-24876	SUD	_	
134-10	24877-24884	samples	_	
134-11	24885-24889	that	_	
134-12	24890-24900	heightened	_	
134-13	24901-24911	activation	_	
134-14	24912-24914	of	_	
134-15	24915-24920	these	_	
134-16	24921-24926	areas	_	
134-17	24927-24933	during	_	
134-18	24934-24947	exteroceptive	_	
134-19	24948-24957	awareness	_	
134-20	24958-24959	(	_	
134-21	24959-24969	evaluative	_	
134-22	24970-24980	processing	_	
134-23	24981-24983	of	_	
134-24	24984-24992	external	_	
134-25	24993-25000	stimuli	_	
134-26	25000-25001	)	_	
134-27	25002-25005	may	_	
134-28	25006-25014	underlie	_	
134-29	25015-25018	the	_	
134-30	25019-25030	maintenance	_	
134-31	25031-25034	and	_	
134-32	25035-25047	exacerbation	_	
134-33	25048-25050	of	_	
134-34	25051-25060	substance	_	
134-35	25061-25064	use	_	
134-36	25064-25065	.	_	

#Text=Greater thalamic response to risky reward versus loss feedback in PSU is consistent with research demonstrating that thalamic BOLD signal is linked to relapse in cocaine-dependent individuals.
135-1	25066-25073	Greater	_	
135-2	25074-25082	thalamic	_	
135-3	25083-25091	response	_	
135-4	25092-25094	to	_	
135-5	25095-25100	risky	_	
135-6	25101-25107	reward	_	
135-7	25108-25114	versus	_	
135-8	25115-25119	loss	_	
135-9	25120-25128	feedback	_	
135-10	25129-25131	in	_	
135-11	25132-25135	PSU	_	
135-12	25136-25138	is	_	
135-13	25139-25149	consistent	_	
135-14	25150-25154	with	_	
135-15	25155-25163	research	_	
135-16	25164-25177	demonstrating	_	
135-17	25178-25182	that	_	
135-18	25183-25191	thalamic	_	
135-19	25192-25196	BOLD	_	
135-20	25197-25203	signal	_	
135-21	25204-25206	is	_	
135-22	25207-25213	linked	_	
135-23	25214-25216	to	_	
135-24	25217-25224	relapse	_	
135-25	25225-25227	in	_	
135-26	25228-25245	cocaine-dependent	_	
135-27	25246-25257	individuals	_	
135-28	25257-25258	.	_	

#Text=Thalamus acts as a relay center for the brain by sending sensory information to insula for further interoceptive processing; hypoactivation to loss may reflect differences in relay and integration of information during decision making.
136-1	25259-25267	Thalamus	_	
136-2	25268-25272	acts	_	
136-3	25273-25275	as	_	
136-4	25276-25277	a	_	
136-5	25278-25283	relay	_	
136-6	25284-25290	center	_	
136-7	25291-25294	for	_	
136-8	25295-25298	the	_	
136-9	25299-25304	brain	_	
136-10	25305-25307	by	_	
136-11	25308-25315	sending	_	
136-12	25316-25323	sensory	_	
136-13	25324-25335	information	_	
136-14	25336-25338	to	_	
136-15	25339-25345	insula	_	
136-16	25346-25349	for	_	
136-17	25350-25357	further	_	
136-18	25358-25371	interoceptive	_	
136-19	25372-25382	processing	_	
136-20	25382-25383	;	_	
136-21	25384-25398	hypoactivation	_	
136-22	25399-25401	to	_	
136-23	25402-25406	loss	_	
136-24	25407-25410	may	_	
136-25	25411-25418	reflect	_	
136-26	25419-25430	differences	_	
136-27	25431-25433	in	_	
136-28	25434-25439	relay	_	
136-29	25440-25443	and	_	
136-30	25444-25455	integration	_	
136-31	25456-25458	of	_	
136-32	25459-25470	information	_	
136-33	25471-25477	during	_	
136-34	25478-25486	decision	_	
136-35	25487-25493	making	_	
136-36	25493-25494	.	_	

#Text=With respect to baseline characteristics, DSU endorsed higher baseline levels of state depression than PSU, which may have impacted RGT performance, as depressed individuals tend to be risk-averse.
137-1	25495-25499	With	_	
137-2	25500-25507	respect	_	
137-3	25508-25510	to	_	
137-4	25511-25519	baseline	_	
137-5	25520-25535	characteristics	_	
137-6	25535-25536	,	_	
137-7	25537-25540	DSU	_	
137-8	25541-25549	endorsed	_	
137-9	25550-25556	higher	_	
137-10	25557-25565	baseline	_	
137-11	25566-25572	levels	_	
137-12	25573-25575	of	_	
137-13	25576-25581	state	_	
137-14	25582-25592	depression	_	
137-15	25593-25597	than	_	
137-16	25598-25601	PSU	_	
137-17	25601-25602	,	_	
137-18	25603-25608	which	_	
137-19	25609-25612	may	_	
137-20	25613-25617	have	_	
137-21	25618-25626	impacted	_	
137-22	25627-25630	RGT	_	
137-23	25631-25642	performance	_	
137-24	25642-25643	,	_	
137-25	25644-25646	as	_	
137-26	25647-25656	depressed	_	
137-27	25657-25668	individuals	_	
137-28	25669-25673	tend	_	
137-29	25674-25676	to	_	
137-30	25677-25679	be	_	
137-31	25680-25691	risk-averse	_	
137-32	25691-25692	.	_	

#Text=However, given that mean scores for DSU are substantially below the BDI threshold for clinical depression (in non-clinical populations, scores above 20 indicate depression, it is unlikely that DSU performed in a manner consistent with depressed samples.
138-1	25693-25700	However	_	
138-2	25700-25701	,	_	
138-3	25702-25707	given	_	
138-4	25708-25712	that	_	
138-5	25713-25717	mean	_	
138-6	25718-25724	scores	_	
138-7	25725-25728	for	_	
138-8	25729-25732	DSU	_	
138-9	25733-25736	are	_	
138-10	25737-25750	substantially	_	
138-11	25751-25756	below	_	
138-12	25757-25760	the	_	
138-13	25761-25764	BDI	_	
138-14	25765-25774	threshold	_	
138-15	25775-25778	for	_	
138-16	25779-25787	clinical	_	
138-17	25788-25798	depression	_	
138-18	25799-25800	(	_	
138-19	25800-25802	in	_	
138-20	25803-25815	non-clinical	_	
138-21	25816-25827	populations	_	
138-22	25827-25828	,	_	
138-23	25829-25835	scores	_	
138-24	25836-25841	above	_	
138-25	25842-25844	20	_	
138-26	25845-25853	indicate	_	
138-27	25854-25864	depression	_	
138-28	25864-25865	,	_	
138-29	25866-25868	it	_	
138-30	25869-25871	is	_	
138-31	25872-25880	unlikely	_	
138-32	25881-25885	that	_	
138-33	25886-25889	DSU	_	
138-34	25890-25899	performed	_	
138-35	25900-25902	in	_	
138-36	25903-25904	a	_	
138-37	25905-25911	manner	_	
138-38	25912-25922	consistent	_	
138-39	25923-25927	with	_	
138-40	25928-25937	depressed	_	
138-41	25938-25945	samples	_	
138-42	25945-25946	.	_	

#Text=Dimensional Analyses: Interim Marijuana Use
#Text=Across OSU, lower frontal, temporal, parietal, insular, and thalamic BOLD signal during risky compared to safe decisions predicted greater future marijuana use (when accounting for baseline/future stimulant use and baseline marijuana use).
139-1	25947-25958	Dimensional	_	
139-2	25959-25967	Analyses	_	
139-3	25967-25968	:	_	
139-4	25969-25976	Interim	_	
139-5	25977-25986	Marijuana	_	
139-6	25987-25990	Use	_	
139-7	25991-25997	Across	_	
139-8	25998-26001	OSU	_	
139-9	26001-26002	,	_	
139-10	26003-26008	lower	_	
139-11	26009-26016	frontal	_	
139-12	26016-26017	,	_	
139-13	26018-26026	temporal	_	
139-14	26026-26027	,	_	
139-15	26028-26036	parietal	_	
139-16	26036-26037	,	_	
139-17	26038-26045	insular	_	
139-18	26045-26046	,	_	
139-19	26047-26050	and	_	
139-20	26051-26059	thalamic	_	
139-21	26060-26064	BOLD	_	
139-22	26065-26071	signal	_	
139-23	26072-26078	during	_	
139-24	26079-26084	risky	_	
139-25	26085-26093	compared	_	
139-26	26094-26096	to	_	
139-27	26097-26101	safe	_	
139-28	26102-26111	decisions	_	
139-29	26112-26121	predicted	_	
139-30	26122-26129	greater	_	
139-31	26130-26136	future	_	
139-32	26137-26146	marijuana	_	
139-33	26147-26150	use	_	
139-34	26151-26152	(	_	
139-35	26152-26156	when	_	
139-36	26157-26167	accounting	_	
139-37	26168-26171	for	_	
139-38	26172-26180	baseline	_	
139-39	26180-26181	/	_	
139-40	26181-26187	future	_	
139-41	26188-26197	stimulant	_	
139-42	26198-26201	use	_	
139-43	26202-26205	and	_	
139-44	26206-26214	baseline	_	
139-45	26215-26224	marijuana	_	
139-46	26225-26228	use	_	
139-47	26228-26229	)	_	
139-48	26229-26230	.	_	

#Text=These regions are considered important for executive functions such as inhibitory control, working memory and attention, as well as being relay centers for integrating information critical for decision making.
140-1	26231-26236	These	_	
140-2	26237-26244	regions	_	
140-3	26245-26248	are	_	
140-4	26249-26259	considered	_	
140-5	26260-26269	important	_	
140-6	26270-26273	for	_	
140-7	26274-26283	executive	_	
140-8	26284-26293	functions	_	
140-9	26294-26298	such	_	
140-10	26299-26301	as	_	
140-11	26302-26312	inhibitory	_	
140-12	26313-26320	control	_	
140-13	26320-26321	,	_	
140-14	26322-26329	working	_	
140-15	26330-26336	memory	_	
140-16	26337-26340	and	_	
140-17	26341-26350	attention	_	
140-18	26350-26351	,	_	
140-19	26352-26354	as	_	
140-20	26355-26359	well	_	
140-21	26360-26362	as	_	
140-22	26363-26368	being	_	
140-23	26369-26374	relay	_	
140-24	26375-26382	centers	_	
140-25	26383-26386	for	_	
140-26	26387-26398	integrating	_	
140-27	26399-26410	information	_	
140-28	26411-26419	critical	_	
140-29	26420-26423	for	_	
140-30	26424-26432	decision	_	
140-31	26433-26439	making	_	
140-32	26439-26440	.	_	

#Text=Therefore, blunted responses in these regions while making choices between risky and safe options may predispose young adults to repeatedly choose marijuana consumption despite potential negative consequences.
141-1	26441-26450	Therefore	_	
141-2	26450-26451	,	_	
141-3	26452-26459	blunted	_	
141-4	26460-26469	responses	_	
141-5	26470-26472	in	_	
141-6	26473-26478	these	_	
141-7	26479-26486	regions	_	
141-8	26487-26492	while	_	
141-9	26493-26499	making	_	
141-10	26500-26507	choices	_	
141-11	26508-26515	between	_	
141-12	26516-26521	risky	_	
141-13	26522-26525	and	_	
141-14	26526-26530	safe	_	
141-15	26531-26538	options	_	
141-16	26539-26542	may	_	
141-17	26543-26553	predispose	_	
141-18	26554-26559	young	_	
141-19	26560-26566	adults	_	
141-20	26567-26569	to	_	
141-21	26570-26580	repeatedly	_	
141-22	26581-26587	choose	_	
141-23	26588-26597	marijuana	_	
141-24	26598-26609	consumption	_	
141-25	26610-26617	despite	_	
141-26	26618-26627	potential	_	
141-27	26628-26636	negative	_	
141-28	26637-26649	consequences	_	
141-29	26649-26650	.	_	

#Text=While cumulative marijuana uses (i.e. defined as a continuous variable) between study visits was related to baseline BOLD patterns, lack of relationship between cumulative interim stimulant use and baseline BOLD signal suggests that while a dose-response effect may exist between brain activation and marijuana use, the relationship between brain activation and stimulant use may be better defined through a categorical perspective that includes accompanying clinical symptomology.
142-1	26651-26656	While	_	
142-2	26657-26667	cumulative	_	
142-3	26668-26677	marijuana	_	
142-4	26678-26682	uses	_	
142-5	26683-26684	(	_	
142-6	26684-26687	i.e	_	
142-7	26687-26688	.	_	
142-8	26689-26696	defined	_	
142-9	26697-26699	as	_	
142-10	26700-26701	a	_	
142-11	26702-26712	continuous	_	
142-12	26713-26721	variable	_	
142-13	26721-26722	)	_	
142-14	26723-26730	between	_	
142-15	26731-26736	study	_	
142-16	26737-26743	visits	_	
142-17	26744-26747	was	_	
142-18	26748-26755	related	_	
142-19	26756-26758	to	_	
142-20	26759-26767	baseline	_	
142-21	26768-26772	BOLD	_	
142-22	26773-26781	patterns	_	
142-23	26781-26782	,	_	
142-24	26783-26787	lack	_	
142-25	26788-26790	of	_	
142-26	26791-26803	relationship	_	
142-27	26804-26811	between	_	
142-28	26812-26822	cumulative	_	
142-29	26823-26830	interim	_	
142-30	26831-26840	stimulant	_	
142-31	26841-26844	use	_	
142-32	26845-26848	and	_	
142-33	26849-26857	baseline	_	
142-34	26858-26862	BOLD	_	
142-35	26863-26869	signal	_	
142-36	26870-26878	suggests	_	
142-37	26879-26883	that	_	
142-38	26884-26889	while	_	
142-39	26890-26891	a	_	
142-40	26892-26905	dose-response	_	
142-41	26906-26912	effect	_	
142-42	26913-26916	may	_	
142-43	26917-26922	exist	_	
142-44	26923-26930	between	_	
142-45	26931-26936	brain	_	
142-46	26937-26947	activation	_	
142-47	26948-26951	and	_	
142-48	26952-26961	marijuana	_	
142-49	26962-26965	use	_	
142-50	26965-26966	,	_	
142-51	26967-26970	the	_	
142-52	26971-26983	relationship	_	
142-53	26984-26991	between	_	
142-54	26992-26997	brain	_	
142-55	26998-27008	activation	_	
142-56	27009-27012	and	_	
142-57	27013-27022	stimulant	_	
142-58	27023-27026	use	_	
142-59	27027-27030	may	_	
142-60	27031-27033	be	_	
142-61	27034-27040	better	_	
142-62	27041-27048	defined	_	
142-63	27049-27056	through	_	
142-64	27057-27058	a	_	
142-65	27059-27070	categorical	_	
142-66	27071-27082	perspective	_	
142-67	27083-27087	that	_	
142-68	27088-27096	includes	_	
142-69	27097-27109	accompanying	_	
142-70	27110-27118	clinical	_	
142-71	27119-27131	symptomology	_	
142-72	27131-27132	.	_	

#Text=Though PSU and DSU used marijuana at significantly high rates (range between 0–17,046 sessions), groups did not differ categorically in marijuana abuse/dependence frequency.
143-1	27133-27139	Though	_	
143-2	27140-27143	PSU	_	
143-3	27144-27147	and	_	
143-4	27148-27151	DSU	_	
143-5	27152-27156	used	_	
143-6	27157-27166	marijuana	_	
143-7	27167-27169	at	_	
143-8	27170-27183	significantly	_	
143-9	27184-27188	high	_	
143-10	27189-27194	rates	_	
143-11	27195-27196	(	_	
143-12	27196-27201	range	_	
143-13	27202-27209	between	_	
143-14	27210-27211	0	_	
143-15	27211-27212	–	_	
143-16	27212-27218	17,046	_	
143-17	27219-27227	sessions	_	
143-18	27227-27228	)	_	
143-19	27228-27229	,	_	
143-20	27230-27236	groups	_	
143-21	27237-27240	did	_	
143-22	27241-27244	not	_	
143-23	27245-27251	differ	_	
143-24	27252-27265	categorically	_	
143-25	27266-27268	in	_	
143-26	27269-27278	marijuana	_	
143-27	27279-27284	abuse	_	
143-28	27284-27285	/	_	
143-29	27285-27295	dependence	_	
143-30	27296-27305	frequency	_	
143-31	27305-27306	.	_	

#Text=In contrast, stimulant use in and of itself (range: 3–4862 sessions) may not be related to brain differences unless it is accompanied by clinical problems, suggesting that a categorical perspective is a more useful way to conceptualize differences.
144-1	27307-27309	In	_	
144-2	27310-27318	contrast	_	
144-3	27318-27319	,	_	
144-4	27320-27329	stimulant	_	
144-5	27330-27333	use	_	
144-6	27334-27336	in	_	
144-7	27337-27340	and	_	
144-8	27341-27343	of	_	
144-9	27344-27350	itself	_	
144-10	27351-27352	(	_	
144-11	27352-27357	range	_	
144-12	27357-27358	:	_	
144-13	27359-27360	3	_	
144-14	27360-27361	–	_	
144-15	27361-27365	4862	_	
144-16	27366-27374	sessions	_	
144-17	27374-27375	)	_	
144-18	27376-27379	may	_	
144-19	27380-27383	not	_	
144-20	27384-27386	be	_	
144-21	27387-27394	related	_	
144-22	27395-27397	to	_	
144-23	27398-27403	brain	_	
144-24	27404-27415	differences	_	
144-25	27416-27422	unless	_	
144-26	27423-27425	it	_	
144-27	27426-27428	is	_	
144-28	27429-27440	accompanied	_	
144-29	27441-27443	by	_	
144-30	27444-27452	clinical	_	
144-31	27453-27461	problems	_	
144-32	27461-27462	,	_	
144-33	27463-27473	suggesting	_	
144-34	27474-27478	that	_	
144-35	27479-27480	a	_	
144-36	27481-27492	categorical	_	
144-37	27493-27504	perspective	_	
144-38	27505-27507	is	_	
144-39	27508-27509	a	_	
144-40	27510-27514	more	_	
144-41	27515-27521	useful	_	
144-42	27522-27525	way	_	
144-43	27526-27528	to	_	
144-44	27529-27542	conceptualize	_	
144-45	27543-27554	differences	_	
144-46	27554-27555	.	_	

#Text=Study Design: Strengths and Weaknesses
#Text=This study has several unique strengths including its longitudinal design, use of a model previously applied to chronic stimulant users, and assessment of substance use from both categorical and dimensional perspectives.
145-1	27556-27561	Study	_	
145-2	27562-27568	Design	_	
145-3	27568-27569	:	_	
145-4	27570-27579	Strengths	_	
145-5	27580-27583	and	_	
145-6	27584-27594	Weaknesses	_	
145-7	27595-27599	This	_	
145-8	27600-27605	study	_	
145-9	27606-27609	has	_	
145-10	27610-27617	several	_	
145-11	27618-27624	unique	_	
145-12	27625-27634	strengths	_	
145-13	27635-27644	including	_	
145-14	27645-27648	its	_	
145-15	27649-27661	longitudinal	_	
145-16	27662-27668	design	_	
145-17	27668-27669	,	_	
145-18	27670-27673	use	_	
145-19	27674-27676	of	_	
145-20	27677-27678	a	_	
145-21	27679-27684	model	_	
145-22	27685-27695	previously	_	
145-23	27696-27703	applied	_	
145-24	27704-27706	to	_	
145-25	27707-27714	chronic	_	
145-26	27715-27724	stimulant	_	
145-27	27725-27730	users	_	
145-28	27730-27731	,	_	
145-29	27732-27735	and	_	
145-30	27736-27746	assessment	_	
145-31	27747-27749	of	_	
145-32	27750-27759	substance	_	
145-33	27760-27763	use	_	
145-34	27764-27768	from	_	
145-35	27769-27773	both	_	
145-36	27774-27785	categorical	_	
145-37	27786-27789	and	_	
145-38	27790-27801	dimensional	_	
145-39	27802-27814	perspectives	_	
145-40	27814-27815	.	_	

#Text=However, this study is limited by our sample’s significant co-use of marijuana and the categorical criteria that prioritized differences as a function of SUD over marijuana use disorder, given that PSU and DSU did not differ on baseline/interim marijuana use.
146-1	27816-27823	However	_	
146-2	27823-27824	,	_	
146-3	27825-27829	this	_	
146-4	27830-27835	study	_	
146-5	27836-27838	is	_	
146-6	27839-27846	limited	_	
146-7	27847-27849	by	_	
146-8	27850-27853	our	_	
146-9	27854-27860	sample	_	
146-10	27860-27861	’	_	
146-11	27861-27862	s	_	
146-12	27863-27874	significant	_	
146-13	27875-27881	co-use	_	
146-14	27882-27884	of	_	
146-15	27885-27894	marijuana	_	
146-16	27895-27898	and	_	
146-17	27899-27902	the	_	
146-18	27903-27914	categorical	_	
146-19	27915-27923	criteria	_	
146-20	27924-27928	that	_	
146-21	27929-27940	prioritized	_	
146-22	27941-27952	differences	_	
146-23	27953-27955	as	_	
146-24	27956-27957	a	_	
146-25	27958-27966	function	_	
146-26	27967-27969	of	_	
146-27	27970-27973	SUD	_	
146-28	27974-27978	over	_	
146-29	27979-27988	marijuana	_	
146-30	27989-27992	use	_	
146-31	27993-28001	disorder	_	
146-32	28001-28002	,	_	
146-33	28003-28008	given	_	
146-34	28009-28013	that	_	
146-35	28014-28017	PSU	_	
146-36	28018-28021	and	_	
146-37	28022-28025	DSU	_	
146-38	28026-28029	did	_	
146-39	28030-28033	not	_	
146-40	28034-28040	differ	_	
146-41	28041-28043	on	_	
146-42	28044-28052	baseline	_	
146-43	28052-28053	/	_	
146-44	28053-28060	interim	_	
146-45	28061-28070	marijuana	_	
146-46	28071-28074	use	_	
146-47	28074-28075	.	_	

#Text=Additionally, although SUD has been associated with greater incidence of psychiatric illness, lack of clinical symptom measures collected at follow-up hinders our ability to determine whether mental health symptoms impacted interim substance use.
147-1	28076-28088	Additionally	_	
147-2	28088-28089	,	_	
147-3	28090-28098	although	_	
147-4	28099-28102	SUD	_	
147-5	28103-28106	has	_	
147-6	28107-28111	been	_	
147-7	28112-28122	associated	_	
147-8	28123-28127	with	_	
147-9	28128-28135	greater	_	
147-10	28136-28145	incidence	_	
147-11	28146-28148	of	_	
147-12	28149-28160	psychiatric	_	
147-13	28161-28168	illness	_	
147-14	28168-28169	,	_	
147-15	28170-28174	lack	_	
147-16	28175-28177	of	_	
147-17	28178-28186	clinical	_	
147-18	28187-28194	symptom	_	
147-19	28195-28203	measures	_	
147-20	28204-28213	collected	_	
147-21	28214-28216	at	_	
147-22	28217-28226	follow-up	_	
147-23	28227-28234	hinders	_	
147-24	28235-28238	our	_	
147-25	28239-28246	ability	_	
147-26	28247-28249	to	_	
147-27	28250-28259	determine	_	
147-28	28260-28267	whether	_	
147-29	28268-28274	mental	_	
147-30	28275-28281	health	_	
147-31	28282-28290	symptoms	_	
147-32	28291-28299	impacted	_	
147-33	28300-28307	interim	_	
147-34	28308-28317	substance	_	
147-35	28318-28321	use	_	
147-36	28321-28322	.	_	

#Text=We are also limited by an inability to evaluate the RGT from a trial-by-trial perspective to determine whether BOLD response patterns translate into future behavior or are impacted by the preceding trial; due to the limited number of separate 40 and 80 trials, it would not be possible to obtain sufficient statistical power conduct such an analysis.
148-1	28323-28325	We	_	
148-2	28326-28329	are	_	
148-3	28330-28334	also	_	
148-4	28335-28342	limited	_	
148-5	28343-28345	by	_	
148-6	28346-28348	an	_	
148-7	28349-28358	inability	_	
148-8	28359-28361	to	_	
148-9	28362-28370	evaluate	_	
148-10	28371-28374	the	_	
148-11	28375-28378	RGT	_	
148-12	28379-28383	from	_	
148-13	28384-28385	a	_	
148-14	28386-28400	trial-by-trial	_	
148-15	28401-28412	perspective	_	
148-16	28413-28415	to	_	
148-17	28416-28425	determine	_	
148-18	28426-28433	whether	_	
148-19	28434-28438	BOLD	_	
148-20	28439-28447	response	_	
148-21	28448-28456	patterns	_	
148-22	28457-28466	translate	_	
148-23	28467-28471	into	_	
148-24	28472-28478	future	_	
148-25	28479-28487	behavior	_	
148-26	28488-28490	or	_	
148-27	28491-28494	are	_	
148-28	28495-28503	impacted	_	
148-29	28504-28506	by	_	
148-30	28507-28510	the	_	
148-31	28511-28520	preceding	_	
148-32	28521-28526	trial	_	
148-33	28526-28527	;	_	
148-34	28528-28531	due	_	
148-35	28532-28534	to	_	
148-36	28535-28538	the	_	
148-37	28539-28546	limited	_	
148-38	28547-28553	number	_	
148-39	28554-28556	of	_	
148-40	28557-28565	separate	_	
148-41	28566-28568	40	_	
148-42	28569-28572	and	_	
148-43	28573-28575	80	_	
148-44	28576-28582	trials	_	
148-45	28582-28583	,	_	
148-46	28584-28586	it	_	
148-47	28587-28592	would	_	
148-48	28593-28596	not	_	
148-49	28597-28599	be	_	
148-50	28600-28608	possible	_	
148-51	28609-28611	to	_	
148-52	28612-28618	obtain	_	
148-53	28619-28629	sufficient	_	
148-54	28630-28641	statistical	_	
148-55	28642-28647	power	_	
148-56	28648-28655	conduct	_	
148-57	28656-28660	such	_	
148-58	28661-28663	an	_	
148-59	28664-28672	analysis	_	
148-60	28672-28673	.	_	

#Text=Conclusions and Future Directions
#Text=Pre-existing BOLD signal patterns during risky decision making predicts transition to SUD.
149-1	28674-28685	Conclusions	_	
149-2	28686-28689	and	_	
149-3	28690-28696	Future	_	
149-4	28697-28707	Directions	_	
149-5	28708-28720	Pre-existing	_	
149-6	28721-28725	BOLD	_	
149-7	28726-28732	signal	_	
149-8	28733-28741	patterns	_	
149-9	28742-28748	during	_	
149-10	28749-28754	risky	_	
149-11	28755-28763	decision	_	
149-12	28764-28770	making	_	
149-13	28771-28779	predicts	_	
149-14	28780-28790	transition	_	
149-15	28791-28793	to	_	
149-16	28794-28797	SUD	_	
149-17	28797-28798	.	_	

#Text=Frontocingulate, insular, and striatal blunting to feedback after selection of a risky choice may predispose young adults to future decision making impairments (continuing to use stimulants despite clinical problems).
150-1	28799-28814	Frontocingulate	_	
150-2	28814-28815	,	_	
150-3	28816-28823	insular	_	
150-4	28823-28824	,	_	
150-5	28825-28828	and	_	
150-6	28829-28837	striatal	_	
150-7	28838-28846	blunting	_	
150-8	28847-28849	to	_	
150-9	28850-28858	feedback	_	
150-10	28859-28864	after	_	
150-11	28865-28874	selection	_	
150-12	28875-28877	of	_	
150-13	28878-28879	a	_	
150-14	28880-28885	risky	_	
150-15	28886-28892	choice	_	
150-16	28893-28896	may	_	
150-17	28897-28907	predispose	_	
150-18	28908-28913	young	_	
150-19	28914-28920	adults	_	
150-20	28921-28923	to	_	
150-21	28924-28930	future	_	
150-22	28931-28939	decision	_	
150-23	28940-28946	making	_	
150-24	28947-28958	impairments	_	
150-25	28959-28960	(	_	
150-26	28960-28970	continuing	_	
150-27	28971-28973	to	_	
150-28	28974-28977	use	_	
150-29	28978-28988	stimulants	_	
150-30	28989-28996	despite	_	
150-31	28997-29005	clinical	_	
150-32	29006-29014	problems	_	
150-33	29014-29015	)	_	
150-34	29015-29016	.	_	

#Text=Moreover, blunted frontal, insular, and striatal BOLD signal during action selection predicts greater frequency of future marijuana use.
151-1	29017-29025	Moreover	_	
151-2	29025-29026	,	_	
151-3	29027-29034	blunted	_	
151-4	29035-29042	frontal	_	
151-5	29042-29043	,	_	
151-6	29044-29051	insular	_	
151-7	29051-29052	,	_	
151-8	29053-29056	and	_	
151-9	29057-29065	striatal	_	
151-10	29066-29070	BOLD	_	
151-11	29071-29077	signal	_	
151-12	29078-29084	during	_	
151-13	29085-29091	action	_	
151-14	29092-29101	selection	_	
151-15	29102-29110	predicts	_	
151-16	29111-29118	greater	_	
151-17	29119-29128	frequency	_	
151-18	29129-29131	of	_	
151-19	29132-29138	future	_	
151-20	29139-29148	marijuana	_	
151-21	29149-29152	use	_	
151-22	29152-29153	.	_	

#Text=Future research is needed to determine if these biomarkers can identify at-risk individuals who might benefit from targeted interventions.
152-1	29154-29160	Future	_	
152-2	29161-29169	research	_	
152-3	29170-29172	is	_	
152-4	29173-29179	needed	_	
152-5	29180-29182	to	_	
152-6	29183-29192	determine	_	
152-7	29193-29195	if	_	
152-8	29196-29201	these	_	
152-9	29202-29212	biomarkers	_	
152-10	29213-29216	can	_	
152-11	29217-29225	identify	_	
152-12	29226-29233	at-risk	_	
152-13	29234-29245	individuals	_	
152-14	29246-29249	who	_	
152-15	29250-29255	might	_	
152-16	29256-29263	benefit	_	
152-17	29264-29268	from	_	
152-18	29269-29277	targeted	_	
152-19	29278-29291	interventions	_	
152-20	29291-29292	.	_	

#Text=Supplementary Material
#Text=           Disclosures         
#Text=The authors report no financial interests or potential conflicts of interest.
153-1	29293-29306	Supplementary	_	
153-2	29307-29315	Material	_	
153-3	29327-29338	Disclosures	_	
153-4	29348-29351	The	_	
153-5	29352-29359	authors	_	
153-6	29360-29366	report	_	
153-7	29367-29369	no	_	
153-8	29370-29379	financial	_	
153-9	29380-29389	interests	_	
153-10	29390-29392	or	_	
153-11	29393-29402	potential	_	
153-12	29403-29412	conflicts	_	
153-13	29413-29415	of	_	
153-14	29416-29424	interest	_	
153-15	29424-29425	.	_	

#Text=This is a PDF file of an unedited manuscript that has been accepted for publication.
154-1	29426-29430	This	_	
154-2	29431-29433	is	_	
154-3	29434-29435	a	_	
154-4	29436-29439	PDF	_	
154-5	29440-29444	file	_	
154-6	29445-29447	of	_	
154-7	29448-29450	an	_	
154-8	29451-29459	unedited	_	
154-9	29460-29470	manuscript	_	
154-10	29471-29475	that	_	
154-11	29476-29479	has	_	
154-12	29480-29484	been	_	
154-13	29485-29493	accepted	_	
154-14	29494-29497	for	_	
154-15	29498-29509	publication	_	
154-16	29509-29510	.	_	

#Text=As a service to our customers we are providing this early version of the manuscript.
155-1	29511-29513	As	_	
155-2	29514-29515	a	_	
155-3	29516-29523	service	_	
155-4	29524-29526	to	_	
155-5	29527-29530	our	_	
155-6	29531-29540	customers	_	
155-7	29541-29543	we	_	
155-8	29544-29547	are	_	
155-9	29548-29557	providing	_	
155-10	29558-29562	this	_	
155-11	29563-29568	early	_	
155-12	29569-29576	version	_	
155-13	29577-29579	of	_	
155-14	29580-29583	the	_	
155-15	29584-29594	manuscript	_	
155-16	29594-29595	.	_	

#Text=The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form.
156-1	29596-29599	The	_	
156-2	29600-29610	manuscript	_	
156-3	29611-29615	will	_	
156-4	29616-29623	undergo	_	
156-5	29624-29635	copyediting	_	
156-6	29635-29636	,	_	
156-7	29637-29648	typesetting	_	
156-8	29648-29649	,	_	
156-9	29650-29653	and	_	
156-10	29654-29660	review	_	
156-11	29661-29663	of	_	
156-12	29664-29667	the	_	
156-13	29668-29677	resulting	_	
156-14	29678-29683	proof	_	
156-15	29684-29690	before	_	
156-16	29691-29693	it	_	
156-17	29694-29696	is	_	
156-18	29697-29706	published	_	
156-19	29707-29709	in	_	
156-20	29710-29713	its	_	
156-21	29714-29719	final	_	
156-22	29720-29727	citable	_	
156-23	29728-29732	form	_	
156-24	29732-29733	.	_	

#Text=Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
157-1	29734-29740	Please	_	
157-2	29741-29745	note	_	
157-3	29746-29750	that	_	
157-4	29751-29757	during	_	
157-5	29758-29761	the	_	
157-6	29762-29772	production	_	
157-7	29773-29780	process	_	
157-8	29781-29787	errors	_	
157-9	29788-29791	may	_	
157-10	29792-29794	be	_	
157-11	29795-29805	discovered	_	
157-12	29806-29811	which	_	
157-13	29812-29817	could	_	
157-14	29818-29824	affect	_	
157-15	29825-29828	the	_	
157-16	29829-29836	content	_	
157-17	29836-29837	,	_	
157-18	29838-29841	and	_	
157-19	29842-29845	all	_	
157-20	29846-29851	legal	_	
157-21	29852-29863	disclaimers	_	
157-22	29864-29868	that	_	
157-23	29869-29874	apply	_	
157-24	29875-29877	to	_	
157-25	29878-29881	the	_	
157-26	29882-29889	journal	_	
157-27	29890-29897	pertain	_	
157-28	29897-29898	.	_	

#Text=Misuse and Diversion of Stimulants Prescribed for ADHD: A Systematic Review of the Literature
#Text=From First Drug Use to Drug Dependence Developmental Periods of Risk for Dependence upon Marijuana, Cocaine, and Alcohol
#Text=The maturation of incentive processing and cognitive control
#Text=Results From the 1995 National College Health Risk Behavior Survey
#Text=Depressive symptoms and clustering of risk behaviours among adolescents and young adults attending vocational education: a cross-sectional study
#Text=Clustering of health-related behaviors, health outcomes and demographics in Dutch adolescents: a cross-sectional study
#Text=Parallel Development of Risk Behaviors in Adolescence: Potential Pathways to Co-occurrence
#Text=Dopamine, Affordance and Active Inference
#Text=An evolutionary computational theory of prefrontal executive function in decision-making
#Text=Location, location: Using functional magnetic resonance imaging to pinpoint brain differences relevant to stimulant use
#Text=Decision-making and addiction (part I): impaired activation of somatic states in substance dependent individuals when pondering decisions with negative future consequences
#Text=Orbitofrontal cortex dysfunction in abstinent cocaine abusers performing a decision-making task
#Text=Imaging the Addicted Human Brain
#Text=Diffusion tensor imaging and decision making in cocaine dependence
#Text=Decision making, impulse control and loss of willpower to resist drugs: a neurocognitive perspective
#Text=Dysfunction of the prefrontal cortex in addiction: neuroimaging findings and clinical implications
#Text=Prefrontal Cortical Dysfunction in Abstinent Cocaine Abusers
#Text=Behavioral and Functional Neuroimaging Evidence for Prefrontal Dysfunction in Methamphetamine-Dependent Subjects
#Text=Role of the anterior cingulate and medial orbitofrontal cortex in processing drug cues in cocaine addiction
#Text=Decision making by methamphetamine-dependent subjects is associated with error-rate-independent decrease in prefrontal and parietal activation
#Text=The addicted human brain: Insights from imaging studies
#Text=The basal ganglia and adaptive motor control
#Text=Multiple parallel memory systems in the brain of the rat
#Text=Insensitivity to future consequences following damage to human prefrontal cortex
#Text=Functional activity related to risk anticipation during performance of the Iowa gambling task
#Text=Distinct Roles of Prefrontal Cortical Subregions in the Iowa Gambling Task
#Text=Risky Decision Making, Prefrontal Cortex, and Mesocorticolimbic Functional Connectivity in Methamphetamine Dependence
#Text=Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART)
#Text=Abnormal frontal activations related to decision-making in current and former amphetamine and opiate dependent individuals
#Text=The impact of prior risk experiences on subsequent risky decision-making: The role of the insula
#Text=The hidden island of addiction: the insula
#Text=Anterior Cingulate Cortex: Unique Role in Cognition and Emotion
#Text=Cingulate hypoactivity in cocaine users during a GO-NOGO task as revealed by event-related functional magnetic resonance imaging
#Text=Neural Correlates of Impulse Control During Stop Signal Inhibition in Cocaine-Dependent Men
#Text=Impaired Prefrontal Cortical Function and Disrupted Adaptive Cognitive Control in Methamphetamine Abusers: A Functional Magnetic Resonance Imaging Study
#Text=Inhibitory Control and Emotional Stress Regulation: Neuroimaging Evidence for Frontal-Limbic Dysfunction in Psycho-stimulant
#Text=Impaired inhibitory control in recreational cocaine users
#Text=Recreational cocaine polydrug use impairs cognitive flexibility but not working memory
#Text=Neuropsychological effects associated with recreational cocaine use
#Text=Cognitive dysfunctions in recreational and dependent cocaine users: role of attention-deficit hyperactivity disorder, craving and early age at onset
#Text=Attenuated neural processing of risk in young adults at risk for stimulant dependence
#Text=Risk Taking and the Adolescent Reward System: A Potential Common Link to Substance Abuse
#Text=Blunted ventral striatal responses to anticipated rewards foreshadow problematic drug use in novelty-seeking adolescents
#Text=Smaller amygdala and medial prefrontal cortex predict escalating stimulant use
#Text=Neuropsychosocial profiles of current and future adolescent alcohol misusers
#Text=Cocaine dependence and concurrent marijuana use: a comparison of clinical characteristics
#Text=A new, semi-structured psychiatric interview for use in genetic linkage studies: a report on the reliability of the SSAGA
#Text=
#Text=Altered frontocingulate activation during aversive interoceptive processing in young adults transitioning to problem stimulant use
#Text=Response inhibition and elevated parietal-cerebellar correlations in chronic adolescent cannabis users
#Text=Altered cingulate and insular cortex activation during risk-taking in methamphetamine dependence: losses lose impact
#Text=Attenuated Insular Processing During Risk Predicts Relapse in Early Abstinent Methamphetamine-Dependent Individuals
#Text=Increased risk-taking decision-making but not altered response to punishment in stimulant-using young adults
#Text=Dissociation of inhibition from error processing using a parametric inhibitory task during functional magnetic resonance imaging
#Text=Young adults at risk for stimulant dependence show reward dysfunction during reinforcement-based decision making
#Text=Use of methods from chaos theory to quantify a fundamental dysfunction in the behavioral organization of schizophrenic patients
#Text=Commentary on Stewart et al. (2017): Stimulants and marijuana-the potential value in studying substance co-use
#Text=
#Text=Drug use desistance
#Text=Individual differences in childhood neurobehavior disinhibition predict decision to desist substance use during adolescence and substance use disorder in young adulthood: A prospective study
#Text=AFNI: software for analysis and visualization of functional magnetic resonance neuroimages
#Text=
#Text=Visual cortex activation to drug cues: a meta-analysis of functional neuroimaging papers in addiction and substance abuse literature
#Text=The medial temporal lobes are critical for reward-based decision making under conditions that promote episodic future thinking
#Text=Neural responses to risk and reward predict transition to problem stimulant use
#Text=The hyper-sentient addict: an exteroception model of addiction HHS Public Access
#Text=Error processing and gender-shared and -specific neural predictors of relapse in cocaine dependence
#Text=Decision-making and risk aversion among depressive adults
#Text=Issues and recommendations regarding use of the Beck Depression Inventory
#Text=The addicted human brain viewed in the light of imaging studies: Brain circuits and treatment strategies
#Text=Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity
#Text=The epidemiology of co-occurring addictive and mental disorders: implications for prevention and service utilization
#Text=Use of the AUDIT and the DAST-10 to identify alcohol and drug use disorders among adults with a severe and persistent mental illness
#Text=Overview of study design and data analyses.
158-1	29900-29906	Misuse	_	
158-2	29907-29910	and	_	
158-3	29911-29920	Diversion	_	
158-4	29921-29923	of	_	
158-5	29924-29934	Stimulants	_	
158-6	29935-29945	Prescribed	_	
158-7	29946-29949	for	_	
158-8	29950-29954	ADHD	_	
158-9	29954-29955	:	_	
158-10	29956-29957	A	_	
158-11	29958-29968	Systematic	_	
158-12	29969-29975	Review	_	
158-13	29976-29978	of	_	
158-14	29979-29982	the	_	
158-15	29983-29993	Literature	_	
158-16	29994-29998	From	_	
158-17	29999-30004	First	_	
158-18	30005-30009	Drug	_	
158-19	30010-30013	Use	_	
158-20	30014-30016	to	_	
158-21	30017-30021	Drug	_	
158-22	30022-30032	Dependence	_	
158-23	30033-30046	Developmental	_	
158-24	30047-30054	Periods	_	
158-25	30055-30057	of	_	
158-26	30058-30062	Risk	_	
158-27	30063-30066	for	_	
158-28	30067-30077	Dependence	_	
158-29	30078-30082	upon	_	
158-30	30083-30092	Marijuana	_	
158-31	30092-30093	,	_	
158-32	30094-30101	Cocaine	_	
158-33	30101-30102	,	_	
158-34	30103-30106	and	_	
158-35	30107-30114	Alcohol	_	
158-36	30115-30118	The	_	
158-37	30119-30129	maturation	_	
158-38	30130-30132	of	_	
158-39	30133-30142	incentive	_	
158-40	30143-30153	processing	_	
158-41	30154-30157	and	_	
158-42	30158-30167	cognitive	_	
158-43	30168-30175	control	_	
158-44	30176-30183	Results	_	
158-45	30184-30188	From	_	
158-46	30189-30192	the	_	
158-47	30193-30197	1995	_	
158-48	30198-30206	National	_	
158-49	30207-30214	College	_	
158-50	30215-30221	Health	_	
158-51	30222-30226	Risk	_	
158-52	30227-30235	Behavior	_	
158-53	30236-30242	Survey	_	
158-54	30243-30253	Depressive	_	
158-55	30254-30262	symptoms	_	
158-56	30263-30266	and	_	
158-57	30267-30277	clustering	_	
158-58	30278-30280	of	_	
158-59	30281-30285	risk	_	
158-60	30286-30296	behaviours	_	
158-61	30297-30302	among	_	
158-62	30303-30314	adolescents	_	
158-63	30315-30318	and	_	
158-64	30319-30324	young	_	
158-65	30325-30331	adults	_	
158-66	30332-30341	attending	_	
158-67	30342-30352	vocational	_	
158-68	30353-30362	education	_	
158-69	30362-30363	:	_	
158-70	30364-30365	a	_	
158-71	30366-30381	cross-sectional	_	
158-72	30382-30387	study	_	
158-73	30388-30398	Clustering	_	
158-74	30399-30401	of	_	
158-75	30402-30416	health-related	_	
158-76	30417-30426	behaviors	_	
158-77	30426-30427	,	_	
158-78	30428-30434	health	_	
158-79	30435-30443	outcomes	_	
158-80	30444-30447	and	_	
158-81	30448-30460	demographics	_	
158-82	30461-30463	in	_	
158-83	30464-30469	Dutch	_	
158-84	30470-30481	adolescents	_	
158-85	30481-30482	:	_	
158-86	30483-30484	a	_	
158-87	30485-30500	cross-sectional	_	
158-88	30501-30506	study	_	
158-89	30507-30515	Parallel	_	
158-90	30516-30527	Development	_	
158-91	30528-30530	of	_	
158-92	30531-30535	Risk	_	
158-93	30536-30545	Behaviors	_	
158-94	30546-30548	in	_	
158-95	30549-30560	Adolescence	_	
158-96	30560-30561	:	_	
158-97	30562-30571	Potential	_	
158-98	30572-30580	Pathways	_	
158-99	30581-30583	to	_	
158-100	30584-30597	Co-occurrence	_	
158-101	30598-30606	Dopamine	_	
158-102	30606-30607	,	_	
158-103	30608-30618	Affordance	_	
158-104	30619-30622	and	_	
158-105	30623-30629	Active	_	
158-106	30630-30639	Inference	_	
158-107	30640-30642	An	_	
158-108	30643-30655	evolutionary	_	
158-109	30656-30669	computational	_	
158-110	30670-30676	theory	_	
158-111	30677-30679	of	_	
158-112	30680-30690	prefrontal	_	
158-113	30691-30700	executive	_	
158-114	30701-30709	function	_	
158-115	30710-30712	in	_	
158-116	30713-30728	decision-making	_	
158-117	30729-30737	Location	_	
158-118	30737-30738	,	_	
158-119	30739-30747	location	_	
158-120	30747-30748	:	_	
158-121	30749-30754	Using	_	
158-122	30755-30765	functional	_	
158-123	30766-30774	magnetic	_	
158-124	30775-30784	resonance	_	
158-125	30785-30792	imaging	_	
158-126	30793-30795	to	_	
158-127	30796-30804	pinpoint	_	
158-128	30805-30810	brain	_	
158-129	30811-30822	differences	_	
158-130	30823-30831	relevant	_	
158-131	30832-30834	to	_	
158-132	30835-30844	stimulant	_	
158-133	30845-30848	use	_	
158-134	30849-30864	Decision-making	_	
158-135	30865-30868	and	_	
158-136	30869-30878	addiction	_	
158-137	30879-30880	(	_	
158-138	30880-30884	part	_	
158-139	30885-30886	I	_	
158-140	30886-30887	)	_	
158-141	30887-30888	:	_	
158-142	30889-30897	impaired	_	
158-143	30898-30908	activation	_	
158-144	30909-30911	of	_	
158-145	30912-30919	somatic	_	
158-146	30920-30926	states	_	
158-147	30927-30929	in	_	
158-148	30930-30939	substance	_	
158-149	30940-30949	dependent	_	
158-150	30950-30961	individuals	_	
158-151	30962-30966	when	_	
158-152	30967-30976	pondering	_	
158-153	30977-30986	decisions	_	
158-154	30987-30991	with	_	
158-155	30992-31000	negative	_	
158-156	31001-31007	future	_	
158-157	31008-31020	consequences	_	
158-158	31021-31034	Orbitofrontal	_	
158-159	31035-31041	cortex	_	
158-160	31042-31053	dysfunction	_	
158-161	31054-31056	in	_	
158-162	31057-31066	abstinent	_	
158-163	31067-31074	cocaine	_	
158-164	31075-31082	abusers	_	
158-165	31083-31093	performing	_	
158-166	31094-31095	a	_	
158-167	31096-31111	decision-making	_	
158-168	31112-31116	task	_	
158-169	31117-31124	Imaging	_	
158-170	31125-31128	the	_	
158-171	31129-31137	Addicted	_	
158-172	31138-31143	Human	_	
158-173	31144-31149	Brain	_	
158-174	31150-31159	Diffusion	_	
158-175	31160-31166	tensor	_	
158-176	31167-31174	imaging	_	
158-177	31175-31178	and	_	
158-178	31179-31187	decision	_	
158-179	31188-31194	making	_	
158-180	31195-31197	in	_	
158-181	31198-31205	cocaine	_	
158-182	31206-31216	dependence	_	
158-183	31217-31225	Decision	_	
158-184	31226-31232	making	_	
158-185	31232-31233	,	_	
158-186	31234-31241	impulse	_	
158-187	31242-31249	control	_	
158-188	31250-31253	and	_	
158-189	31254-31258	loss	_	
158-190	31259-31261	of	_	
158-191	31262-31271	willpower	_	
158-192	31272-31274	to	_	
158-193	31275-31281	resist	_	
158-194	31282-31287	drugs	_	
158-195	31287-31288	:	_	
158-196	31289-31290	a	_	
158-197	31291-31305	neurocognitive	_	
158-198	31306-31317	perspective	_	
158-199	31318-31329	Dysfunction	_	
158-200	31330-31332	of	_	
158-201	31333-31336	the	_	
158-202	31337-31347	prefrontal	_	
158-203	31348-31354	cortex	_	
158-204	31355-31357	in	_	
158-205	31358-31367	addiction	_	
158-206	31367-31368	:	_	
158-207	31369-31381	neuroimaging	_	
158-208	31382-31390	findings	_	
158-209	31391-31394	and	_	
158-210	31395-31403	clinical	_	
158-211	31404-31416	implications	_	
158-212	31417-31427	Prefrontal	_	
158-213	31428-31436	Cortical	_	
158-214	31437-31448	Dysfunction	_	
158-215	31449-31451	in	_	
158-216	31452-31461	Abstinent	_	
158-217	31462-31469	Cocaine	_	
158-218	31470-31477	Abusers	_	
158-219	31478-31488	Behavioral	_	
158-220	31489-31492	and	_	
158-221	31493-31503	Functional	_	
158-222	31504-31516	Neuroimaging	_	
158-223	31517-31525	Evidence	_	
158-224	31526-31529	for	_	
158-225	31530-31540	Prefrontal	_	
158-226	31541-31552	Dysfunction	_	
158-227	31553-31555	in	_	
158-228	31556-31581	Methamphetamine-Dependent	_	
158-229	31582-31590	Subjects	_	
158-230	31591-31595	Role	_	
158-231	31596-31598	of	_	
158-232	31599-31602	the	_	
158-233	31603-31611	anterior	_	
158-234	31612-31621	cingulate	_	
158-235	31622-31625	and	_	
158-236	31626-31632	medial	_	
158-237	31633-31646	orbitofrontal	_	
158-238	31647-31653	cortex	_	
158-239	31654-31656	in	_	
158-240	31657-31667	processing	_	
158-241	31668-31672	drug	_	
158-242	31673-31677	cues	_	
158-243	31678-31680	in	_	
158-244	31681-31688	cocaine	_	
158-245	31689-31698	addiction	_	
158-246	31699-31707	Decision	_	
158-247	31708-31714	making	_	
158-248	31715-31717	by	_	
158-249	31718-31743	methamphetamine-dependent	_	
158-250	31744-31752	subjects	_	
158-251	31753-31755	is	_	
158-252	31756-31766	associated	_	
158-253	31767-31771	with	_	
158-254	31772-31794	error-rate-independent	_	
158-255	31795-31803	decrease	_	
158-256	31804-31806	in	_	
158-257	31807-31817	prefrontal	_	
158-258	31818-31821	and	_	
158-259	31822-31830	parietal	_	
158-260	31831-31841	activation	_	
158-261	31842-31845	The	_	
158-262	31846-31854	addicted	_	
158-263	31855-31860	human	_	
158-264	31861-31866	brain	_	
158-265	31866-31867	:	_	
158-266	31868-31876	Insights	_	
158-267	31877-31881	from	_	
158-268	31882-31889	imaging	_	
158-269	31890-31897	studies	_	
158-270	31898-31901	The	_	
158-271	31902-31907	basal	_	
158-272	31908-31915	ganglia	_	
158-273	31916-31919	and	_	
158-274	31920-31928	adaptive	_	
158-275	31929-31934	motor	_	
158-276	31935-31942	control	_	
158-277	31943-31951	Multiple	_	
158-278	31952-31960	parallel	_	
158-279	31961-31967	memory	_	
158-280	31968-31975	systems	_	
158-281	31976-31978	in	_	
158-282	31979-31982	the	_	
158-283	31983-31988	brain	_	
158-284	31989-31991	of	_	
158-285	31992-31995	the	_	
158-286	31996-31999	rat	_	
158-287	32000-32013	Insensitivity	_	
158-288	32014-32016	to	_	
158-289	32017-32023	future	_	
158-290	32024-32036	consequences	_	
158-291	32037-32046	following	_	
158-292	32047-32053	damage	_	
158-293	32054-32056	to	_	
158-294	32057-32062	human	_	
158-295	32063-32073	prefrontal	_	
158-296	32074-32080	cortex	_	
158-297	32081-32091	Functional	_	
158-298	32092-32100	activity	_	
158-299	32101-32108	related	_	
158-300	32109-32111	to	_	
158-301	32112-32116	risk	_	
158-302	32117-32129	anticipation	_	
158-303	32130-32136	during	_	
158-304	32137-32148	performance	_	
158-305	32149-32151	of	_	
158-306	32152-32155	the	_	
158-307	32156-32160	Iowa	_	
158-308	32161-32169	gambling	_	
158-309	32170-32174	task	_	
158-310	32175-32183	Distinct	_	
158-311	32184-32189	Roles	_	
158-312	32190-32192	of	_	
158-313	32193-32203	Prefrontal	_	
158-314	32204-32212	Cortical	_	
158-315	32213-32223	Subregions	_	
158-316	32224-32226	in	_	
158-317	32227-32230	the	_	
158-318	32231-32235	Iowa	_	
158-319	32236-32244	Gambling	_	
158-320	32245-32249	Task	_	
158-321	32250-32255	Risky	_	
158-322	32256-32264	Decision	_	
158-323	32265-32271	Making	_	
158-324	32271-32272	,	_	
158-325	32273-32283	Prefrontal	_	
158-326	32284-32290	Cortex	_	
158-327	32290-32291	,	_	
158-328	32292-32295	and	_	
158-329	32296-32313	Mesocorticolimbic	_	
158-330	32314-32324	Functional	_	
158-331	32325-32337	Connectivity	_	
158-332	32338-32340	in	_	
158-333	32341-32356	Methamphetamine	_	
158-334	32357-32367	Dependence	_	
158-335	32368-32378	Evaluation	_	
158-336	32379-32381	of	_	
158-337	32382-32383	a	_	
158-338	32384-32394	behavioral	_	
158-339	32395-32402	measure	_	
158-340	32403-32405	of	_	
158-341	32406-32410	risk	_	
158-342	32411-32417	taking	_	
158-343	32417-32418	:	_	
158-344	32419-32422	the	_	
158-345	32423-32430	Balloon	_	
158-346	32431-32439	Analogue	_	
158-347	32440-32444	Risk	_	
158-348	32445-32449	Task	_	
158-349	32450-32451	(	_	
158-350	32451-32455	BART	_	
158-351	32455-32456	)	_	
158-352	32457-32465	Abnormal	_	
158-353	32466-32473	frontal	_	
158-354	32474-32485	activations	_	
158-355	32486-32493	related	_	
158-356	32494-32496	to	_	
158-357	32497-32512	decision-making	_	
158-358	32513-32515	in	_	
158-359	32516-32523	current	_	
158-360	32524-32527	and	_	
158-361	32528-32534	former	_	
158-362	32535-32546	amphetamine	_	
158-363	32547-32550	and	_	
158-364	32551-32557	opiate	_	
158-365	32558-32567	dependent	_	
158-366	32568-32579	individuals	_	
158-367	32580-32583	The	_	
158-368	32584-32590	impact	_	
158-369	32591-32593	of	_	
158-370	32594-32599	prior	_	
158-371	32600-32604	risk	_	
158-372	32605-32616	experiences	_	
158-373	32617-32619	on	_	
158-374	32620-32630	subsequent	_	
158-375	32631-32636	risky	_	
158-376	32637-32652	decision-making	_	
158-377	32652-32653	:	_	
158-378	32654-32657	The	_	
158-379	32658-32662	role	_	
158-380	32663-32665	of	_	
158-381	32666-32669	the	_	
158-382	32670-32676	insula	_	
158-383	32677-32680	The	_	
158-384	32681-32687	hidden	_	
158-385	32688-32694	island	_	
158-386	32695-32697	of	_	
158-387	32698-32707	addiction	_	
158-388	32707-32708	:	_	
158-389	32709-32712	the	_	
158-390	32713-32719	insula	_	
158-391	32720-32728	Anterior	_	
158-392	32729-32738	Cingulate	_	
158-393	32739-32745	Cortex	_	
158-394	32745-32746	:	_	
158-395	32747-32753	Unique	_	
158-396	32754-32758	Role	_	
158-397	32759-32761	in	_	
158-398	32762-32771	Cognition	_	
158-399	32772-32775	and	_	
158-400	32776-32783	Emotion	_	
158-401	32784-32793	Cingulate	_	
158-402	32794-32806	hypoactivity	_	
158-403	32807-32809	in	_	
158-404	32810-32817	cocaine	_	
158-405	32818-32823	users	_	
158-406	32824-32830	during	_	
158-407	32831-32832	a	_	
158-408	32833-32840	GO-NOGO	_	
158-409	32841-32845	task	_	
158-410	32846-32848	as	_	
158-411	32849-32857	revealed	_	
158-412	32858-32860	by	_	
158-413	32861-32874	event-related	_	
158-414	32875-32885	functional	_	
158-415	32886-32894	magnetic	_	
158-416	32895-32904	resonance	_	
158-417	32905-32912	imaging	_	
158-418	32913-32919	Neural	_	
158-419	32920-32930	Correlates	_	
158-420	32931-32933	of	_	
158-421	32934-32941	Impulse	_	
158-422	32942-32949	Control	_	
158-423	32950-32956	During	_	
158-424	32957-32961	Stop	_	
158-425	32962-32968	Signal	_	
158-426	32969-32979	Inhibition	_	
158-427	32980-32982	in	_	
158-428	32983-33000	Cocaine-Dependent	_	
158-429	33001-33004	Men	_	
158-430	33005-33013	Impaired	_	
158-431	33014-33024	Prefrontal	_	
158-432	33025-33033	Cortical	_	
158-433	33034-33042	Function	_	
158-434	33043-33046	and	_	
158-435	33047-33056	Disrupted	_	
158-436	33057-33065	Adaptive	_	
158-437	33066-33075	Cognitive	_	
158-438	33076-33083	Control	_	
158-439	33084-33086	in	_	
158-440	33087-33102	Methamphetamine	_	
158-441	33103-33110	Abusers	_	
158-442	33110-33111	:	_	
158-443	33112-33113	A	_	
158-444	33114-33124	Functional	_	
158-445	33125-33133	Magnetic	_	
158-446	33134-33143	Resonance	_	
158-447	33144-33151	Imaging	_	
158-448	33152-33157	Study	_	
158-449	33158-33168	Inhibitory	_	
158-450	33169-33176	Control	_	
158-451	33177-33180	and	_	
158-452	33181-33190	Emotional	_	
158-453	33191-33197	Stress	_	
158-454	33198-33208	Regulation	_	
158-455	33208-33209	:	_	
158-456	33210-33222	Neuroimaging	_	
158-457	33223-33231	Evidence	_	
158-458	33232-33235	for	_	
158-459	33236-33250	Frontal-Limbic	_	
158-460	33251-33262	Dysfunction	_	
158-461	33263-33265	in	_	
158-462	33266-33282	Psycho-stimulant	_	
158-463	33283-33291	Impaired	_	
158-464	33292-33302	inhibitory	_	
158-465	33303-33310	control	_	
158-466	33311-33313	in	_	
158-467	33314-33326	recreational	_	
158-468	33327-33334	cocaine	_	
158-469	33335-33340	users	_	
158-470	33341-33353	Recreational	_	
158-471	33354-33361	cocaine	_	
158-472	33362-33370	polydrug	_	
158-473	33371-33374	use	_	
158-474	33375-33382	impairs	_	
158-475	33383-33392	cognitive	_	
158-476	33393-33404	flexibility	_	
158-477	33405-33408	but	_	
158-478	33409-33412	not	_	
158-479	33413-33420	working	_	
158-480	33421-33427	memory	_	
158-481	33428-33446	Neuropsychological	_	
158-482	33447-33454	effects	_	
158-483	33455-33465	associated	_	
158-484	33466-33470	with	_	
158-485	33471-33483	recreational	_	
158-486	33484-33491	cocaine	_	
158-487	33492-33495	use	_	
158-488	33496-33505	Cognitive	_	
158-489	33506-33518	dysfunctions	_	
158-490	33519-33521	in	_	
158-491	33522-33534	recreational	_	
158-492	33535-33538	and	_	
158-493	33539-33548	dependent	_	
158-494	33549-33556	cocaine	_	
158-495	33557-33562	users	_	
158-496	33562-33563	:	_	
158-497	33564-33568	role	_	
158-498	33569-33571	of	_	
158-499	33572-33589	attention-deficit	_	
158-500	33590-33603	hyperactivity	_	
158-501	33604-33612	disorder	_	
158-502	33612-33613	,	_	
158-503	33614-33621	craving	_	
158-504	33622-33625	and	_	
158-505	33626-33631	early	_	
158-506	33632-33635	age	_	
158-507	33636-33638	at	_	
158-508	33639-33644	onset	_	
158-509	33645-33655	Attenuated	_	
158-510	33656-33662	neural	_	
158-511	33663-33673	processing	_	
158-512	33674-33676	of	_	
158-513	33677-33681	risk	_	
158-514	33682-33684	in	_	
158-515	33685-33690	young	_	
158-516	33691-33697	adults	_	
158-517	33698-33700	at	_	
158-518	33701-33705	risk	_	
158-519	33706-33709	for	_	
158-520	33710-33719	stimulant	_	
158-521	33720-33730	dependence	_	
158-522	33731-33735	Risk	_	
158-523	33736-33742	Taking	_	
158-524	33743-33746	and	_	
158-525	33747-33750	the	_	
158-526	33751-33761	Adolescent	_	
158-527	33762-33768	Reward	_	
158-528	33769-33775	System	_	
158-529	33775-33776	:	_	
158-530	33777-33778	A	_	
158-531	33779-33788	Potential	_	
158-532	33789-33795	Common	_	
158-533	33796-33800	Link	_	
158-534	33801-33803	to	_	
158-535	33804-33813	Substance	_	
158-536	33814-33819	Abuse	_	
158-537	33820-33827	Blunted	_	
158-538	33828-33835	ventral	_	
158-539	33836-33844	striatal	_	
158-540	33845-33854	responses	_	
158-541	33855-33857	to	_	
158-542	33858-33869	anticipated	_	
158-543	33870-33877	rewards	_	
158-544	33878-33888	foreshadow	_	
158-545	33889-33900	problematic	_	
158-546	33901-33905	drug	_	
158-547	33906-33909	use	_	
158-548	33910-33912	in	_	
158-549	33913-33928	novelty-seeking	_	
158-550	33929-33940	adolescents	_	
158-551	33941-33948	Smaller	_	
158-552	33949-33957	amygdala	_	
158-553	33958-33961	and	_	
158-554	33962-33968	medial	_	
158-555	33969-33979	prefrontal	_	
158-556	33980-33986	cortex	_	
158-557	33987-33994	predict	_	
158-558	33995-34005	escalating	_	
158-559	34006-34015	stimulant	_	
158-560	34016-34019	use	_	
158-561	34020-34037	Neuropsychosocial	_	
158-562	34038-34046	profiles	_	
158-563	34047-34049	of	_	
158-564	34050-34057	current	_	
158-565	34058-34061	and	_	
158-566	34062-34068	future	_	
158-567	34069-34079	adolescent	_	
158-568	34080-34087	alcohol	_	
158-569	34088-34096	misusers	_	
158-570	34097-34104	Cocaine	_	
158-571	34105-34115	dependence	_	
158-572	34116-34119	and	_	
158-573	34120-34130	concurrent	_	
158-574	34131-34140	marijuana	_	
158-575	34141-34144	use	_	
158-576	34144-34145	:	_	
158-577	34146-34147	a	_	
158-578	34148-34158	comparison	_	
158-579	34159-34161	of	_	
158-580	34162-34170	clinical	_	
158-581	34171-34186	characteristics	_	
158-582	34187-34188	A	_	
158-583	34189-34192	new	_	
158-584	34192-34193	,	_	
158-585	34194-34209	semi-structured	_	
158-586	34210-34221	psychiatric	_	
158-587	34222-34231	interview	_	
158-588	34232-34235	for	_	
158-589	34236-34239	use	_	
158-590	34240-34242	in	_	
158-591	34243-34250	genetic	_	
158-592	34251-34258	linkage	_	
158-593	34259-34266	studies	_	
158-594	34266-34267	:	_	
158-595	34268-34269	a	_	
158-596	34270-34276	report	_	
158-597	34277-34279	on	_	
158-598	34280-34283	the	_	
158-599	34284-34295	reliability	_	
158-600	34296-34298	of	_	
158-601	34299-34302	the	_	
158-602	34303-34308	SSAGA	_	
158-603	34310-34317	Altered	_	
158-604	34318-34333	frontocingulate	_	
158-605	34334-34344	activation	_	
158-606	34345-34351	during	_	
158-607	34352-34360	aversive	_	
158-608	34361-34374	interoceptive	_	
158-609	34375-34385	processing	_	
158-610	34386-34388	in	_	
158-611	34389-34394	young	_	
158-612	34395-34401	adults	_	
158-613	34402-34415	transitioning	_	
158-614	34416-34418	to	_	
158-615	34419-34426	problem	_	
158-616	34427-34436	stimulant	_	
158-617	34437-34440	use	_	
158-618	34441-34449	Response	_	
158-619	34450-34460	inhibition	_	
158-620	34461-34464	and	_	
158-621	34465-34473	elevated	_	
158-622	34474-34493	parietal-cerebellar	_	
158-623	34494-34506	correlations	_	
158-624	34507-34509	in	_	
158-625	34510-34517	chronic	_	
158-626	34518-34528	adolescent	_	
158-627	34529-34537	cannabis	_	
158-628	34538-34543	users	_	
158-629	34544-34551	Altered	_	
158-630	34552-34561	cingulate	_	
158-631	34562-34565	and	_	
158-632	34566-34573	insular	_	
158-633	34574-34580	cortex	_	
158-634	34581-34591	activation	_	
158-635	34592-34598	during	_	
158-636	34599-34610	risk-taking	_	
158-637	34611-34613	in	_	
158-638	34614-34629	methamphetamine	_	
158-639	34630-34640	dependence	_	
158-640	34640-34641	:	_	
158-641	34642-34648	losses	_	
158-642	34649-34653	lose	_	
158-643	34654-34660	impact	_	
158-644	34661-34671	Attenuated	_	
158-645	34672-34679	Insular	_	
158-646	34680-34690	Processing	_	
158-647	34691-34697	During	_	
158-648	34698-34702	Risk	_	
158-649	34703-34711	Predicts	_	
158-650	34712-34719	Relapse	_	
158-651	34720-34722	in	_	
158-652	34723-34728	Early	_	
158-653	34729-34738	Abstinent	_	
158-654	34739-34764	Methamphetamine-Dependent	_	
158-655	34765-34776	Individuals	_	
158-656	34777-34786	Increased	_	
158-657	34787-34798	risk-taking	_	
158-658	34799-34814	decision-making	_	
158-659	34815-34818	but	_	
158-660	34819-34822	not	_	
158-661	34823-34830	altered	_	
158-662	34831-34839	response	_	
158-663	34840-34842	to	_	
158-664	34843-34853	punishment	_	
158-665	34854-34856	in	_	
158-666	34857-34872	stimulant-using	_	
158-667	34873-34878	young	_	
158-668	34879-34885	adults	_	
158-669	34886-34898	Dissociation	_	
158-670	34899-34901	of	_	
158-671	34902-34912	inhibition	_	
158-672	34913-34917	from	_	
158-673	34918-34923	error	_	
158-674	34924-34934	processing	_	
158-675	34935-34940	using	_	
158-676	34941-34942	a	_	
158-677	34943-34953	parametric	_	
158-678	34954-34964	inhibitory	_	
158-679	34965-34969	task	_	
158-680	34970-34976	during	_	
158-681	34977-34987	functional	_	
158-682	34988-34996	magnetic	_	
158-683	34997-35006	resonance	_	
158-684	35007-35014	imaging	_	
158-685	35015-35020	Young	_	
158-686	35021-35027	adults	_	
158-687	35028-35030	at	_	
158-688	35031-35035	risk	_	
158-689	35036-35039	for	_	
158-690	35040-35049	stimulant	_	
158-691	35050-35060	dependence	_	
158-692	35061-35065	show	_	
158-693	35066-35072	reward	_	
158-694	35073-35084	dysfunction	_	
158-695	35085-35091	during	_	
158-696	35092-35111	reinforcement-based	_	
158-697	35112-35120	decision	_	
158-698	35121-35127	making	_	
158-699	35128-35131	Use	_	
158-700	35132-35134	of	_	
158-701	35135-35142	methods	_	
158-702	35143-35147	from	_	
158-703	35148-35153	chaos	_	
158-704	35154-35160	theory	_	
158-705	35161-35163	to	_	
158-706	35164-35172	quantify	_	
158-707	35173-35174	a	_	
158-708	35175-35186	fundamental	_	
158-709	35187-35198	dysfunction	_	
158-710	35199-35201	in	_	
158-711	35202-35205	the	_	
158-712	35206-35216	behavioral	_	
158-713	35217-35229	organization	_	
158-714	35230-35232	of	_	
158-715	35233-35246	schizophrenic	_	
158-716	35247-35255	patients	_	
158-717	35256-35266	Commentary	_	
158-718	35267-35269	on	_	
158-719	35270-35277	Stewart	_	
158-720	35278-35280	et	_	
158-721	35281-35283	al	_	
158-722	35283-35284	.	_	
158-723	35285-35286	(	_	
158-724	35286-35290	2017	_	
158-725	35290-35291	)	_	
158-726	35291-35292	:	_	
158-727	35293-35303	Stimulants	_	
158-728	35304-35307	and	_	
158-729	35308-35321	marijuana-the	_	
158-730	35322-35331	potential	_	
158-731	35332-35337	value	_	
158-732	35338-35340	in	_	
158-733	35341-35349	studying	_	
158-734	35350-35359	substance	_	
158-735	35360-35366	co-use	_	
158-736	35368-35372	Drug	_	
158-737	35373-35376	use	_	
158-738	35377-35387	desistance	_	
158-739	35388-35398	Individual	_	
158-740	35399-35410	differences	_	
158-741	35411-35413	in	_	
158-742	35414-35423	childhood	_	
158-743	35424-35437	neurobehavior	_	
158-744	35438-35451	disinhibition	_	
158-745	35452-35459	predict	_	
158-746	35460-35468	decision	_	
158-747	35469-35471	to	_	
158-748	35472-35478	desist	_	
158-749	35479-35488	substance	_	
158-750	35489-35492	use	_	
158-751	35493-35499	during	_	
158-752	35500-35511	adolescence	_	
158-753	35512-35515	and	_	
158-754	35516-35525	substance	_	
158-755	35526-35529	use	_	
158-756	35530-35538	disorder	_	
158-757	35539-35541	in	_	
158-758	35542-35547	young	_	
158-759	35548-35557	adulthood	_	
158-760	35557-35558	:	_	
158-761	35559-35560	A	_	
158-762	35561-35572	prospective	_	
158-763	35573-35578	study	_	
158-764	35579-35583	AFNI	_	
158-765	35583-35584	:	_	
158-766	35585-35593	software	_	
158-767	35594-35597	for	_	
158-768	35598-35606	analysis	_	
158-769	35607-35610	and	_	
158-770	35611-35624	visualization	_	
158-771	35625-35627	of	_	
158-772	35628-35638	functional	_	
158-773	35639-35647	magnetic	_	
158-774	35648-35657	resonance	_	
158-775	35658-35669	neuroimages	_	
158-776	35671-35677	Visual	_	
158-777	35678-35684	cortex	_	
158-778	35685-35695	activation	_	
158-779	35696-35698	to	_	
158-780	35699-35703	drug	_	
158-781	35704-35708	cues	_	
158-782	35708-35709	:	_	
158-783	35710-35711	a	_	
158-784	35712-35725	meta-analysis	_	
158-785	35726-35728	of	_	
158-786	35729-35739	functional	_	
158-787	35740-35752	neuroimaging	_	
158-788	35753-35759	papers	_	
158-789	35760-35762	in	_	
158-790	35763-35772	addiction	_	
158-791	35773-35776	and	_	
158-792	35777-35786	substance	_	
158-793	35787-35792	abuse	_	
158-794	35793-35803	literature	_	
158-795	35804-35807	The	_	
158-796	35808-35814	medial	_	
158-797	35815-35823	temporal	_	
158-798	35824-35829	lobes	_	
158-799	35830-35833	are	_	
158-800	35834-35842	critical	_	
158-801	35843-35846	for	_	
158-802	35847-35859	reward-based	_	
158-803	35860-35868	decision	_	
158-804	35869-35875	making	_	
158-805	35876-35881	under	_	
158-806	35882-35892	conditions	_	
158-807	35893-35897	that	_	
158-808	35898-35905	promote	_	
158-809	35906-35914	episodic	_	
158-810	35915-35921	future	_	
158-811	35922-35930	thinking	_	
158-812	35931-35937	Neural	_	
158-813	35938-35947	responses	_	
158-814	35948-35950	to	_	
158-815	35951-35955	risk	_	
158-816	35956-35959	and	_	
158-817	35960-35966	reward	_	
158-818	35967-35974	predict	_	
158-819	35975-35985	transition	_	
158-820	35986-35988	to	_	
158-821	35989-35996	problem	_	
158-822	35997-36006	stimulant	_	
158-823	36007-36010	use	_	
158-824	36011-36014	The	_	
158-825	36015-36029	hyper-sentient	_	
158-826	36030-36036	addict	_	
158-827	36036-36037	:	_	
158-828	36038-36040	an	_	
158-829	36041-36054	exteroception	_	
158-830	36055-36060	model	_	
158-831	36061-36063	of	_	
158-832	36064-36073	addiction	_	
158-833	36074-36077	HHS	_	
158-834	36078-36084	Public	_	
158-835	36085-36091	Access	_	
158-836	36092-36097	Error	_	
158-837	36098-36108	processing	_	
158-838	36109-36112	and	_	
158-839	36113-36126	gender-shared	_	
158-840	36127-36130	and	_	
158-841	36131-36132	-	_	
158-842	36132-36140	specific	_	
158-843	36141-36147	neural	_	
158-844	36148-36158	predictors	_	
158-845	36159-36161	of	_	
158-846	36162-36169	relapse	_	
158-847	36170-36172	in	_	
158-848	36173-36180	cocaine	_	
158-849	36181-36191	dependence	_	
158-850	36192-36207	Decision-making	_	
158-851	36208-36211	and	_	
158-852	36212-36216	risk	_	
158-853	36217-36225	aversion	_	
158-854	36226-36231	among	_	
158-855	36232-36242	depressive	_	
158-856	36243-36249	adults	_	
158-857	36250-36256	Issues	_	
158-858	36257-36260	and	_	
158-859	36261-36276	recommendations	_	
158-860	36277-36286	regarding	_	
158-861	36287-36290	use	_	
158-862	36291-36293	of	_	
158-863	36294-36297	the	_	
158-864	36298-36302	Beck	_	
158-865	36303-36313	Depression	_	
158-866	36314-36323	Inventory	_	
158-867	36324-36327	The	_	
158-868	36328-36336	addicted	_	
158-869	36337-36342	human	_	
158-870	36343-36348	brain	_	
158-871	36349-36355	viewed	_	
158-872	36356-36358	in	_	
158-873	36359-36362	the	_	
158-874	36363-36368	light	_	
158-875	36369-36371	of	_	
158-876	36372-36379	imaging	_	
158-877	36380-36387	studies	_	
158-878	36387-36388	:	_	
158-879	36389-36394	Brain	_	
158-880	36395-36403	circuits	_	
158-881	36404-36407	and	_	
158-882	36408-36417	treatment	_	
158-883	36418-36428	strategies	_	
158-884	36429-36438	Decreased	_	
158-885	36439-36447	dopamine	_	
158-886	36448-36453	brain	_	
158-887	36454-36464	reactivity	_	
158-888	36465-36467	in	_	
158-889	36468-36477	marijuana	_	
158-890	36478-36485	abusers	_	
158-891	36486-36488	is	_	
158-892	36489-36499	associated	_	
158-893	36500-36504	with	_	
158-894	36505-36513	negative	_	
158-895	36514-36526	emotionality	_	
158-896	36527-36530	and	_	
158-897	36531-36540	addiction	_	
158-898	36541-36549	severity	_	
158-899	36550-36553	The	_	
158-900	36554-36566	epidemiology	_	
158-901	36567-36569	of	_	
158-902	36570-36582	co-occurring	_	
158-903	36583-36592	addictive	_	
158-904	36593-36596	and	_	
158-905	36597-36603	mental	_	
158-906	36604-36613	disorders	_	
158-907	36613-36614	:	_	
158-908	36615-36627	implications	_	
158-909	36628-36631	for	_	
158-910	36632-36642	prevention	_	
158-911	36643-36646	and	_	
158-912	36647-36654	service	_	
158-913	36655-36666	utilization	_	
158-914	36667-36670	Use	_	
158-915	36671-36673	of	_	
158-916	36674-36677	the	_	
158-917	36678-36683	AUDIT	_	
158-918	36684-36687	and	_	
158-919	36688-36691	the	_	
158-920	36692-36696	DAST	_	
158-921	36696-36697	-	_	
158-922	36697-36699	10	_	
158-923	36700-36702	to	_	
158-924	36703-36711	identify	_	
158-925	36712-36719	alcohol	_	
158-926	36720-36723	and	_	
158-927	36724-36728	drug	_	
158-928	36729-36732	use	_	
158-929	36733-36742	disorders	_	
158-930	36743-36748	among	_	
158-931	36749-36755	adults	_	
158-932	36756-36760	with	_	
158-933	36761-36762	a	_	
158-934	36763-36769	severe	_	
158-935	36770-36773	and	_	
158-936	36774-36784	persistent	_	
158-937	36785-36791	mental	_	
158-938	36792-36799	illness	_	
158-939	36800-36808	Overview	_	
158-940	36809-36811	of	_	
158-941	36812-36817	study	_	
158-942	36818-36824	design	_	
158-943	36825-36828	and	_	
158-944	36829-36833	data	_	
158-945	36834-36842	analyses	_	
158-946	36842-36843	.	_	

#Text=At baseline, occasional stimulant users (OSU) completed questionnaires, a clinical interview, and a functional magnetic resonance imaging (fMRI) scan recorded during the Risky Gains Task (RGT).
159-1	36844-36846	At	_	
159-2	36847-36855	baseline	_	
159-3	36855-36856	,	_	
159-4	36857-36867	occasional	_	
159-5	36868-36877	stimulant	_	
159-6	36878-36883	users	_	
159-7	36884-36885	(	_	
159-8	36885-36888	OSU	_	
159-9	36888-36889	)	_	
159-10	36890-36899	completed	_	
159-11	36900-36914	questionnaires	_	
159-12	36914-36915	,	_	
159-13	36916-36917	a	_	
159-14	36918-36926	clinical	_	
159-15	36927-36936	interview	_	
159-16	36936-36937	,	_	
159-17	36938-36941	and	_	
159-18	36942-36943	a	_	
159-19	36944-36954	functional	_	
159-20	36955-36963	magnetic	_	
159-21	36964-36973	resonance	_	
159-22	36974-36981	imaging	_	
159-23	36982-36983	(	_	
159-24	36983-36987	fMRI	_	
159-25	36987-36988	)	_	
159-26	36989-36993	scan	_	
159-27	36994-37002	recorded	_	
159-28	37003-37009	during	_	
159-29	37010-37013	the	_	
159-30	37014-37019	Risky	_	
159-31	37020-37025	Gains	_	
159-32	37026-37030	Task	_	
159-33	37031-37032	(	_	
159-34	37032-37035	RGT	_	
159-35	37035-37036	)	_	
159-36	37036-37037	.	_	

#Text=OSU then completed a follow-up clinical interview three years later that included assessment of interim drug use.
160-1	37038-37041	OSU	_	
160-2	37042-37046	then	_	
160-3	37047-37056	completed	_	
160-4	37057-37058	a	_	
160-5	37059-37068	follow-up	_	
160-6	37069-37077	clinical	_	
160-7	37078-37087	interview	_	
160-8	37088-37093	three	_	
160-9	37094-37099	years	_	
160-10	37100-37105	later	_	
160-11	37106-37110	that	_	
160-12	37111-37119	included	_	
160-13	37120-37130	assessment	_	
160-14	37131-37133	of	_	
160-15	37134-37141	interim	_	
160-16	37142-37146	drug	_	
160-17	37147-37150	use	_	
160-18	37150-37151	.	_	

#Text=Only OSU with both usable fMRI data at baseline and complete follow-up drug use data were included in longitudinal analyses.
161-1	37152-37156	Only	_	
161-2	37157-37160	OSU	_	
161-3	37161-37165	with	_	
161-4	37166-37170	both	_	
161-5	37171-37177	usable	_	
161-6	37178-37182	fMRI	_	
161-7	37183-37187	data	_	
161-8	37188-37190	at	_	
161-9	37191-37199	baseline	_	
161-10	37200-37203	and	_	
161-11	37204-37212	complete	_	
161-12	37213-37222	follow-up	_	
161-13	37223-37227	drug	_	
161-14	37228-37231	use	_	
161-15	37232-37236	data	_	
161-16	37237-37241	were	_	
161-17	37242-37250	included	_	
161-18	37251-37253	in	_	
161-19	37254-37266	longitudinal	_	
161-20	37267-37275	analyses	_	
161-21	37275-37276	.	_	

#Text=Categorical analysis of baseline self-report and fMRI data included a subset of OSU who either met criteria for problem stimulant user (PSU) or desisted stimulant user (DSU) groups on the basis of interim drug use patterns and follow-up interview diagnostic criteria.
162-1	37277-37288	Categorical	_	
162-2	37289-37297	analysis	_	
162-3	37298-37300	of	_	
162-4	37301-37309	baseline	_	
162-5	37310-37321	self-report	_	
162-6	37322-37325	and	_	
162-7	37326-37330	fMRI	_	
162-8	37331-37335	data	_	
162-9	37336-37344	included	_	
162-10	37345-37346	a	_	
162-11	37347-37353	subset	_	
162-12	37354-37356	of	_	
162-13	37357-37360	OSU	_	
162-14	37361-37364	who	_	
162-15	37365-37371	either	_	
162-16	37372-37375	met	_	
162-17	37376-37384	criteria	_	
162-18	37385-37388	for	_	
162-19	37389-37396	problem	_	
162-20	37397-37406	stimulant	_	
162-21	37407-37411	user	_	
162-22	37412-37413	(	_	
162-23	37413-37416	PSU	_	
162-24	37416-37417	)	_	
162-25	37418-37420	or	_	
162-26	37421-37429	desisted	_	
162-27	37430-37439	stimulant	_	
162-28	37440-37444	user	_	
162-29	37445-37446	(	_	
162-30	37446-37449	DSU	_	
162-31	37449-37450	)	_	
162-32	37451-37457	groups	_	
162-33	37458-37460	on	_	
162-34	37461-37464	the	_	
162-35	37465-37470	basis	_	
162-36	37471-37473	of	_	
162-37	37474-37481	interim	_	
162-38	37482-37486	drug	_	
162-39	37487-37490	use	_	
162-40	37491-37499	patterns	_	
162-41	37500-37503	and	_	
162-42	37504-37513	follow-up	_	
162-43	37514-37523	interview	_	
162-44	37524-37534	diagnostic	_	
162-45	37535-37543	criteria	_	
162-46	37543-37544	.	_	

#Text=Dimensional analysis included all OSU and compared relationships between interim stimulant and marijuana use to baseline self-report and fMRI data, controlling for baseline stimulant and marijuana use.
163-1	37545-37556	Dimensional	_	
163-2	37557-37565	analysis	_	
163-3	37566-37574	included	_	
163-4	37575-37578	all	_	
163-5	37579-37582	OSU	_	
163-6	37583-37586	and	_	
163-7	37587-37595	compared	_	
163-8	37596-37609	relationships	_	
163-9	37610-37617	between	_	
163-10	37618-37625	interim	_	
163-11	37626-37635	stimulant	_	
163-12	37636-37639	and	_	
163-13	37640-37649	marijuana	_	
163-14	37650-37653	use	_	
163-15	37654-37656	to	_	
163-16	37657-37665	baseline	_	
163-17	37666-37677	self-report	_	
163-18	37678-37681	and	_	
163-19	37682-37686	fMRI	_	
163-20	37687-37691	data	_	
163-21	37691-37692	,	_	
163-22	37693-37704	controlling	_	
163-23	37705-37708	for	_	
163-24	37709-37717	baseline	_	
163-25	37718-37727	stimulant	_	
163-26	37728-37731	and	_	
163-27	37732-37741	marijuana	_	
163-28	37742-37745	use	_	
163-29	37745-37746	.	_	

#Text=Depiction of trial types presented during the Risky Gains Task (RGT): (A) lose 80; (B) win 20; (C) win 40; and (D) lose 40.
164-1	37747-37756	Depiction	_	
164-2	37757-37759	of	_	
164-3	37760-37765	trial	_	
164-4	37766-37771	types	_	
164-5	37772-37781	presented	_	
164-6	37782-37788	during	_	
164-7	37789-37792	the	_	
164-8	37793-37798	Risky	_	
164-9	37799-37804	Gains	_	
164-10	37805-37809	Task	_	
164-11	37810-37811	(	_	
164-12	37811-37814	RGT	_	
164-13	37814-37815	)	_	
164-14	37815-37816	:	_	
164-15	37817-37818	(	_	
164-16	37818-37819	A	_	
164-17	37819-37820	)	_	
164-18	37821-37825	lose	_	
164-19	37826-37828	80	_	
164-20	37828-37829	;	_	
164-21	37830-37831	(	_	
164-22	37831-37832	B	_	
164-23	37832-37833	)	_	
164-24	37834-37837	win	_	
164-25	37838-37840	20	_	
164-26	37840-37841	;	_	
164-27	37842-37843	(	_	
164-28	37843-37844	C	_	
164-29	37844-37845	)	_	
164-30	37846-37849	win	_	
164-31	37850-37852	40	_	
164-32	37852-37853	;	_	
164-33	37854-37857	and	_	
164-34	37858-37859	(	_	
164-35	37859-37860	D	_	
164-36	37860-37861	)	_	
164-37	37862-37866	lose	_	
164-38	37867-37869	40	_	
164-39	37869-37870	.	_	

#Text=The blue arrow indicates which value the participant chose (Connolly et al., 2014).
165-1	37871-37874	The	_	
165-2	37875-37879	blue	_	
165-3	37880-37885	arrow	_	
165-4	37886-37895	indicates	_	
165-5	37896-37901	which	_	
165-6	37902-37907	value	_	
165-7	37908-37911	the	_	
165-8	37912-37923	participant	_	
165-9	37924-37929	chose	_	
165-10	37930-37931	(	_	
165-11	37931-37939	Connolly	_	
165-12	37940-37942	et	_	
165-13	37943-37945	al	_	
165-14	37945-37946	.	_	
165-15	37946-37947	,	_	
165-16	37948-37952	2014	_	
165-17	37952-37953	)	_	
165-18	37953-37954	.	_	

#Text=Group x Decision Interaction: Problem stimulant users (PSU) displayed greater BOLD signal in precuneus and cingulate regions for risky than safe decisions when compared to desisted stimulant users (DSU).
166-1	37955-37960	Group	_	
166-2	37961-37962	x	_	
166-3	37963-37971	Decision	_	
166-4	37972-37983	Interaction	_	
166-5	37983-37984	:	_	
166-6	37985-37992	Problem	_	
166-7	37993-38002	stimulant	_	
166-8	38003-38008	users	_	
166-9	38009-38010	(	_	
166-10	38010-38013	PSU	_	
166-11	38013-38014	)	_	
166-12	38015-38024	displayed	_	
166-13	38025-38032	greater	_	
166-14	38033-38037	BOLD	_	
166-15	38038-38044	signal	_	
166-16	38045-38047	in	_	
166-17	38048-38057	precuneus	_	
166-18	38058-38061	and	_	
166-19	38062-38071	cingulate	_	
166-20	38072-38079	regions	_	
166-21	38080-38083	for	_	
166-22	38084-38089	risky	_	
166-23	38090-38094	than	_	
166-24	38095-38099	safe	_	
166-25	38100-38109	decisions	_	
166-26	38110-38114	when	_	
166-27	38115-38123	compared	_	
166-28	38124-38126	to	_	
166-29	38127-38135	desisted	_	
166-30	38136-38145	stimulant	_	
166-31	38146-38151	users	_	
166-32	38152-38153	(	_	
166-33	38153-38156	DSU	_	
166-34	38156-38157	)	_	
166-35	38157-38158	.	_	

#Text=Outcome Group Main Effect: Across risky wins and losses, problem stimulant users (PSU) exhibited lower BOLD signal than desisted stimulant users (DSU) in left frontal, central, parietal and limbic regions as well as right posterior cingulate and precuneus.
167-1	38159-38166	Outcome	_	
167-2	38167-38172	Group	_	
167-3	38173-38177	Main	_	
167-4	38178-38184	Effect	_	
167-5	38184-38185	:	_	
167-6	38186-38192	Across	_	
167-7	38193-38198	risky	_	
167-8	38199-38203	wins	_	
167-9	38204-38207	and	_	
167-10	38208-38214	losses	_	
167-11	38214-38215	,	_	
167-12	38216-38223	problem	_	
167-13	38224-38233	stimulant	_	
167-14	38234-38239	users	_	
167-15	38240-38241	(	_	
167-16	38241-38244	PSU	_	
167-17	38244-38245	)	_	
167-18	38246-38255	exhibited	_	
167-19	38256-38261	lower	_	
167-20	38262-38266	BOLD	_	
167-21	38267-38273	signal	_	
167-22	38274-38278	than	_	
167-23	38279-38287	desisted	_	
167-24	38288-38297	stimulant	_	
167-25	38298-38303	users	_	
167-26	38304-38305	(	_	
167-27	38305-38308	DSU	_	
167-28	38308-38309	)	_	
167-29	38310-38312	in	_	
167-30	38313-38317	left	_	
167-31	38318-38325	frontal	_	
167-32	38325-38326	,	_	
167-33	38327-38334	central	_	
167-34	38334-38335	,	_	
167-35	38336-38344	parietal	_	
167-36	38345-38348	and	_	
167-37	38349-38355	limbic	_	
167-38	38356-38363	regions	_	
167-39	38364-38366	as	_	
167-40	38367-38371	well	_	
167-41	38372-38374	as	_	
167-42	38375-38380	right	_	
167-43	38381-38390	posterior	_	
167-44	38391-38400	cingulate	_	
167-45	38401-38404	and	_	
167-46	38405-38414	precuneus	_	
167-47	38414-38415	.	_	

#Text=Group x Outcome Interaction: Problem stimulant users exhibited greater BOLD signal to risky wins than risky losses when compared to desisted stimulant users (DSU) in right thalamus and left middle/inferior temporal and occipital gyri.
168-1	38416-38421	Group	_	
168-2	38422-38423	x	_	
168-3	38424-38431	Outcome	_	
168-4	38432-38443	Interaction	_	
168-5	38443-38444	:	_	
168-6	38445-38452	Problem	_	
168-7	38453-38462	stimulant	_	
168-8	38463-38468	users	_	
168-9	38469-38478	exhibited	_	
168-10	38479-38486	greater	_	
168-11	38487-38491	BOLD	_	
168-12	38492-38498	signal	_	
168-13	38499-38501	to	_	
168-14	38502-38507	risky	_	
168-15	38508-38512	wins	_	
168-16	38513-38517	than	_	
168-17	38518-38523	risky	_	
168-18	38524-38530	losses	_	
168-19	38531-38535	when	_	
168-20	38536-38544	compared	_	
168-21	38545-38547	to	_	
168-22	38548-38556	desisted	_	
168-23	38557-38566	stimulant	_	
168-24	38567-38572	users	_	
168-25	38573-38574	(	_	
168-26	38574-38577	DSU	_	
168-27	38577-38578	)	_	
168-28	38579-38581	in	_	
168-29	38582-38587	right	_	
168-30	38588-38596	thalamus	_	
168-31	38597-38600	and	_	
168-32	38601-38605	left	_	
168-33	38606-38612	middle	_	
168-34	38612-38613	/	_	
168-35	38613-38621	inferior	_	
168-36	38622-38630	temporal	_	
168-37	38631-38634	and	_	
168-38	38635-38644	occipital	_	
168-39	38645-38649	gyri	_	
168-40	38649-38650	.	_	

#Text=Interim marijuana use predicting BOLD Signal for Risky minus Safe Decisions: Higher interim marijuana use was linked to lower superior/middle/inferior frontal gyri, inferior parietal lobule, superior/middle temporal gyri, thalamus, and precuneus activation for risky compared to safe decisions at baseline.
169-1	38651-38658	Interim	_	
169-2	38659-38668	marijuana	_	
169-3	38669-38672	use	_	
169-4	38673-38683	predicting	_	
169-5	38684-38688	BOLD	_	
169-6	38689-38695	Signal	_	
169-7	38696-38699	for	_	
169-8	38700-38705	Risky	_	
169-9	38706-38711	minus	_	
169-10	38712-38716	Safe	_	
169-11	38717-38726	Decisions	_	
169-12	38726-38727	:	_	
169-13	38728-38734	Higher	_	
169-14	38735-38742	interim	_	
169-15	38743-38752	marijuana	_	
169-16	38753-38756	use	_	
169-17	38757-38760	was	_	
169-18	38761-38767	linked	_	
169-19	38768-38770	to	_	
169-20	38771-38776	lower	_	
169-21	38777-38785	superior	_	
169-22	38785-38786	/	_	
169-23	38786-38792	middle	_	
169-24	38792-38793	/	_	
169-25	38793-38801	inferior	_	
169-26	38802-38809	frontal	_	
169-27	38810-38814	gyri	_	
169-28	38814-38815	,	_	
169-29	38816-38824	inferior	_	
169-30	38825-38833	parietal	_	
169-31	38834-38840	lobule	_	
169-32	38840-38841	,	_	
169-33	38842-38850	superior	_	
169-34	38850-38851	/	_	
169-35	38851-38857	middle	_	
169-36	38858-38866	temporal	_	
169-37	38867-38871	gyri	_	
169-38	38871-38872	,	_	
169-39	38873-38881	thalamus	_	
169-40	38881-38882	,	_	
169-41	38883-38886	and	_	
169-42	38887-38896	precuneus	_	
169-43	38897-38907	activation	_	
169-44	38908-38911	for	_	
169-45	38912-38917	risky	_	
169-46	38918-38926	compared	_	
169-47	38927-38929	to	_	
169-48	38930-38934	safe	_	
169-49	38935-38944	decisions	_	
169-50	38945-38947	at	_	
169-51	38948-38956	baseline	_	
169-52	38956-38957	.	_	

#Text=Group Demographics.
170-1	38958-38963	Group	_	
170-2	38964-38976	Demographics	_	
170-3	38976-38977	.	_	

#Text=PSU (n=35)\tDSU (n=75)\tStatistics\t \t\t \t\tPercentage (%)\tPercentage (%)\tdf\tχ2\tp\t \t Female Gender\t45.71\t38.67\t1\t0.49\t.48\t \t Marijuana-Positive Urine*\t40.0\t37.3\t2\t0.52\t.77\t \t Right Handedness\t97.14\t96\t1\t0.09\t.77\t \t Caucasian Race/Ethnicity\t74.30\t77.30\t1\t0.12\t.73\t \tMet Criteria for History at Baseline\t\t\t\t\t\t \t Alcohol Abuse\t45.71\t52.00\t1\t0.38\t.54\t \t Alcohol Dependence\t9.33\t5.71\t1\t0.42\t.52\t \t Marijuana Abuse\t52\t62.85\t1\t1.14\t.29\t \t Marijuana Dependence\t24\t28.57\t1\t0.26\t.61\t \tMet Criteria for Interim Abuse or Dependence\t\t\t\t\t\t \t Alcohol Abuse\t54.29\t38.67\t2\t3.67\t.30\t \t Alcohol Dependence\t11.43\t8.00\t2\t2.70\t.44\t \t Marijuana Abuse\t51.43\t37.33\t2\t3.03\t.22\t \t Marijuana Dependence\t8.57\t6.67\t2\t2.38\t.31\t \t\tM\tSD\tM\tSD\tdf\tt\tp\t \t Age\t20.74\t1.70\t20.95\t1.43\t108\t0.65\t.52\t \t Education\t14.60\t1.48\t14.63\t1.35\t108\t0.09\t.93\t \t Verbal IQ\t109.71\t6.07\t108.87\t7.74\t103\t0.56\t.58\t \t Impulsivity (BIS-11)\t67\t9.75\t64.53\t9.06\t108\t1.15\t.25\t \t Sensation Seeking (SSS-V)\t25\t4.81\t24.59\t4.45\t108\t0.38\t.97\t \t Depression (BDI)\t1.53\t1.54\t3.03\t3.81\t104\t2.21\t.03\t \tBehavioral Performance\t\t\t\t\t\t\t\t \t Won $ Followed by Risk\t.58\t1.91\t.50\t.18\t108\t2.05\t.04\t \t Lost $ Followed by Risk\t.32\t.16\t.29\t.20\t108\t0.72\t.48\t \tBaseline Drug Use1\t\t\t\t\t\t\t\t \t Amphetamine\t28.63\t38.74\t21.04\t64.40\t108\t0.65\t.52\t \t Cocaine\t26.03\t41.73\t17.72\t38.82\t108\t1.02\t.31\t \t Marijuana\t814.09\t1118.75\t842.08\t1271.89\t108\t0.11\t.91\t \tInterim Three-Year Drug Use2\t\t\t\t\t\t\t\t \t Prescription Stimulant\t62.63\t88.79\t5.58\t23.13\t106\t5.18\t<.001\t \t Cocaine\t283.03\t622.56\t8.49\t35.58\t106\t3.80\t<.001\t \t Marijuana\t588.62\t946.77\t838.28\t1974.42\t106\t0.70\t.49\t \t Methamphetamine\t38.35\t215.985\t\t\t\t\t\t \t All stimulants\t384.01\t627.911\t14.09\t41.64\t106\t5.07\t<.001\t \tRecency of Drug Use (Time of Scan)3\t\t\t\t\t\t\t\t \t Prescription Stimulant\t74.56\t88.93\t193.43\t294.44\t70\t−2.71\t.01\t \t Cocaine\t78.29\t100.33\t125.46\t223.12\t72\t−0.99\t.33\t \t Marijuana\t57.17\t149.62\t30.46\t73.56\t35\t0.93\t.36\t \t
#Text=Note:
#Text=Determined by urine screen at the outset of the neuroimaging session.
171-1	38979-38982	PSU	_	
171-2	38983-38984	(	_	
171-3	38984-38985	n	_	
171-4	38985-38986	=	_	
171-5	38986-38988	35	_	
171-6	38988-38989	)	_	
171-7	38990-38993	DSU	_	
171-8	38994-38995	(	_	
171-9	38995-38996	n	_	
171-10	38996-38997	=	_	
171-11	38997-38999	75	_	
171-12	38999-39000	)	_	
171-13	39001-39011	Statistics	_	
171-14	39018-39028	Percentage	_	
171-15	39029-39030	(	_	
171-16	39030-39031	%	_	
171-17	39031-39032	)	_	
171-18	39033-39043	Percentage	_	
171-19	39044-39045	(	_	
171-20	39045-39046	%	_	
171-21	39046-39047	)	_	
171-22	39048-39050	df	_	
171-23	39051-39053	χ2	_	
171-24	39054-39055	p	_	
171-25	39059-39065	Female	_	
171-26	39066-39072	Gender	_	
171-27	39073-39078	45.71	_	
171-28	39079-39084	38.67	_	
171-29	39085-39086	1	_	
171-30	39087-39091	0.49	_	
171-31	39092-39095	.48	_	
171-32	39099-39117	Marijuana-Positive	_	
171-33	39118-39123	Urine	_	
171-34	39123-39124	*	_	
171-35	39125-39129	40.0	_	
171-36	39130-39134	37.3	_	
171-37	39135-39136	2	_	
171-38	39137-39141	0.52	_	
171-39	39142-39145	.77	_	
171-40	39149-39154	Right	_	
171-41	39155-39165	Handedness	_	
171-42	39166-39171	97.14	_	
171-43	39172-39174	96	_	
171-44	39175-39176	1	_	
171-45	39177-39181	0.09	_	
171-46	39182-39185	.77	_	
171-47	39189-39198	Caucasian	_	
171-48	39199-39203	Race	_	
171-49	39203-39204	/	_	
171-50	39204-39213	Ethnicity	_	
171-51	39214-39219	74.30	_	
171-52	39220-39225	77.30	_	
171-53	39226-39227	1	_	
171-54	39228-39232	0.12	_	
171-55	39233-39236	.73	_	
171-56	39239-39242	Met	_	
171-57	39243-39251	Criteria	_	
171-58	39252-39255	for	_	
171-59	39256-39263	History	_	
171-60	39264-39266	at	_	
171-61	39267-39275	Baseline	_	
171-62	39284-39291	Alcohol	_	
171-63	39292-39297	Abuse	_	
171-64	39298-39303	45.71	_	
171-65	39304-39309	52.00	_	
171-66	39310-39311	1	_	
171-67	39312-39316	0.38	_	
171-68	39317-39320	.54	_	
171-69	39324-39331	Alcohol	_	
171-70	39332-39342	Dependence	_	
171-71	39343-39347	9.33	_	
171-72	39348-39352	5.71	_	
171-73	39353-39354	1	_	
171-74	39355-39359	0.42	_	
171-75	39360-39363	.52	_	
171-76	39367-39376	Marijuana	_	
171-77	39377-39382	Abuse	_	
171-78	39383-39385	52	_	
171-79	39386-39391	62.85	_	
171-80	39392-39393	1	_	
171-81	39394-39398	1.14	_	
171-82	39399-39402	.29	_	
171-83	39406-39415	Marijuana	_	
171-84	39416-39426	Dependence	_	
171-85	39427-39429	24	_	
171-86	39430-39435	28.57	_	
171-87	39436-39437	1	_	
171-88	39438-39442	0.26	_	
171-89	39443-39446	.61	_	
171-90	39449-39452	Met	_	
171-91	39453-39461	Criteria	_	
171-92	39462-39465	for	_	
171-93	39466-39473	Interim	_	
171-94	39474-39479	Abuse	_	
171-95	39480-39482	or	_	
171-96	39483-39493	Dependence	_	
171-97	39502-39509	Alcohol	_	
171-98	39510-39515	Abuse	_	
171-99	39516-39521	54.29	_	
171-100	39522-39527	38.67	_	
171-101	39528-39529	2	_	
171-102	39530-39534	3.67	_	
171-103	39535-39538	.30	_	
171-104	39542-39549	Alcohol	_	
171-105	39550-39560	Dependence	_	
171-106	39561-39566	11.43	_	
171-107	39567-39571	8.00	_	
171-108	39572-39573	2	_	
171-109	39574-39578	2.70	_	
171-110	39579-39582	.44	_	
171-111	39586-39595	Marijuana	_	
171-112	39596-39601	Abuse	_	
171-113	39602-39607	51.43	_	
171-114	39608-39613	37.33	_	
171-115	39614-39615	2	_	
171-116	39616-39620	3.03	_	
171-117	39621-39624	.22	_	
171-118	39628-39637	Marijuana	_	
171-119	39638-39648	Dependence	_	
171-120	39649-39653	8.57	_	
171-121	39654-39658	6.67	_	
171-122	39659-39660	2	_	
171-123	39661-39665	2.38	_	
171-124	39666-39669	.31	_	
171-125	39673-39674	M	_	
171-126	39675-39677	SD	_	
171-127	39678-39679	M	_	
171-128	39680-39682	SD	_	
171-129	39683-39685	df	_	
171-130	39686-39687	t	_	
171-131	39688-39689	p	_	
171-132	39693-39696	Age	_	
171-133	39697-39702	20.74	_	
171-134	39703-39707	1.70	_	
171-135	39708-39713	20.95	_	
171-136	39714-39718	1.43	_	
171-137	39719-39722	108	_	
171-138	39723-39727	0.65	_	
171-139	39728-39731	.52	_	
171-140	39735-39744	Education	_	
171-141	39745-39750	14.60	_	
171-142	39751-39755	1.48	_	
171-143	39756-39761	14.63	_	
171-144	39762-39766	1.35	_	
171-145	39767-39770	108	_	
171-146	39771-39775	0.09	_	
171-147	39776-39779	.93	_	
171-148	39783-39789	Verbal	_	
171-149	39790-39792	IQ	_	
171-150	39793-39799	109.71	_	
171-151	39800-39804	6.07	_	
171-152	39805-39811	108.87	_	
171-153	39812-39816	7.74	_	
171-154	39817-39820	103	_	
171-155	39821-39825	0.56	_	
171-156	39826-39829	.58	_	
171-157	39833-39844	Impulsivity	_	
171-158	39845-39846	(	_	
171-159	39846-39849	BIS	_	
171-160	39849-39850	-	_	
171-161	39850-39852	11	_	
171-162	39852-39853	)	_	
171-163	39854-39856	67	_	
171-164	39857-39861	9.75	_	
171-165	39862-39867	64.53	_	
171-166	39868-39872	9.06	_	
171-167	39873-39876	108	_	
171-168	39877-39881	1.15	_	
171-169	39882-39885	.25	_	
171-170	39889-39898	Sensation	_	
171-171	39899-39906	Seeking	_	
171-172	39907-39908	(	_	
171-173	39908-39913	SSS-V	_	
171-174	39913-39914	)	_	
171-175	39915-39917	25	_	
171-176	39918-39922	4.81	_	
171-177	39923-39928	24.59	_	
171-178	39929-39933	4.45	_	
171-179	39934-39937	108	_	
171-180	39938-39942	0.38	_	
171-181	39943-39946	.97	_	
171-182	39950-39960	Depression	_	
171-183	39961-39962	(	_	
171-184	39962-39965	BDI	_	
171-185	39965-39966	)	_	
171-186	39967-39971	1.53	_	
171-187	39972-39976	1.54	_	
171-188	39977-39981	3.03	_	
171-189	39982-39986	3.81	_	
171-190	39987-39990	104	_	
171-191	39991-39995	2.21	_	
171-192	39996-39999	.03	_	
171-193	40002-40012	Behavioral	_	
171-194	40013-40024	Performance	_	
171-195	40035-40038	Won	_	
171-196	40039-40040	$	_	
171-197	40041-40049	Followed	_	
171-198	40050-40052	by	_	
171-199	40053-40057	Risk	_	
171-200	40058-40061	.58	_	
171-201	40062-40066	1.91	_	
171-202	40067-40070	.50	_	
171-203	40071-40074	.18	_	
171-204	40075-40078	108	_	
171-205	40079-40083	2.05	_	
171-206	40084-40087	.04	_	
171-207	40091-40095	Lost	_	
171-208	40096-40097	$	_	
171-209	40098-40106	Followed	_	
171-210	40107-40109	by	_	
171-211	40110-40114	Risk	_	
171-212	40115-40118	.32	_	
171-213	40119-40122	.16	_	
171-214	40123-40126	.29	_	
171-215	40127-40130	.20	_	
171-216	40131-40134	108	_	
171-217	40135-40139	0.72	_	
171-218	40140-40143	.48	_	
171-219	40146-40154	Baseline	_	
171-220	40155-40159	Drug	_	
171-221	40160-40164	Use1	_	
171-222	40175-40186	Amphetamine	_	
171-223	40187-40192	28.63	_	
171-224	40193-40198	38.74	_	
171-225	40199-40204	21.04	_	
171-226	40205-40210	64.40	_	
171-227	40211-40214	108	_	
171-228	40215-40219	0.65	_	
171-229	40220-40223	.52	_	
171-230	40227-40234	Cocaine	_	
171-231	40235-40240	26.03	_	
171-232	40241-40246	41.73	_	
171-233	40247-40252	17.72	_	
171-234	40253-40258	38.82	_	
171-235	40259-40262	108	_	
171-236	40263-40267	1.02	_	
171-237	40268-40271	.31	_	
171-238	40275-40284	Marijuana	_	
171-239	40285-40291	814.09	_	
171-240	40292-40299	1118.75	_	
171-241	40300-40306	842.08	_	
171-242	40307-40314	1271.89	_	
171-243	40315-40318	108	_	
171-244	40319-40323	0.11	_	
171-245	40324-40327	.91	_	
171-246	40330-40337	Interim	_	
171-247	40338-40348	Three-Year	_	
171-248	40349-40353	Drug	_	
171-249	40354-40358	Use2	_	
171-250	40369-40381	Prescription	_	
171-251	40382-40391	Stimulant	_	
171-252	40392-40397	62.63	_	
171-253	40398-40403	88.79	_	
171-254	40404-40408	5.58	_	
171-255	40409-40414	23.13	_	
171-256	40415-40418	106	_	
171-257	40419-40423	5.18	_	
171-258	40424-40425	<	_	
171-259	40425-40429	.001	_	
171-260	40433-40440	Cocaine	_	
171-261	40441-40447	283.03	_	
171-262	40448-40454	622.56	_	
171-263	40455-40459	8.49	_	
171-264	40460-40465	35.58	_	
171-265	40466-40469	106	_	
171-266	40470-40474	3.80	_	
171-267	40475-40476	<	_	
171-268	40476-40480	.001	_	
171-269	40484-40493	Marijuana	_	
171-270	40494-40500	588.62	_	
171-271	40501-40507	946.77	_	
171-272	40508-40514	838.28	_	
171-273	40515-40522	1974.42	_	
171-274	40523-40526	106	_	
171-275	40527-40531	0.70	_	
171-276	40532-40535	.49	_	
171-277	40539-40554	Methamphetamine	_	
171-278	40555-40560	38.35	_	
171-279	40561-40568	215.985	_	
171-280	40577-40580	All	_	
171-281	40581-40591	stimulants	_	
171-282	40592-40598	384.01	_	
171-283	40599-40606	627.911	_	
171-284	40607-40612	14.09	_	
171-285	40613-40618	41.64	_	
171-286	40619-40622	106	_	
171-287	40623-40627	5.07	_	
171-288	40628-40629	<	_	
171-289	40629-40633	.001	_	
171-290	40636-40643	Recency	_	
171-291	40644-40646	of	_	
171-292	40647-40651	Drug	_	
171-293	40652-40655	Use	_	
171-294	40656-40657	(	_	
171-295	40657-40661	Time	_	
171-296	40662-40664	of	_	
171-297	40665-40669	Scan	_	
171-298	40669-40670	)	_	
171-299	40670-40671	3	_	
171-300	40682-40694	Prescription	_	
171-301	40695-40704	Stimulant	_	
171-302	40705-40710	74.56	_	
171-303	40711-40716	88.93	_	
171-304	40717-40723	193.43	_	
171-305	40724-40730	294.44	_	
171-306	40731-40733	70	_	
171-307	40734-40735	−	_	
171-308	40735-40739	2.71	_	
171-309	40740-40743	.01	_	
171-310	40747-40754	Cocaine	_	
171-311	40755-40760	78.29	_	
171-312	40761-40767	100.33	_	
171-313	40768-40774	125.46	_	
171-314	40775-40781	223.12	_	
171-315	40782-40784	72	_	
171-316	40785-40786	−	_	
171-317	40786-40790	0.99	_	
171-318	40791-40794	.33	_	
171-319	40798-40807	Marijuana	_	
171-320	40808-40813	57.17	_	
171-321	40814-40820	149.62	_	
171-322	40821-40826	30.46	_	
171-323	40827-40832	73.56	_	
171-324	40833-40835	35	_	
171-325	40836-40840	0.93	_	
171-326	40841-40844	.36	_	
171-327	40848-40852	Note	_	
171-328	40852-40853	:	_	
171-329	40854-40864	Determined	_	
171-330	40865-40867	by	_	
171-331	40868-40873	urine	_	
171-332	40874-40880	screen	_	
171-333	40881-40883	at	_	
171-334	40884-40887	the	_	
171-335	40888-40894	outset	_	
171-336	40895-40897	of	_	
171-337	40898-40901	the	_	
171-338	40902-40914	neuroimaging	_	
171-339	40915-40922	session	_	
171-340	40922-40923	.	_	

#Text=Lifetime uses of the drug at the time of baseline clinical interview were quantified by the number of discrete sessions consumed.
172-1	40924-40932	Lifetime	_	
172-2	40933-40937	uses	_	
172-3	40938-40940	of	_	
172-4	40941-40944	the	_	
172-5	40945-40949	drug	_	
172-6	40950-40952	at	_	
172-7	40953-40956	the	_	
172-8	40957-40961	time	_	
172-9	40962-40964	of	_	
172-10	40965-40973	baseline	_	
172-11	40974-40982	clinical	_	
172-12	40983-40992	interview	_	
172-13	40993-40997	were	_	
172-14	40998-41008	quantified	_	
172-15	41009-41011	by	_	
172-16	41012-41015	the	_	
172-17	41016-41022	number	_	
172-18	41023-41025	of	_	
172-19	41026-41034	discrete	_	
172-20	41035-41043	sessions	_	
172-21	41044-41052	consumed	_	
172-22	41052-41053	.	_	

#Text=Number of discrete sessions of drug use from the time of the baseline clinical interview to the time of three-year follow-up interview.
173-1	41054-41060	Number	_	
173-2	41061-41063	of	_	
173-3	41064-41072	discrete	_	
173-4	41073-41081	sessions	_	
173-5	41082-41084	of	_	
173-6	41085-41089	drug	_	
173-7	41090-41093	use	_	
173-8	41094-41098	from	_	
173-9	41099-41102	the	_	
173-10	41103-41107	time	_	
173-11	41108-41110	of	_	
173-12	41111-41114	the	_	
173-13	41115-41123	baseline	_	
173-14	41124-41132	clinical	_	
173-15	41133-41142	interview	_	
173-16	41143-41145	to	_	
173-17	41146-41149	the	_	
173-18	41150-41154	time	_	
173-19	41155-41157	of	_	
173-20	41158-41168	three-year	_	
173-21	41169-41178	follow-up	_	
173-22	41179-41188	interview	_	
173-23	41188-41189	.	_	

#Text=Recency of drug use at the time of the neuroimaging session was quantified by days since last use.
174-1	41190-41197	Recency	_	
174-2	41198-41200	of	_	
174-3	41201-41205	drug	_	
174-4	41206-41209	use	_	
174-5	41210-41212	at	_	
174-6	41213-41216	the	_	
174-7	41217-41221	time	_	
174-8	41222-41224	of	_	
174-9	41225-41228	the	_	
174-10	41229-41241	neuroimaging	_	
174-11	41242-41249	session	_	
174-12	41250-41253	was	_	
174-13	41254-41264	quantified	_	
174-14	41265-41267	by	_	
174-15	41268-41272	days	_	
174-16	41273-41278	since	_	
174-17	41279-41283	last	_	
174-18	41284-41287	use	_	
174-19	41287-41288	.	_	

#Text=PSU = problem stimulant users.
175-1	41289-41292	PSU	_	
175-2	41293-41294	=	_	
175-3	41295-41302	problem	_	
175-4	41303-41312	stimulant	_	
175-5	41313-41318	users	_	
175-6	41318-41319	.	_	

#Text=DSU = desisted stimulant users.
176-1	41320-41323	DSU	_	
176-2	41324-41325	=	_	
176-3	41326-41334	desisted	_	
176-4	41335-41344	stimulant	_	
176-5	41345-41350	users	_	
176-6	41350-41351	.	_	

#Text=IQ = intelligence quotient.
177-1	41352-41354	IQ	_	
177-2	41355-41356	=	_	
177-3	41357-41369	intelligence	_	
177-4	41370-41378	quotient	_	
177-5	41378-41379	.	_	

#Text=Chi-Square Results Evaluating Whether Preference of Stimulant Type at Baseline Differed Between DSU and PSU.
178-1	41380-41390	Chi-Square	_	
178-2	41391-41398	Results	_	
178-3	41399-41409	Evaluating	_	
178-4	41410-41417	Whether	_	
178-5	41418-41428	Preference	_	
178-6	41429-41431	of	_	
178-7	41432-41441	Stimulant	_	
178-8	41442-41446	Type	_	
178-9	41447-41449	at	_	
178-10	41450-41458	Baseline	_	
178-11	41459-41467	Differed	_	
178-12	41468-41475	Between	_	
178-13	41476-41479	DSU	_	
178-14	41480-41483	and	_	
178-15	41484-41487	PSU	_	
178-16	41487-41488	.	_	

#Text=Group\tPreference\tTotal\t \t\tCocaine\tNONE\tPrescription Amphetamines\t\t \t\t\t \tDSU\t\t\t\t\t \tCount\t27\t14\t34\t75\t \t% within Group\t36%\t18.7%\t45.3%\t100.0%\t \tExpected Count\t25.9\t13\t36.1\t75\t \tPSU\t\t\t\t\t \tCount\t11\t5\t19\t35\t \t% within Group\t31.4%\t14.3%\t54.3%\t100.0%\t \tExpected Count\t12.1\t6\t16.9\t35\t \t\t38\t19\t53\t110\t \t\tdf\tχ2\tp\t\t \t\t\t\t \t\t2\t.81\t.67\t\t \t
#Text=Note: DSU = desisted stimulant users.
179-1	41489-41494	Group	_	
179-2	41495-41505	Preference	_	
179-3	41506-41511	Total	_	
179-4	41515-41522	Cocaine	_	
179-5	41523-41527	NONE	_	
179-6	41528-41540	Prescription	_	
179-7	41541-41553	Amphetamines	_	
179-8	41561-41564	DSU	_	
179-9	41571-41576	Count	_	
179-10	41577-41579	27	_	
179-11	41580-41582	14	_	
179-12	41583-41585	34	_	
179-13	41586-41588	75	_	
179-14	41591-41592	%	_	
179-15	41593-41599	within	_	
179-16	41600-41605	Group	_	
179-17	41606-41609	36%	_	
179-18	41610-41615	18.7%	_	
179-19	41616-41621	45.3%	_	
179-20	41622-41628	100.0%	_	
179-21	41631-41639	Expected	_	
179-22	41640-41645	Count	_	
179-23	41646-41650	25.9	_	
179-24	41651-41653	13	_	
179-25	41654-41658	36.1	_	
179-26	41659-41661	75	_	
179-27	41664-41667	PSU	_	
179-28	41674-41679	Count	_	
179-29	41680-41682	11	_	
179-30	41683-41684	5	_	
179-31	41685-41687	19	_	
179-32	41688-41690	35	_	
179-33	41693-41694	%	_	
179-34	41695-41701	within	_	
179-35	41702-41707	Group	_	
179-36	41708-41713	31.4%	_	
179-37	41714-41719	14.3%	_	
179-38	41720-41725	54.3%	_	
179-39	41726-41732	100.0%	_	
179-40	41735-41743	Expected	_	
179-41	41744-41749	Count	_	
179-42	41750-41754	12.1	_	
179-43	41755-41756	6	_	
179-44	41757-41761	16.9	_	
179-45	41762-41764	35	_	
179-46	41768-41770	38	_	
179-47	41771-41773	19	_	
179-48	41774-41776	53	_	
179-49	41777-41780	110	_	
179-50	41784-41786	df	_	
179-51	41787-41789	χ2	_	
179-52	41790-41791	p	_	
179-53	41801-41802	2	_	
179-54	41803-41806	.81	_	
179-55	41807-41810	.67	_	
179-56	41815-41819	Note	_	
179-57	41819-41820	:	_	
179-58	41821-41824	DSU	_	
179-59	41825-41826	=	_	
179-60	41827-41835	desisted	_	
179-61	41836-41845	stimulant	_	
179-62	41846-41851	users	_	
179-63	41851-41852	.	_	

#Text=PSU = problem stimulant users
#Text=Behavioral Performance.
180-1	41853-41856	PSU	_	
180-2	41857-41858	=	_	
180-3	41859-41866	problem	_	
180-4	41867-41876	stimulant	_	
180-5	41877-41882	users	_	
180-6	41883-41893	Behavioral	_	
180-7	41894-41905	Performance	_	
180-8	41905-41906	.	_	

#Text=PSU (n = 35)\tDSU (n= 75)\tStatistics\t \t\t \t\tM\tSD\tM\tSD\tdf\tt\tp\t \tTotal 20 Trials\t39.43\t18.00\t45.53\t16.23\t108\t−1.77\t.08\t \tTotal 40 Trials\t35.71\t11.23\t34.03\t10.33\t108\t0.78\t.44\t \tTotal 80 Trials\t20.77\t13.32\t16.27\t10.81\t108\t1.89\t.06\t \tTotal Risk Trials (40 and 80 combined)\t56.49\t18.07\t50.29\t16.23\t108\t1.80\t.08\t \tWon $ Followed by Risky Choice\t.58\t1.91\t.50\t.18\t108\t2.05\t.04\t \tWon $ Followed by Safe Choice\t.42\t.17\t.50\t.18\t108\t−2.15\t.03\t \tLost $ Followed by Risky Choice\t.32\t.16\t.29\t.20\t108\t0.72\t.48\t \tLost $ Followed by Safe Choice\t.45\t.28\t.52\t.28\t108\t−1.19\t.24\t \tTotal Risky Win Trials\t.58\t.19\t.51\t.17\t108\t1.91\t.06\t \tTotal Risky Loss Trials\t18.46\t7.34\t16.07\t6.32\t108\t1.75\t.08\t \t% of Loss after a Loss Trial\t.22\t.14\t.20\t.13\t108\t.51\t.61\t \t
#Text=Note: PSU = problem stimulant users.
181-1	41908-41911	PSU	_	
181-2	41912-41913	(	_	
181-3	41913-41914	n	_	
181-4	41915-41916	=	_	
181-5	41917-41919	35	_	
181-6	41919-41920	)	_	
181-7	41921-41924	DSU	_	
181-8	41925-41926	(	_	
181-9	41926-41927	n	_	
181-10	41927-41928	=	_	
181-11	41929-41931	75	_	
181-12	41931-41932	)	_	
181-13	41933-41943	Statistics	_	
181-14	41950-41951	M	_	
181-15	41952-41954	SD	_	
181-16	41955-41956	M	_	
181-17	41957-41959	SD	_	
181-18	41960-41962	df	_	
181-19	41963-41964	t	_	
181-20	41965-41966	p	_	
181-21	41969-41974	Total	_	
181-22	41975-41977	20	_	
181-23	41978-41984	Trials	_	
181-24	41985-41990	39.43	_	
181-25	41991-41996	18.00	_	
181-26	41997-42002	45.53	_	
181-27	42003-42008	16.23	_	
181-28	42009-42012	108	_	
181-29	42013-42014	−	_	
181-30	42014-42018	1.77	_	
181-31	42019-42022	.08	_	
181-32	42025-42030	Total	_	
181-33	42031-42033	40	_	
181-34	42034-42040	Trials	_	
181-35	42041-42046	35.71	_	
181-36	42047-42052	11.23	_	
181-37	42053-42058	34.03	_	
181-38	42059-42064	10.33	_	
181-39	42065-42068	108	_	
181-40	42069-42073	0.78	_	
181-41	42074-42077	.44	_	
181-42	42080-42085	Total	_	
181-43	42086-42088	80	_	
181-44	42089-42095	Trials	_	
181-45	42096-42101	20.77	_	
181-46	42102-42107	13.32	_	
181-47	42108-42113	16.27	_	
181-48	42114-42119	10.81	_	
181-49	42120-42123	108	_	
181-50	42124-42128	1.89	_	
181-51	42129-42132	.06	_	
181-52	42135-42140	Total	_	
181-53	42141-42145	Risk	_	
181-54	42146-42152	Trials	_	
181-55	42153-42154	(	_	
181-56	42154-42156	40	_	
181-57	42157-42160	and	_	
181-58	42161-42163	80	_	
181-59	42164-42172	combined	_	
181-60	42172-42173	)	_	
181-61	42174-42179	56.49	_	
181-62	42180-42185	18.07	_	
181-63	42186-42191	50.29	_	
181-64	42192-42197	16.23	_	
181-65	42198-42201	108	_	
181-66	42202-42206	1.80	_	
181-67	42207-42210	.08	_	
181-68	42213-42216	Won	_	
181-69	42217-42218	$	_	
181-70	42219-42227	Followed	_	
181-71	42228-42230	by	_	
181-72	42231-42236	Risky	_	
181-73	42237-42243	Choice	_	
181-74	42244-42247	.58	_	
181-75	42248-42252	1.91	_	
181-76	42253-42256	.50	_	
181-77	42257-42260	.18	_	
181-78	42261-42264	108	_	
181-79	42265-42269	2.05	_	
181-80	42270-42273	.04	_	
181-81	42276-42279	Won	_	
181-82	42280-42281	$	_	
181-83	42282-42290	Followed	_	
181-84	42291-42293	by	_	
181-85	42294-42298	Safe	_	
181-86	42299-42305	Choice	_	
181-87	42306-42309	.42	_	
181-88	42310-42313	.17	_	
181-89	42314-42317	.50	_	
181-90	42318-42321	.18	_	
181-91	42322-42325	108	_	
181-92	42326-42327	−	_	
181-93	42327-42331	2.15	_	
181-94	42332-42335	.03	_	
181-95	42338-42342	Lost	_	
181-96	42343-42344	$	_	
181-97	42345-42353	Followed	_	
181-98	42354-42356	by	_	
181-99	42357-42362	Risky	_	
181-100	42363-42369	Choice	_	
181-101	42370-42373	.32	_	
181-102	42374-42377	.16	_	
181-103	42378-42381	.29	_	
181-104	42382-42385	.20	_	
181-105	42386-42389	108	_	
181-106	42390-42394	0.72	_	
181-107	42395-42398	.48	_	
181-108	42401-42405	Lost	_	
181-109	42406-42407	$	_	
181-110	42408-42416	Followed	_	
181-111	42417-42419	by	_	
181-112	42420-42424	Safe	_	
181-113	42425-42431	Choice	_	
181-114	42432-42435	.45	_	
181-115	42436-42439	.28	_	
181-116	42440-42443	.52	_	
181-117	42444-42447	.28	_	
181-118	42448-42451	108	_	
181-119	42452-42453	−	_	
181-120	42453-42457	1.19	_	
181-121	42458-42461	.24	_	
181-122	42464-42469	Total	_	
181-123	42470-42475	Risky	_	
181-124	42476-42479	Win	_	
181-125	42480-42486	Trials	_	
181-126	42487-42490	.58	_	
181-127	42491-42494	.19	_	
181-128	42495-42498	.51	_	
181-129	42499-42502	.17	_	
181-130	42503-42506	108	_	
181-131	42507-42511	1.91	_	
181-132	42512-42515	.06	_	
181-133	42518-42523	Total	_	
181-134	42524-42529	Risky	_	
181-135	42530-42534	Loss	_	
181-136	42535-42541	Trials	_	
181-137	42542-42547	18.46	_	
181-138	42548-42552	7.34	_	
181-139	42553-42558	16.07	_	
181-140	42559-42563	6.32	_	
181-141	42564-42567	108	_	
181-142	42568-42572	1.75	_	
181-143	42573-42576	.08	_	
181-144	42579-42580	%	_	
181-145	42581-42583	of	_	
181-146	42584-42588	Loss	_	
181-147	42589-42594	after	_	
181-148	42595-42596	a	_	
181-149	42597-42601	Loss	_	
181-150	42602-42607	Trial	_	
181-151	42608-42611	.22	_	
181-152	42612-42615	.14	_	
181-153	42616-42619	.20	_	
181-154	42620-42623	.13	_	
181-155	42624-42627	108	_	
181-156	42628-42631	.51	_	
181-157	42632-42635	.61	_	
181-158	42639-42643	Note	_	
181-159	42643-42644	:	_	
181-160	42645-42648	PSU	_	
181-161	42649-42650	=	_	
181-162	42651-42658	problem	_	
181-163	42659-42668	stimulant	_	
181-164	42669-42674	users	_	
181-165	42674-42675	.	_	

#Text=DSU = desisted stimulant users.
182-1	42676-42679	DSU	_	
182-2	42680-42681	=	_	
182-3	42682-42690	desisted	_	
182-4	42691-42700	stimulant	_	
182-5	42701-42706	users	_	
182-6	42706-42707	.	_	

#Text=Categorical Neuroimaging Results: Problem Stimulant Users (PSU) versus Desisted Stimulant Users (DSU)
#Text=Group x Decision Interaction\t \t\tx\ty\tz\tL/R\tRegions in Cluster\tBA\tResults\t \tVoxels\t \t29\t12\t−56\t29\tR\tPrecuneus, Cingulate Gyrus\t7/31\tSafe: DSU > PSU; d = .65Risky: NS\t \tOutcome Group Main Effect\t \t43\t−22\t−32\t60\tL\tPostcentral/Precentral Gyrus, Superior/Middle Frontal Gyrus, Superior Parietal Lobule, Paracentral Lobule\t3–7/40\tDSU > PSU; d = .90\t \t30\t−30\t−14\t21\tL\tInsula, Lentiform Nucleus, Putamen, Claustrum\t13\tDSU > PSU; d = 1.06\t \t20\t9\t−52\t30\tR\tPrecuneus, Cingulate Gyrus, Posterior Cingulate\t7/31\tDSU > PSU; d = .82\t \tGroup x Outcome Interaction\t \t34\t6\t−19\t10\tR\tThalamus, Medial Dorsal Nucleus, Pulvinar, Ventral Lateral Nucleus\t\tLose Risky: DSU > PSU; d = .58Win Risky: NS\t \t24\t−41\t−68\t5\tL\tMiddle/Inferior Occipital Gyrus, Inferior/Middle Temporal Gyrus\t19/37\tLose Risky: DSU > PSU; d = .40Win Risky: DSU < PSU d = .24\t \t
#Text=Note.
183-1	42708-42719	Categorical	_	
183-2	42720-42732	Neuroimaging	_	
183-3	42733-42740	Results	_	
183-4	42740-42741	:	_	
183-5	42742-42749	Problem	_	
183-6	42750-42759	Stimulant	_	
183-7	42760-42765	Users	_	
183-8	42766-42767	(	_	
183-9	42767-42770	PSU	_	
183-10	42770-42771	)	_	
183-11	42772-42778	versus	_	
183-12	42779-42787	Desisted	_	
183-13	42788-42797	Stimulant	_	
183-14	42798-42803	Users	_	
183-15	42804-42805	(	_	
183-16	42805-42808	DSU	_	
183-17	42808-42809	)	_	
183-18	42810-42815	Group	_	
183-19	42816-42817	x	_	
183-20	42818-42826	Decision	_	
183-21	42827-42838	Interaction	_	
183-22	42842-42843	x	_	
183-23	42844-42845	y	_	
183-24	42846-42847	z	_	
183-25	42848-42849	L	_	
183-26	42849-42850	/	_	
183-27	42850-42851	R	_	
183-28	42852-42859	Regions	_	
183-29	42860-42862	in	_	
183-30	42863-42870	Cluster	_	
183-31	42871-42873	BA	_	
183-32	42874-42881	Results	_	
183-33	42884-42890	Voxels	_	
183-34	42893-42895	29	_	
183-35	42896-42898	12	_	
183-36	42899-42900	−	_	
183-37	42900-42902	56	_	
183-38	42903-42905	29	_	
183-39	42906-42907	R	_	
183-40	42908-42917	Precuneus	_	
183-41	42917-42918	,	_	
183-42	42919-42928	Cingulate	_	
183-43	42929-42934	Gyrus	_	
183-44	42935-42936	7	_	
183-45	42936-42937	/	_	
183-46	42937-42939	31	_	
183-47	42940-42944	Safe	_	
183-48	42944-42945	:	_	
183-49	42946-42949	DSU	_	
183-50	42950-42951	>	_	
183-51	42952-42955	PSU	_	
183-52	42955-42956	;	_	
183-53	42957-42958	d	_	
183-54	42959-42960	=	_	
183-55	42961-42969	.65Risky	_	
183-56	42969-42970	:	_	
183-57	42971-42973	NS	_	
183-58	42976-42983	Outcome	_	
183-59	42984-42989	Group	_	
183-60	42990-42994	Main	_	
183-61	42995-43001	Effect	_	
183-62	43004-43006	43	_	
183-63	43007-43008	−	_	
183-64	43008-43010	22	_	
183-65	43011-43012	−	_	
183-66	43012-43014	32	_	
183-67	43015-43017	60	_	
183-68	43018-43019	L	_	
183-69	43020-43031	Postcentral	_	
183-70	43031-43032	/	_	
183-71	43032-43042	Precentral	_	
183-72	43043-43048	Gyrus	_	
183-73	43048-43049	,	_	
183-74	43050-43058	Superior	_	
183-75	43058-43059	/	_	
183-76	43059-43065	Middle	_	
183-77	43066-43073	Frontal	_	
183-78	43074-43079	Gyrus	_	
183-79	43079-43080	,	_	
183-80	43081-43089	Superior	_	
183-81	43090-43098	Parietal	_	
183-82	43099-43105	Lobule	_	
183-83	43105-43106	,	_	
183-84	43107-43118	Paracentral	_	
183-85	43119-43125	Lobule	_	
183-86	43126-43127	3	_	
183-87	43127-43128	–	_	
183-88	43128-43129	7	_	
183-89	43129-43130	/	_	
183-90	43130-43132	40	_	
183-91	43133-43136	DSU	_	
183-92	43137-43138	>	_	
183-93	43139-43142	PSU	_	
183-94	43142-43143	;	_	
183-95	43144-43145	d	_	
183-96	43146-43147	=	_	
183-97	43148-43151	.90	_	
183-98	43154-43156	30	_	
183-99	43157-43158	−	_	
183-100	43158-43160	30	_	
183-101	43161-43162	−	_	
183-102	43162-43164	14	_	
183-103	43165-43167	21	_	
183-104	43168-43169	L	_	
183-105	43170-43176	Insula	_	
183-106	43176-43177	,	_	
183-107	43178-43187	Lentiform	_	
183-108	43188-43195	Nucleus	_	
183-109	43195-43196	,	_	
183-110	43197-43204	Putamen	_	
183-111	43204-43205	,	_	
183-112	43206-43215	Claustrum	_	
183-113	43216-43218	13	_	
183-114	43219-43222	DSU	_	
183-115	43223-43224	>	_	
183-116	43225-43228	PSU	_	
183-117	43228-43229	;	_	
183-118	43230-43231	d	_	
183-119	43232-43233	=	_	
183-120	43234-43238	1.06	_	
183-121	43241-43243	20	_	
183-122	43244-43245	9	_	
183-123	43246-43247	−	_	
183-124	43247-43249	52	_	
183-125	43250-43252	30	_	
183-126	43253-43254	R	_	
183-127	43255-43264	Precuneus	_	
183-128	43264-43265	,	_	
183-129	43266-43275	Cingulate	_	
183-130	43276-43281	Gyrus	_	
183-131	43281-43282	,	_	
183-132	43283-43292	Posterior	_	
183-133	43293-43302	Cingulate	_	
183-134	43303-43304	7	_	
183-135	43304-43305	/	_	
183-136	43305-43307	31	_	
183-137	43308-43311	DSU	_	
183-138	43312-43313	>	_	
183-139	43314-43317	PSU	_	
183-140	43317-43318	;	_	
183-141	43319-43320	d	_	
183-142	43321-43322	=	_	
183-143	43323-43326	.82	_	
183-144	43329-43334	Group	_	
183-145	43335-43336	x	_	
183-146	43337-43344	Outcome	_	
183-147	43345-43356	Interaction	_	
183-148	43359-43361	34	_	
183-149	43362-43363	6	_	
183-150	43364-43365	−	_	
183-151	43365-43367	19	_	
183-152	43368-43370	10	_	
183-153	43371-43372	R	_	
183-154	43373-43381	Thalamus	_	
183-155	43381-43382	,	_	
183-156	43383-43389	Medial	_	
183-157	43390-43396	Dorsal	_	
183-158	43397-43404	Nucleus	_	
183-159	43404-43405	,	_	
183-160	43406-43414	Pulvinar	_	
183-161	43414-43415	,	_	
183-162	43416-43423	Ventral	_	
183-163	43424-43431	Lateral	_	
183-164	43432-43439	Nucleus	_	
183-165	43441-43445	Lose	_	
183-166	43446-43451	Risky	_	
183-167	43451-43452	:	_	
183-168	43453-43456	DSU	_	
183-169	43457-43458	>	_	
183-170	43459-43462	PSU	_	
183-171	43462-43463	;	_	
183-172	43464-43465	d	_	
183-173	43466-43467	=	_	
183-174	43468-43474	.58Win	_	
183-175	43475-43480	Risky	_	
183-176	43480-43481	:	_	
183-177	43482-43484	NS	_	
183-178	43487-43489	24	_	
183-179	43490-43491	−	_	
183-180	43491-43493	41	_	
183-181	43494-43495	−	_	
183-182	43495-43497	68	_	
183-183	43498-43499	5	_	
183-184	43500-43501	L	_	
183-185	43502-43508	Middle	_	
183-186	43508-43509	/	_	
183-187	43509-43517	Inferior	_	
183-188	43518-43527	Occipital	_	
183-189	43528-43533	Gyrus	_	
183-190	43533-43534	,	_	
183-191	43535-43543	Inferior	_	
183-192	43543-43544	/	_	
183-193	43544-43550	Middle	_	
183-194	43551-43559	Temporal	_	
183-195	43560-43565	Gyrus	_	
183-196	43566-43568	19	_	
183-197	43568-43569	/	_	
183-198	43569-43571	37	_	
183-199	43572-43576	Lose	_	
183-200	43577-43582	Risky	_	
183-201	43582-43583	:	_	
183-202	43584-43587	DSU	_	
183-203	43588-43589	>	_	
183-204	43590-43593	PSU	_	
183-205	43593-43594	;	_	
183-206	43595-43596	d	_	
183-207	43597-43598	=	_	
183-208	43599-43605	.40Win	_	
183-209	43606-43611	Risky	_	
183-210	43611-43612	:	_	
183-211	43613-43616	DSU	_	
183-212	43617-43618	<	_	
183-213	43619-43622	PSU	_	
183-214	43623-43624	d	_	
183-215	43625-43626	=	_	
183-216	43627-43630	.24	_	
183-217	43634-43638	Note	_	
183-218	43638-43639	.	_	

#Text=L= left hemisphere.
184-1	43640-43641	L	_	
184-2	43641-43642	=	_	
184-3	43643-43647	left	_	
184-4	43648-43658	hemisphere	_	
184-5	43658-43659	.	_	

#Text=R = right hemisphere.
185-1	43660-43661	R	_	
185-2	43662-43663	=	_	
185-3	43664-43669	right	_	
185-4	43670-43680	hemisphere	_	
185-5	43680-43681	.	_	

#Text=BA = Brodmann Area.
186-1	43682-43684	BA	_	
186-2	43685-43686	=	_	
186-3	43687-43695	Brodmann	_	
186-4	43696-43700	Area	_	
186-5	43700-43701	.	_	

#Text=NS = Not significant.
187-1	43702-43704	NS	_	
187-2	43705-43706	=	_	
187-3	43707-43710	Not	_	
187-4	43711-43722	significant	_	
187-5	43722-43723	.	_	

#Text=Coordinates (x, y, z) reflect center of mass.
188-1	43724-43735	Coordinates	_	
188-2	43736-43737	(	_	
188-3	43737-43738	x	_	
188-4	43738-43739	,	_	
188-5	43740-43741	y	_	
188-6	43741-43742	,	_	
188-7	43743-43744	z	_	
188-8	43744-43745	)	_	
188-9	43746-43753	reflect	_	
188-10	43754-43760	center	_	
188-11	43761-43763	of	_	
188-12	43764-43768	mass	_	
188-13	43768-43769	.	_	

#Text=Voxelwise threshold for effect > F(1,108) = 6.88, p < .01 two-tailed for ≥ 19 contiguous voxels.
189-1	43770-43779	Voxelwise	_	
189-2	43780-43789	threshold	_	
189-3	43790-43793	for	_	
189-4	43794-43800	effect	_	
189-5	43801-43802	>	_	
189-6	43803-43804	F	_	
189-7	43804-43805	(	_	
189-8	43805-43810	1,108	_	
189-9	43810-43811	)	_	
189-10	43812-43813	=	_	
189-11	43814-43818	6.88	_	
189-12	43818-43819	,	_	
189-13	43820-43821	p	_	
189-14	43822-43823	<	_	
189-15	43824-43827	.01	_	
189-16	43828-43838	two-tailed	_	
189-17	43839-43842	for	_	
189-18	43843-43844	≥	_	
189-19	43845-43847	19	_	
189-20	43848-43858	contiguous	_	
189-21	43859-43865	voxels	_	
189-22	43865-43866	.	_	

#Text=Cohen’s d = effect size.
190-1	43867-43872	Cohen	_	
190-2	43872-43873	’	_	
190-3	43873-43874	s	_	
190-4	43875-43876	d	_	
190-5	43877-43878	=	_	
190-6	43879-43885	effect	_	
190-7	43886-43890	size	_	
190-8	43890-43891	.	_	

#Text=Dimensional Neuroimaging Results: Interim Marijuana Use Predicting BOLD Signal for Risky Minus Safe Decisions
#Text=Interim Marijuana Use\t \tVoxels\tx\ty\tz\tL/R\tRegions in Cluster\tBA\tStandardized Beta\t \t365\t39\t−19\t43\tR\tPostcentral Gyrus, Inferior Parietal Lobule, Middle/Superior/Inferior Frontal Gyrus, Precentral Gyrus, Supramarginal Gyrus, Superior Parietal Lobule\t2–4/6/9/40\t−.56\t \t108\t−48\t−55\t−9\tL\tMiddle/Inferior Temporal Gyrus, Fusiform gyrus, Declive, Culmen, Middle Occipital Gyrus\t19–20/37\t−.51\t \t105\t−29\t−53\t40\tL\tSuperior/Inferior Parietal Lobule, Precuneus\t7/40\t−.48\t \t64\t30\t54\t14\tR\tSuperior/Middle Frontal Gyrus\t5/10\t−.50\t \t52\t49\t−49\t−12\tR\tFusiform Gyrus, Declive, Middle/Inferior Temporal Gyrus, Culmen\t20/37\t−.46\t \t45\t−41\t−6\t39\tL\tPrecentral Gyrus, Inferior/Middle Frontal Gyrus\t6\t−.46\t \t36\t−51\t7\t−3\tL\tSuperior Temporal Gyrus, Insula, Inferior Frontal Gyrus\t13/22/38\t−.54\t \t34\t5\t10\t46\tR\tMedial/Superior Frontal Gyrus, Cingulate Gyrus\t6/32\t−.42\t \t26\t4\t−68\t52\tR\tPrecuneus, Superior Parietal Lobule\t7\t−.34\t \t24\t51\t−44\t18\tR\tSuperior/Middle Temporal Gyrus, Inferior Parietal Lobule, Supramarginal Gyrus\t13/21–22\t−.40\t \t24\t−30\t52\t15\tL\tSuperior/Middle Frontal Gyrus\t10\t−.41\t \t21\t52\t−19\t−4\tR\tSuperior/Middle Temporal Gyrus\t22\t−.45\t \t21\t9\t−9\t7\tR\tThalamus, Caudate, Caudate Body, Mammillary Body, Ventral Anterior Nucleus, Lentiform Nucleus\t\t−.40\t \t20\t−11\t−76\t−22\tL\tDeclive, Lingual Gyrus, Uvula\t\t−.40\t \t20\t6\t−49\t−12\tR\tCulmen, Fastigium, Cerebellar Lingual\t\t−.42\t \t20\t−26\t−2\t53\tL\tMiddle Frontal Gyrus\t6\t−.39\t \t19\t−3\t−65\t−6\tL\tCulmen of Vermis, Lingual Gyrus, Culmen, Declive\t\t−.36\t \t
#Text=Note.
191-1	43892-43903	Dimensional	_	
191-2	43904-43916	Neuroimaging	_	
191-3	43917-43924	Results	_	
191-4	43924-43925	:	_	
191-5	43926-43933	Interim	_	
191-6	43934-43943	Marijuana	_	
191-7	43944-43947	Use	_	
191-8	43948-43958	Predicting	_	
191-9	43959-43963	BOLD	_	
191-10	43964-43970	Signal	_	
191-11	43971-43974	for	_	
191-12	43975-43980	Risky	_	
191-13	43981-43986	Minus	_	
191-14	43987-43991	Safe	_	
191-15	43992-44001	Decisions	_	
191-16	44002-44009	Interim	_	
191-17	44010-44019	Marijuana	_	
191-18	44020-44023	Use	_	
191-19	44026-44032	Voxels	_	
191-20	44033-44034	x	_	
191-21	44035-44036	y	_	
191-22	44037-44038	z	_	
191-23	44039-44040	L	_	
191-24	44040-44041	/	_	
191-25	44041-44042	R	_	
191-26	44043-44050	Regions	_	
191-27	44051-44053	in	_	
191-28	44054-44061	Cluster	_	
191-29	44062-44064	BA	_	
191-30	44065-44077	Standardized	_	
191-31	44078-44082	Beta	_	
191-32	44085-44088	365	_	
191-33	44089-44091	39	_	
191-34	44092-44093	−	_	
191-35	44093-44095	19	_	
191-36	44096-44098	43	_	
191-37	44099-44100	R	_	
191-38	44101-44112	Postcentral	_	
191-39	44113-44118	Gyrus	_	
191-40	44118-44119	,	_	
191-41	44120-44128	Inferior	_	
191-42	44129-44137	Parietal	_	
191-43	44138-44144	Lobule	_	
191-44	44144-44145	,	_	
191-45	44146-44152	Middle	_	
191-46	44152-44153	/	_	
191-47	44153-44161	Superior	_	
191-48	44161-44162	/	_	
191-49	44162-44170	Inferior	_	
191-50	44171-44178	Frontal	_	
191-51	44179-44184	Gyrus	_	
191-52	44184-44185	,	_	
191-53	44186-44196	Precentral	_	
191-54	44197-44202	Gyrus	_	
191-55	44202-44203	,	_	
191-56	44204-44217	Supramarginal	_	
191-57	44218-44223	Gyrus	_	
191-58	44223-44224	,	_	
191-59	44225-44233	Superior	_	
191-60	44234-44242	Parietal	_	
191-61	44243-44249	Lobule	_	
191-62	44250-44251	2	_	
191-63	44251-44252	–	_	
191-64	44252-44253	4	_	
191-65	44253-44254	/	_	
191-66	44254-44255	6	_	
191-67	44255-44256	/	_	
191-68	44256-44257	9	_	
191-69	44257-44258	/	_	
191-70	44258-44260	40	_	
191-71	44261-44262	−	_	
191-72	44262-44265	.56	_	
191-73	44268-44271	108	_	
191-74	44272-44273	−	_	
191-75	44273-44275	48	_	
191-76	44276-44277	−	_	
191-77	44277-44279	55	_	
191-78	44280-44281	−	_	
191-79	44281-44282	9	_	
191-80	44283-44284	L	_	
191-81	44285-44291	Middle	_	
191-82	44291-44292	/	_	
191-83	44292-44300	Inferior	_	
191-84	44301-44309	Temporal	_	
191-85	44310-44315	Gyrus	_	
191-86	44315-44316	,	_	
191-87	44317-44325	Fusiform	_	
191-88	44326-44331	gyrus	_	
191-89	44331-44332	,	_	
191-90	44333-44340	Declive	_	
191-91	44340-44341	,	_	
191-92	44342-44348	Culmen	_	
191-93	44348-44349	,	_	
191-94	44350-44356	Middle	_	
191-95	44357-44366	Occipital	_	
191-96	44367-44372	Gyrus	_	
191-97	44373-44375	19	_	
191-98	44375-44376	–	_	
191-99	44376-44378	20	_	
191-100	44378-44379	/	_	
191-101	44379-44381	37	_	
191-102	44382-44383	−	_	
191-103	44383-44386	.51	_	
191-104	44389-44392	105	_	
191-105	44393-44394	−	_	
191-106	44394-44396	29	_	
191-107	44397-44398	−	_	
191-108	44398-44400	53	_	
191-109	44401-44403	40	_	
191-110	44404-44405	L	_	
191-111	44406-44414	Superior	_	
191-112	44414-44415	/	_	
191-113	44415-44423	Inferior	_	
191-114	44424-44432	Parietal	_	
191-115	44433-44439	Lobule	_	
191-116	44439-44440	,	_	
191-117	44441-44450	Precuneus	_	
191-118	44451-44452	7	_	
191-119	44452-44453	/	_	
191-120	44453-44455	40	_	
191-121	44456-44457	−	_	
191-122	44457-44460	.48	_	
191-123	44463-44465	64	_	
191-124	44466-44468	30	_	
191-125	44469-44471	54	_	
191-126	44472-44474	14	_	
191-127	44475-44476	R	_	
191-128	44477-44485	Superior	_	
191-129	44485-44486	/	_	
191-130	44486-44492	Middle	_	
191-131	44493-44500	Frontal	_	
191-132	44501-44506	Gyrus	_	
191-133	44507-44508	5	_	
191-134	44508-44509	/	_	
191-135	44509-44511	10	_	
191-136	44512-44513	−	_	
191-137	44513-44516	.50	_	
191-138	44519-44521	52	_	
191-139	44522-44524	49	_	
191-140	44525-44526	−	_	
191-141	44526-44528	49	_	
191-142	44529-44530	−	_	
191-143	44530-44532	12	_	
191-144	44533-44534	R	_	
191-145	44535-44543	Fusiform	_	
191-146	44544-44549	Gyrus	_	
191-147	44549-44550	,	_	
191-148	44551-44558	Declive	_	
191-149	44558-44559	,	_	
191-150	44560-44566	Middle	_	
191-151	44566-44567	/	_	
191-152	44567-44575	Inferior	_	
191-153	44576-44584	Temporal	_	
191-154	44585-44590	Gyrus	_	
191-155	44590-44591	,	_	
191-156	44592-44598	Culmen	_	
191-157	44599-44601	20	_	
191-158	44601-44602	/	_	
191-159	44602-44604	37	_	
191-160	44605-44606	−	_	
191-161	44606-44609	.46	_	
191-162	44612-44614	45	_	
191-163	44615-44616	−	_	
191-164	44616-44618	41	_	
191-165	44619-44620	−	_	
191-166	44620-44621	6	_	
191-167	44622-44624	39	_	
191-168	44625-44626	L	_	
191-169	44627-44637	Precentral	_	
191-170	44638-44643	Gyrus	_	
191-171	44643-44644	,	_	
191-172	44645-44653	Inferior	_	
191-173	44653-44654	/	_	
191-174	44654-44660	Middle	_	
191-175	44661-44668	Frontal	_	
191-176	44669-44674	Gyrus	_	
191-177	44675-44676	6	_	
191-178	44677-44678	−	_	
191-179	44678-44681	.46	_	
191-180	44684-44686	36	_	
191-181	44687-44688	−	_	
191-182	44688-44690	51	_	
191-183	44691-44692	7	_	
191-184	44693-44694	−	_	
191-185	44694-44695	3	_	
191-186	44696-44697	L	_	
191-187	44698-44706	Superior	_	
191-188	44707-44715	Temporal	_	
191-189	44716-44721	Gyrus	_	
191-190	44721-44722	,	_	
191-191	44723-44729	Insula	_	
191-192	44729-44730	,	_	
191-193	44731-44739	Inferior	_	
191-194	44740-44747	Frontal	_	
191-195	44748-44753	Gyrus	_	
191-196	44754-44756	13	_	
191-197	44756-44757	/	_	
191-198	44757-44759	22	_	
191-199	44759-44760	/	_	
191-200	44760-44762	38	_	
191-201	44763-44764	−	_	
191-202	44764-44767	.54	_	
191-203	44770-44772	34	_	
191-204	44773-44774	5	_	
191-205	44775-44777	10	_	
191-206	44778-44780	46	_	
191-207	44781-44782	R	_	
191-208	44783-44789	Medial	_	
191-209	44789-44790	/	_	
191-210	44790-44798	Superior	_	
191-211	44799-44806	Frontal	_	
191-212	44807-44812	Gyrus	_	
191-213	44812-44813	,	_	
191-214	44814-44823	Cingulate	_	
191-215	44824-44829	Gyrus	_	
191-216	44830-44831	6	_	
191-217	44831-44832	/	_	
191-218	44832-44834	32	_	
191-219	44835-44836	−	_	
191-220	44836-44839	.42	_	
191-221	44842-44844	26	_	
191-222	44845-44846	4	_	
191-223	44847-44848	−	_	
191-224	44848-44850	68	_	
191-225	44851-44853	52	_	
191-226	44854-44855	R	_	
191-227	44856-44865	Precuneus	_	
191-228	44865-44866	,	_	
191-229	44867-44875	Superior	_	
191-230	44876-44884	Parietal	_	
191-231	44885-44891	Lobule	_	
191-232	44892-44893	7	_	
191-233	44894-44895	−	_	
191-234	44895-44898	.34	_	
191-235	44901-44903	24	_	
191-236	44904-44906	51	_	
191-237	44907-44908	−	_	
191-238	44908-44910	44	_	
191-239	44911-44913	18	_	
191-240	44914-44915	R	_	
191-241	44916-44924	Superior	_	
191-242	44924-44925	/	_	
191-243	44925-44931	Middle	_	
191-244	44932-44940	Temporal	_	
191-245	44941-44946	Gyrus	_	
191-246	44946-44947	,	_	
191-247	44948-44956	Inferior	_	
191-248	44957-44965	Parietal	_	
191-249	44966-44972	Lobule	_	
191-250	44972-44973	,	_	
191-251	44974-44987	Supramarginal	_	
191-252	44988-44993	Gyrus	_	
191-253	44994-44996	13	_	
191-254	44996-44997	/	_	
191-255	44997-44999	21	_	
191-256	44999-45000	–	_	
191-257	45000-45002	22	_	
191-258	45003-45004	−	_	
191-259	45004-45007	.40	_	
191-260	45010-45012	24	_	
191-261	45013-45014	−	_	
191-262	45014-45016	30	_	
191-263	45017-45019	52	_	
191-264	45020-45022	15	_	
191-265	45023-45024	L	_	
191-266	45025-45033	Superior	_	
191-267	45033-45034	/	_	
191-268	45034-45040	Middle	_	
191-269	45041-45048	Frontal	_	
191-270	45049-45054	Gyrus	_	
191-271	45055-45057	10	_	
191-272	45058-45059	−	_	
191-273	45059-45062	.41	_	
191-274	45065-45067	21	_	
191-275	45068-45070	52	_	
191-276	45071-45072	−	_	
191-277	45072-45074	19	_	
191-278	45075-45076	−	_	
191-279	45076-45077	4	_	
191-280	45078-45079	R	_	
191-281	45080-45088	Superior	_	
191-282	45088-45089	/	_	
191-283	45089-45095	Middle	_	
191-284	45096-45104	Temporal	_	
191-285	45105-45110	Gyrus	_	
191-286	45111-45113	22	_	
191-287	45114-45115	−	_	
191-288	45115-45118	.45	_	
191-289	45121-45123	21	_	
191-290	45124-45125	9	_	
191-291	45126-45127	−	_	
191-292	45127-45128	9	_	
191-293	45129-45130	7	_	
191-294	45131-45132	R	_	
191-295	45133-45141	Thalamus	_	
191-296	45141-45142	,	_	
191-297	45143-45150	Caudate	_	
191-298	45150-45151	,	_	
191-299	45152-45159	Caudate	_	
191-300	45160-45164	Body	_	
191-301	45164-45165	,	_	
191-302	45166-45176	Mammillary	_	
191-303	45177-45181	Body	_	
191-304	45181-45182	,	_	
191-305	45183-45190	Ventral	_	
191-306	45191-45199	Anterior	_	
191-307	45200-45207	Nucleus	_	
191-308	45207-45208	,	_	
191-309	45209-45218	Lentiform	_	
191-310	45219-45226	Nucleus	_	
191-311	45228-45229	−	_	
191-312	45229-45232	.40	_	
191-313	45235-45237	20	_	
191-314	45238-45239	−	_	
191-315	45239-45241	11	_	
191-316	45242-45243	−	_	
191-317	45243-45245	76	_	
191-318	45246-45247	−	_	
191-319	45247-45249	22	_	
191-320	45250-45251	L	_	
191-321	45252-45259	Declive	_	
191-322	45259-45260	,	_	
191-323	45261-45268	Lingual	_	
191-324	45269-45274	Gyrus	_	
191-325	45274-45275	,	_	
191-326	45276-45281	Uvula	_	
191-327	45283-45284	−	_	
191-328	45284-45287	.40	_	
191-329	45290-45292	20	_	
191-330	45293-45294	6	_	
191-331	45295-45296	−	_	
191-332	45296-45298	49	_	
191-333	45299-45300	−	_	
191-334	45300-45302	12	_	
191-335	45303-45304	R	_	
191-336	45305-45311	Culmen	_	
191-337	45311-45312	,	_	
191-338	45313-45322	Fastigium	_	
191-339	45322-45323	,	_	
191-340	45324-45334	Cerebellar	_	
191-341	45335-45342	Lingual	_	
191-342	45344-45345	−	_	
191-343	45345-45348	.42	_	
191-344	45351-45353	20	_	
191-345	45354-45355	−	_	
191-346	45355-45357	26	_	
191-347	45358-45359	−	_	
191-348	45359-45360	2	_	
191-349	45361-45363	53	_	
191-350	45364-45365	L	_	
191-351	45366-45372	Middle	_	
191-352	45373-45380	Frontal	_	
191-353	45381-45386	Gyrus	_	
191-354	45387-45388	6	_	
191-355	45389-45390	−	_	
191-356	45390-45393	.39	_	
191-357	45396-45398	19	_	
191-358	45399-45400	−	_	
191-359	45400-45401	3	_	
191-360	45402-45403	−	_	
191-361	45403-45405	65	_	
191-362	45406-45407	−	_	
191-363	45407-45408	6	_	
191-364	45409-45410	L	_	
191-365	45411-45417	Culmen	_	
191-366	45418-45420	of	_	
191-367	45421-45427	Vermis	_	
191-368	45427-45428	,	_	
191-369	45429-45436	Lingual	_	
191-370	45437-45442	Gyrus	_	
191-371	45442-45443	,	_	
191-372	45444-45450	Culmen	_	
191-373	45450-45451	,	_	
191-374	45452-45459	Declive	_	
191-375	45461-45462	−	_	
191-376	45462-45465	.36	_	
191-377	45469-45473	Note	_	
191-378	45473-45474	.	_	

#Text=L= left hemisphere.
192-1	45475-45476	L	_	
192-2	45476-45477	=	_	
192-3	45478-45482	left	_	
192-4	45483-45493	hemisphere	_	
192-5	45493-45494	.	_	

#Text=R = right hemisphere.
193-1	45495-45496	R	_	
193-2	45497-45498	=	_	
193-3	45499-45504	right	_	
193-4	45505-45515	hemisphere	_	
193-5	45515-45516	.	_	

#Text=BA = Brodmann Area.
194-1	45517-45519	BA	_	
194-2	45520-45521	=	_	
194-3	45522-45530	Brodmann	_	
194-4	45531-45535	Area	_	
194-5	45535-45536	.	_	

#Text=Coordinates (x, y, z) reflect center of mass.
195-1	45537-45548	Coordinates	_	
195-2	45549-45550	(	_	
195-3	45550-45551	x	_	
195-4	45551-45552	,	_	
195-5	45553-45554	y	_	
195-6	45554-45555	,	_	
195-7	45556-45557	z	_	
195-8	45557-45558	)	_	
195-9	45559-45566	reflect	_	
195-10	45567-45573	center	_	
195-11	45574-45576	of	_	
195-12	45577-45581	mass	_	
195-13	45581-45582	.	_	

#Text=Voxelwise threshold for effect > t(139) = 2.61, p < .01 two-tailed for ≥ 19 contiguous voxels.
196-1	45583-45592	Voxelwise	_	
196-2	45593-45602	threshold	_	
196-3	45603-45606	for	_	
196-4	45607-45613	effect	_	
196-5	45614-45615	>	_	
196-6	45616-45617	t	_	
196-7	45617-45618	(	_	
196-8	45618-45621	139	_	
196-9	45621-45622	)	_	
196-10	45623-45624	=	_	
196-11	45625-45629	2.61	_	
196-12	45629-45630	,	_	
196-13	45631-45632	p	_	
196-14	45633-45634	<	_	
196-15	45635-45638	.01	_	
196-16	45639-45649	two-tailed	_	
196-17	45650-45653	for	_	
196-18	45654-45655	≥	_	
196-19	45656-45658	19	_	
196-20	45659-45669	contiguous	_	
196-21	45670-45676	voxels	_	
196-22	45676-45677	.	_	
